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ABSTRACT 
Steroidogenic CYPs are crucial enzymes in the biosyntheses of steroid hormones, which are responsible 
for the maintenance of gender characteristics, as well as for the regulation of carbohydrate metabolism, 
immune system and homeostasis of electrolytes and fluids. It has been established that abnormal 
concentrations of these hormones are associated with some complicated diseases. Therefore, the control of 
these hormone levels as promising therapies are imperative. To attain this goal, the inhibition of 
steroidogenic CYP enzymes catalyzing the production of these hormones is an elegant way. 
Since androgen stimulates the proliferation of prostate cancer cells, the inhibition of CYP17, which is the 
crucial enzyme in androgen biosynthesis, was proposed as a promising therapy. In mimicking the natural 
steroidal substrates, series of biphenyl methylene heterocycles were designed. After the evolution from 
imidazoles to pyridines, potent and selective CYP17 inhibitors were identified, for example IV-16, which 
exceed the drug candidate Abiraterone in terms of inhibitory potency and selectivity patterns. Considering 
the fact that mutated androgen receptor can be activated by cortisol and in some prostate cancer patients high 
cortisol levels lead to Cushing’s syndrome, dual inhibitors of CYP17 and CYP11B1 are designed by 
combining important structure features of both inhibitors. Compound III-6 was successfully obtained as a 
lead for dual inhibition, although the inhibitory potency and selectivity over CYP11B2 requires further 
improvement. 
Moreover, high aldosterone levels are widely acknowledged to show some deleterious effects on heart, 
vessels, kidney, brain and central nerve system. Due to its pivotal role in aldosterone biosynthesis, CYP11B2 
is a superior target for the treatment of diseases related to high aldosterone levels. Based on the previously 
identified lead compounds, a series of novel heterocycle substituted 4,5-dihydro-[1,2,4]triazolo[4,3-
a]quinolines were designed, synthesized and biologically evaluated. The resulted compound VI-24 exhibits 
an IC50 of 4 nM and excellent selectivity over CYP11B1, which shares 93% of homology with CYP11B2. 
CYP11B2 inhibition is also considered necessary for breast cancer patients under aromatase inhibitor therapy 
because the estrogen deficiency caused by menopausal and the application of aromatase inhibitor eventually 
increases aldosterone concentration. Design via hybridization of both CYP19 and CYP11B2 inhibitors leads 
to compound V-11 as a promising dual inhibitor.  
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ZUSAMMENFASSUNG 
Steroidogene CYP-Enzyme sind für die Biosynthese von Steroidhormonen essentiell. Letztere sind 
verantwortlich für die Ausbildung von Geschlechtsmerkmalen und deren Aufrechterhaltung sowie für die 
Regulation des Kohlenhydratstoffwechsels, des Immunsystems und der Homöostase von Elektrolyten und 
Flüssigkeit. Es ist schon lange bekannt, dass von der Norm abweichende Hormon-Konzentrationen mit 
schwerwiegenden Krankheiten verbunden sind. Eine Kontrolle der Hormonspiegel stellt daher eine 
vielversprechende therapeutische Option dar. Zur Erreichung dieses Ziels ist die Hemmung steroidogener 
CYP-Enzyme, die die entsprechende Hormon- Biosynthese katalysieren, ein eleganter Weg.  
Da Androgene die Proliferation von Prostatakarzinomzellen stimulieren, ist die Hemmung von CYP17, dem 
Schlüssel-Enzym in der Androgen Biosynthese, die Strategie der Wahl. Als Mimetika der natürlichen 
steroidogenen Substrate, wurde eine Serie an Biphenylmethylen-Heterocyclen konzipiert. Durch 
Weiterentwicklung von den Imidazolen zu den Pyridinen, konnten potente und selektive CYP17 Hemmstoffe 
identifiziert werden, z. B. IV-16, das bezüglich Hemmpotenz und Selektivität den Arzneistoffkandidaten 
Abirateron übertrifft. Nach dem bekannt geworden war, dass ein mutierter Androgen-Rezeptor durch 
Cortisol aktiviert werden kann und dass in einigen Prostatakarzinompatienten hohe Cortisolspiegel zu 
Cushing-Syndrom führen, wurden duale Hemmstoffe von CYP17 und CYP11B1 konzipiert, in dem 
entscheidende Strukturmerkmale von beiden Hemmstofftypen strukturell vereint wurden. Verbindung III-6 
wurde dabei als Leitverbindung für einen dualen Hemmstoff erhalten. Dies war zweifelsohne ein Erfolg, 
wenn gleich Hemmpotenz und Selektivität gegenüber CYP11B2 weiter optimiert werden sollten.  
Es ist weiterhin bekannt, dass hohe Aldosteronspiegel einige sehr negative Effekte auf Herz, Blutgefäße, 
Niere, Gehirn und zentrales Nervensystem aufweisen. CYP11B2 ist ein hervorragendes Target für die 
Behandlung dieser Krankheiten, da es eine entscheidende Rolle in der Aldosteron-Biosynthese spielt. 
Basierend auf den kürzlich identifizierten Leitverbindungen, wurde eine Serie von neuen heterocyclisch 
substituierten 4,5-Dihydro-[1,2,4 ]triazolo[4,3-a]Chinolinen konzipiert, synthetisiert und biochemisch 
evaluiert. Die resultierende Verbindung VI-24 zeigt einen IC50 Wert von 4 nM und eine exzellente 
Selektivität gegenüber CYP11B1, das eine 93%ige Homologie zu CYP11B2 aufweist. Die Hemmung von 
CYP11B2 wird auch als notwendig für Brustkrebspatientinnen unter Aromatasehemmer-Therapie angesehen, 
da der Estrogenmangel, hervorgerufen durch Menopause oder Applikation von Aromatasehemmstoffen, zur 
Ausbildung hoher Aldosteronkonzentrationen führt. Durch Hybridisierung von Aromatase - und CYP11B2 - 
Inhibitoren wurde letztendlich Verbindung V-11 als vielversprechender dualer Hemmstoff erhalten.  
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1 Introduction 
1.1 Cytochrome P450 Enzymes 
1.1.1 General 
It has been postulated that the first cytochrome P450 (CYP) gene 
emerged about 3.5 billion years ago before the advent of eukaryotes and 
the existence of an oxygen-rich atmosphere.1 Accompanying the 
evolution of life, cytochrome P450 widely spread into every branch of 
the tree of life, from bacteria to human being. At the same time, the function of cytochrome P450 shifted 
from nitro-reduction to oxidation. Cytochrome P450 is a huge superfamily, it comprises around 10,000 
identified cytochrome P450 genomic and cDNA sequences that have been divided into 781 different families. 
As the research in genomics and proteomics is intensifying, the members of this superfamily keep increasing. 
CYPs are categorized into families and subfamilies according to amino acid (AA) sequence identity with 
CYP as the superfamily name. When CYP enzymes have more than 40% of sequence identity, they are 
designated as one family, for example CYP1. Sequences that are greater than 55% identical are in the same 
subfamily labelling with a capital letter after the family number, such as CYP1A. For each member of the 
subfamily, they are distinguished with an extra number, such as CYP1A2. The corresponding gene for the 
enzyme shares the same name, but in italics. However, the designation of the number to the family, such as 
CYP1 and CYP2, does not reflect the phylogenetic relationship. For example, mammalian CYP3 family is 
more closely related to the insect CYP6 family than to the mammalian CYP4 family.  
1.1.2 Structure: Hemoprotein and associated Electron Transfer Partners 
Most known CYPs are multi-component enzymes consisting of a hemoprotein moiety and associated 
electron transfer partners (Figure 1). Mitochondrial and most bacterial CYPs, such as CYP11B2, are three 
component systems (Class I). Besides a hemoprotein, there is a two-component electron shuttle system 
comprising of ferredoxin and corresponding ferredoxin reductase. The ferredoxin is a kind of iron-sulfur 
protein, while the ferredoxin reductase is NADPH-dependent and contains FAD (flavin adenine 
dinucleotide). On the contrary, the microsomal CYPs (Class II) are two component systems containing a 
heme and a NADPH-dependent cytochrome P450 reductase, which is the combination of FAD and FMN 
(flavin mononucleotide). Both heme and reductase are membrane bound. The cytochrome P450 reductase 
catalyzes the transfer of electrons along the pathway NADPH → FAD → FMN → P450. For some cases, 
cytochrome B5 may also be involved in the electron transfer system, for example CYP17 and CYP3A4. As 
for Class III CYPs, such as P450 BM3 (CYP102A1), the same cofactors as the class II P450s are observed, 
but they are soluble and all components are fused into one continuous polypeptide. Moreover, another class 
of CYPs with all components fused together has been discovered recently. These enzymes are soluble, and 
comprise the heme domain, ferredoxin, and a NADPH-dependent FMN-containing reductase (Class IV). 
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Figure 1. Structures of CYP enzymes. (adopted from http://www.chem.ed.ac.uk/chapman/p450.html) 
The cytochrome P450s are a series of cysteinato-heme enzymes. In the hemoprotein moiety, iron 
protoporphyrin as the prosthetic group covalently links to the protein through the sulphur atom of a proximal 
cysteine ligand (Figure 2).  The iron protoporphyrin is the reactive centre to activate oxygen and to oxidize 
the substrate. Despite poor sequence identity of less than 20% across the superfamily, CYP proteins share 
similar folding configuration and topology with highly conserved helices A–L. The I and L helices connect 
with the heme, whereas residues in the B, F and I helices are involved in the recognition, swig, and release of 
the substrates.3 The most conserved part of the P450 sequence lies in the region containing the Cys, which 
acts as the thiolate ligand to the heme iron. This conserved sequence is used as the identifying character of 
CYPs in gene bank.3  
 
Figure 2. Hemoprotein of CYP enzymes, illustrating with human CYP19 (PDB code: 3EQM2). 
1.1.3 Catalytic Mechanism 
CYP450s are potent oxidants that are able to catalyze a series of oxidation after the activation of molecule 
O2, such as the oxidation of heteroatom, the hydroxylation of saturated carbon-hydrogen bonds, the 
epoxidation of double bonds and the dealkylation reactions. A common oxidation mechanism has been 
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proposed involving the sequential two-electron reduction, spin state alternation of the iron, and two 
protonations4 (Figure 3). In the resting state, water is coordinated to the iron as the sixth ligand (1) before the 
substrate binds in the active site of the enzyme. The binding of substrate often displaces the water molecule, 
and sometimes changes the state of heme iron from low spin to high spin (2). The change of electronic state 
favors the transfer of an electron from NAD(P)H via electron transfer system, reducing the ferric ion to 
ferrous ion (3). This intermediate can be bound by oxygen covalently at the distal axial coordination position 
of the heme iron leading to an oxy-P450 complex (4). Interestingly, it can also coordinate with CO showing 
maximum absorption at wave length around 450 nM, which is the origin of the name P450. The oxy-P450 
complex as the last relatively stable intermediate is subsequently reduced by a second electron to a peroxo-
ferric intermediate (5A), which is then rapidly protonated twice by local transfer from water or from 
surrounding amino acid side chains, releasing one water molecule, and forming a highly reactive iron(IV)-
oxo species (6). After the consequently final oxygenation of the substrate (7) and the release of product, the 
heme returns to the resting state with a water molecule occupying its distal coordination position.  
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Figure 3. Catalytic cycle of cytochrome P450. 
1.1.4 Functions of CYP Enzymes 
Cytochrome P450 enzymes exhibit a wide range of physiological functions. In bacteria and plants, they are 
mainly involved in detoxification and defense, for example, the biosynthesis of antibiotics. However, for 
human and animal, CYPs additional function in the biosynthesis of endogenous modulators. It has been 
established that CYP 1–3 families, which are located predominately in the liver, are responsible for the 
metabolism of xenobiotics (including drugs). These substances were degraded or furnished with polar groups 
to facilitate excretion. Yet, CYP 4–51 families are involved in the biosynthesis and deactivation of critical 
endogenous molecules, which control the development and homeostasis of the body, such as steroid 
hormones, arachidonic acid, fatty acid, thromboxane, bile acid, prostacyclin and vitamins. 
1.1.5 Hepatic CYP Enzymes 
1 Introduction 
胡庆忠博士论文 
- 4 - 
As mentioned above, hepatic CYP enzymes are very important in the drug metabolism and excretion. It 
has been estimated that the metabolism in liver accounts for 73% of the elimination of the 200 top prescribed 
drugs (Figure 4A).5 In this metabolism, 75% of the phase I reactions are achieved by CYP 1–3 families. 
Among them, 46% of drug oxidations were carried out by the CYP3A family, while 16% by CYP2C9 and 
12% for both CYP2C19 and CYP2D6. This ratio is consistent with that of the CYP enzymes expression in 
liver (Figure 4B), whereby CYP3A4 accounts for 34.4% of the total CYP, whereas 17.3% for CYP2C9, and 
CYP2E1 and CYP1A2 are 14.6% and 12.5% respectively.6,7 This expression ratio may be inherited from 
ancestors in that they obtained in the long adventure of evolution, and conserved it in the gene. However, it 
may also be a consequence of induction in the fight with various xenobiotics invading from the outside 
environment. 
 
Figure 4. A) Metabolism and elimination of 200 top prescribed drugs. B) Liver expression ratio of CYP enzymes. 
The hepatic CYP enzymes are very important in drug discovery and development. For the drugs applied 
per oral, the first pass effect significantly decreases the plasma drug concentration because the drug is largely 
metabolized by the hepatic CYPs after gastrointestinal absorption. Therefore, to design drugs hard-to-
metabolize but can be excreted aboriginally is a feasible way to improve pharmacokinetic properties. 
Moreover, compounds inhibiting or inducing hepatic CYP enzymes are at high risk of drug-drug interaction. 
The inhibition of hepatic CYPs delays the deactivation and excretion of some drugs, whose metabolism are 
dependent on these enzymes, leading to the accumulation of these drugs inside the body and the consequent 
toxicity. On the contrary, the induction of hepatic CYP enzymes reducing the plasma drug concentration 
deteriorates the curative effects. Furthermore, the expression of hepatic CYP enzymes varies among people 
of different races, genders, ages, and even living environment. It is possible the drug dosage administered is 
not enough for some people to show response, yet can cause toxicity in other people. Hence, the 
administration of drugs should according to the situation of patients.   
1.1.6 Steroidogenic CYP Enzymes 
Steroidogenic CYPs are crucial enzymes in the biosyntheses of steroid hormones, which are responsible 
for the maintenance of gender characteristics, as well as for the regulation of carbohydrates metabolism, 
immune system and homeostasis of electrolyte and fluid. The biosyntheses begins with cholesterol, whose 
side chain is cleaved by CYP11A1 to form pregnenolone (Figure 5). Pregnenolone and progesterone are 
subsequently converted to dehydroepiandrosterone (DHEA) and androstenedione catalyzed by CYP17, 
A B
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respectively. These two steroids are precursors of androgens (for example: testosterone). Meantime, 
androstenedione and testosterone can be converted to estrogens (estrone and estradiol), which are catalyzed 
by aromatase (CYP19). Besides sex hormones, mineralocorticoids (mainly aldosterone) and glucocorticoids 
(predominantly cortisol) are also synthesized from progesterone and 17α-hydroxyprogesterone catalyzing by 
aldosterone synthase (CYP11B2) and 11β-hydroxylase (CYP11B1), respectively. In these procedures, 
steroid 21-hydroxylase (CYP21) is involved as the common enzyme. Since some diseases are stimulated by 
these steroids, the enzymes catalyzing their biosyntheses are possible therapeutic targets. Since CYP11A1 
and CYP21 influence the biosyntheses of too many hormones, their inhibition would cause severe toxicity, 
and they are not suitable targets to be pursued. On the contrary, CYP17 –– important for androgen 
biosyntheses –– is a promising target for the treatment of hormone dependent prostate cancer (PCa) and the 
inhibition of CYP19, which is crucial in estrogen biosyntheses, has already been widely employed in clinic 
on postmenopausal breast cancer (BC) patients. Moreover, CYP11B1 and CYP11B2, which are responsible 
for the production of glucocorticoids and mineralocorticoids, respectively, have also been proposed as targets 
for diseases related to abnormally high concentration of cortisol and aldosterone, for example: Cushing’ 
symptom and congestive heart failure (CHF). 
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Figure 5. Steroidogenic CYP enzymes in the biosynthesis of steroid hormones. 
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Figure 6. Prostate and male reproductive system. (adopted 
from http://www.liv.ac.uk/researchintelligence/issue21/prostate-
cancer. html) 
1.2 CYP17 Inhibition as Treatment for Prostate Cancer 
1.2.1 Prostate Cancer: Incidence and Diagnosis 
Prostate is an important component of the male 
reproductive system. It lies below the bladder and 
between the rectum and the public bone (Figure 6 
and 7).  The urethra originating from the bladder 
traverses the prostate before exiting to the penis. 
During ejaculation, sperm is pumped out of the 
testes and effused into the seminal vesicles via vas 
deferentia (Figure 7) before being squeezed into 
the urethra together with the fluids secreted by 
seminal vesicles and prostate. The fluid secreted 
by prostate is slightly alkaline to nourish and 
protect the sperm. 
After reaching adulthood, the prostate is vulnerable to some disorders, such as prostatitis, benign prostatic 
hyperplasia (BPH) and the most severe prostate cancer. It has been estimated that between the years 2003–
2007 the incidence rate of prostate cancer was approximately 156.9 per 100,000 men. Moreover,  PCa 
accounted for a quarter of cancer related deaths each year according to NCI report.8 Since the symptoms of 
PCa, like inability and weakness in urination despite a recurring impulse, pains or burning during urination 
and blood urine, are not specific compared to other prostate disorders, it is necessary to perform early 
screening if these symptoms are observed. Two screening methods are currently employed in the clinic:  
 
Figure 7. Progress stages of prostate cancer (A) (adopted from http://visualsonline.cancer.gov); histological character of normal 
prostate tissue with corpora amylacea in the gland lumen as small pink laminated concretion (B right) and prostatic adenocarcinoma 
(B left) (adopted from http://visualsonline.cancer.gov); and a clump of prostate cancer cells (C), where the bluey-green cells are 
fiercely proliferating, whereas the pink ones are in apoptosis (adopted from http://images.wellcome.ac.uk/). 
B 
A 
C 
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digital rectal examination (DRE) and prostate specific antigen (PSA) blood test. DRE means the examination 
of the size, shape and texture of the prostate by a figure through the rectum. Although only the back part of 
the prostate is detectable in this procedure, it is still reliable as most cancers originate there. The observations 
of stiffness increases, lumps and irregular shapes indicate possible PCa. However, most PCas found by DRE 
are in the advanced stages with poor prognosis. The other screening method –– PSA blood test –– determines 
the plasma level of the protease9 produced by the prostate. Patients with a PSA concentration of more than 2.5 
or 4 ng/mL are suspected of having of PCa. Although this method is criticized due to its frequent false 
alarms,10 which are results of the elevated PSA levels induced by prostatitis, BPH and ejaculation, PSA 
screening is acknowledged to be successful in reducing prostate cancer mortality.11,12 Moreover, the PSA 
level is also exploited as a biomarker in the treatment of PCa.13 The suspecyed cases identified by DRE or 
PSA test are ultimately confirmed by ultrasound or magnetic resonance imaging and the most accurate by 
prostate biopsy.  
The tissue obtained through biopsy is subsequently scrutinized under the microscope to check the type, 
stage and grade of the prostate cancer. Prostatic adenocarcinoma is the predominate type diagnosed, whereas 
intra- or interepithelial neoplasia and small cell anaplastic prostate carcinoma are rare cases. The most 
significant discrimination of adenocarcinoma from normal prostate tissue is the shrinkage or even 
disappearsnce of stroma and gland lumen (Figure 7B left). The remaining tumorous glands are also irregular 
in shape. Another hallmark of prostatic adenocarcinoma is the presence of prominent large nucleoli. These 
histologic appearances are the base of the Gleason grading system, which has been employed as a prognostic 
factor to predict a patient’s time to progression. The cancer can also been staged according to the degree of 
metastasis. For primary cancer, it can be divided into stage I and II regarding the size and visibility by 
imaging. Cancer spreading beyond the outer layer of the prostate to nearby tissues, frequently the seminal 
vesicles, is categorized as stage III; whereas metastasis to local lymph nodes and / or distant organs indicates 
stage IV. The prostate cancer can metastasize to the bladder, rectum, liver or lungs, yet the most favorable 
site is bones because the abundant transferrin in bone tissue accelerates the proliferation of caner cells.14 
1.2.2 Prostate Cancer Treatment –– State of Art 
1.2.2.I. Watchful Waiting  
Watchful waiting implies no treatment other than monitoring the PSA level. It usually applies to patients 
with less than 10 years life expectancy when the disease progresses very slowly until the life quality is 
impaired, for example by pain or dysfunction in urination.15 This is reasonable because it is very probable 
that these patients would die with PCa other than die of this disease. It is not necessary to have them suffer 
the possible side effects of the treatment. However, a recent clinical trial showed that the indolent disease 
would progress aggressively locally or metastasize to distant organs after 15 years. Therefore, early radical 
therapy is therefore recommended for patients with a life expectancy of 15 years or more.16 
1.2.2.II. Local Therapy: Prostatectomy, Cryotherapy and Radiation Therapy  
Local therapy is a set of non-pharmaceutical approaches to treat PCa. 
Prostatectomy. The excision of the prostate as well as seminal vesicles is the first line therapy for men 
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with PCa in stage I or II when they are younger than 70 and otherwise healthy.15 Prostatectomy is not 
suitable for advanced disease because it is difficult to remove enough tissue to guarantee negative margins. 
Although this surgery is relatively safe with an extremely low mortality of 0.4–0.7%, side effects like 
impotence and incontinence are expected in up to 50% of patients. 
Radiation Therapy includes external beam radiation therapy and brachytherapy. The difference between 
these two kinds of radiation therapy is to cast radiation outside the body or to implant a radiation source 
(seed) into the tumorous tissue. It is apparent that brachytherapy is more convenient and would usually 
achieve maximum curative effects with minimum damage to nearby normal tissues. It has been demonstrated 
that the combination of radiation therapy and hormone therapy is more effective than radiation therapy alone 
with significantly improved over-all survival and low risk of local recurrency.17 However, radiation therapy 
is only suitable for PCa in early stages and the side effects of radiation are inevitable. 
Cryotherapy is an alternative to prostatectomy and radiation therapy. It is a minimally invasive surgery 
effective for recrudescent and radio-resistant PCa in the early stages. Patients under general anesthesia are 
inserted with needles into the prostate gland through the perineum guided by transrectal ultrasound. Liquid 
nitrogen is subsequently circulated into the needles to produce a rather low temperature freezing the prostate 
gland and sometimes seminal vesicles as well. It showed lower risk and discomfort compared to 
prostatectomy and radiation therapy. It can be repeatedly applied or act as a secondary treatment when other 
primary treatments fail. However, cryotherapy also causes impotence and the long term efficacy still needs to 
be proved.  
1.2.2.III. Chemotherapy  
Cytotoxic agents exert in various ways to destroy cancer cells. Some demolish the membrane integrity of 
the cancer cells resulting in necrosis, during which the cells swell rapidly, leak cytoplasm and organelle, and 
ultimately lyse. Some arrest the mitosis and prevent proliferation and differentiation. Others induce apoptosis 
characterized by cytoplasmic shrinkage, nuclear condensation, and cleavage of DNA into regularly sized 
fragments. However, cytotoxic agents act on all cells mitosing rapidly. Some normal cells other than cancer 
cells are therefore simultaneously damaged, especially cells in the bone marrow, digestive tract, and hair 
follicles, which lead to some common side effects, such as myelosuppression (decreased production of blood 
cells), mucositis (inflammation of the lining of the digestive tract) and alopecia (hair loss). Despite these side 
effects, cytotoxic agents are suitable choices for the advanced PCa. 
Docetaxel (Figure 8) belonging to the taxane class inhibits the dynamic reorganization of microtubule 
networks, which is essential to vital interphase and mitotic cellular functions. Due to this mechanism, 
docetaxel is mainly active in the S phase of the cell cycle. This drug launched in 2004 is the first cytotoxic 
agents approved to treat PCa. Previously, cytotoxic agents had been regarded for a long time as impotent for 
PCa. A clinical trial of the combination of docetaxel and prednisone (a glucocorticosteroid, which is believed 
to be able to augment the efficacy of chemotherapy) demonstrated improved median survival time and 
reduced hazard ratio compared to mitoxantrone (another cytotoxic agent, described in detail below).18 Due to 
the survival achieved, this combination is considered the most effective treatment for metastatic, hormone 
refractory PCa. 
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Figure 8. Structures of cytotoxic agents in the treatment of PCa. 
Estramustine (Figure 8) is postulated to act in a dual mechanism that the intact molecule stabilizes the 
microtubule dynamics, whereas some metabolites exhibits antigonadotrophic effects resulting in the 
suppression of testosterone production.19 Patients showed good response to estramustine solo20 or the 
combination of docetaxel / estramustine.21 However, severe gastrointestinal and cardiovascular toxicity was 
observed. 
Mitoxantrone (Figure 8) is an anthracenedione antitumor antibiotic. It intercalates DNA leading to 
intrastrand cross-linking and binds to the phosphate backbone of DNA resulting in DNA strand rupture. 
Mitoxantrone also interferes with topoisomerase II. These multi actions cause nonspecific arrest of all cell 
cycle phases, with late S phase as the most sensitive one. Mitoxantrone exhibits no improvement to overall 
survival, however it is well tolerated and therefore could be a useful palliative treatment.22 
Ixabepilone (Figure 8) is an epothilone tubulin inhibitor in Phase II development for PCa. This drug acts in 
a similar mechanism as docetaxel by inducing microtubule polymerization, forming multipolar spindles and 
mitotic arrest. It is expected to overcome the resistance that docetaxel has encountered involving the drug 
efflux protein P-glycoprotein.  
Besides, some more cytotoxic agents are under developement; for example: satraplatin (Figure 8), as the 
third generation of platinum complex, is oral bioavailable; as well as irofulven (Figure 8), which is an illudin 
analogue, blocks transcription and induces apoptosis after binding to the DNA. 
Furthermore, there are some other promising agents in the pipeline acting in various mechanisms (Table 1), 
such as anti-angiogenesis, proteasome inhibitors and antisense oligonucleotide. 
1.2.2.IV. Vaccines and Immunotherapy 
Cancer immunotherapy is a set of approaches attempting to awaken the patients’ immune system to kill 
cancer cells after the intervention of vaccines. Although there are still no vaccines launched into the market 
for PCa, several drug candidates in late clinical trial phases are very promising.  
Provenge is composed of modified dendritic cells, which is an important component of immune system 
and can be isolated from the corresponding patient’s blood. These dendritic cells are trained by incubating 
with a fusion protein comprising prostatic acid phosphatase, which is an enzyme produced by PCa cells, and 
a dendritic cell-targeting element for 48 hours before being re-administered to the patient. These cells  
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Table 1. Promising drug candidates in various mechanisms other than cytotoxicity. 
Drug Structure Mechanism Phase Pharmacology Side effects 
Bevacizumab23  Monoclonal antibondy, 
targeting vascular endothelial growth factor A II PSA level reduction thrombosis, fatigue 
Thalidomide24 N
O
O
NH
O
O
 
enhances interleukin-2 (IL-2) activity, 
suppresses TNF-alpha, down-regulates IL-6 
and inhibits angiogenesis induced by beta-
fibroblast growth factor (β-FGF) and VEGF 
II PSA response 
Thromboembolism,  
constipation, 
fatigue,  
neurotoxicities. 
Bortezomib25 
N
N
N
H
O
O
H
N B
OH
OH
 
Proteasome Inhibitors, 
stimulates apoptosis I / II 
PSA level reduction, 
reverse taxane resistance when combined 
diarrhea, peripheral 
neuropathy, 
hyperglycemia, 
neutropenia, 
fatigue 
Atrasentan26 N
O
OH
O N
O
O
O
 
Endothelin-Receptor Antagonists, III Delayed time to progression, PSA level reduction 
peripheral edema, 
bone pain, anemia, 
asthenia 
Gefitinib27 
N
N
O
O
HN
N
O
F
Cl
 
Epidermal Growth Factor Receptor Inhibitors II 
No significant differences in progression 
rates, time to progression, and overall 
survival compared to placebo. 
rash, diarrhea 
Oblimersen28  Antisense oligonucleotide, 
blocks the production of Bcl-2  II 
PSA level reduction when combining 
with docetaxel. 
fatigue, fever, 
nausea 
 
1 Introduction 
胡庆忠博士论文 
- 11 -
consequently lead the immune system to destroy cancer cells producing acid phosphatase. Although this 
vaccine shows little influence on the PSA level, the overall survival is largely improved.29 
Compared to the personalized approach of provenge, GVAX is more general and therefore less expensive. 
GVAX is based on PCa tumor cells genetically engineered to secrete granulocyte-macrophage colony-
stimulating factor, which is a hormone stimulating immune response. This vaccine showed a dose-dependent 
prolongation of survival and longer median progression time.30 However, it sometimes fails to invoke 
immune response in certain patients. 
1.2.2.V. Hormone Therapy  
Although a lot of PCa therapies have emerged, most of them are only suitable for cancer in early stages. 
For advanced diseases, especially the ones with metastasis, hormone therapy is the most effective treatment. 
Androgens Stimulate Prostate Cancer Proliferation. It has been established that the growth of up to 
80% of PCa is androgen dependent.31 Therefore, segregation of tumor cells from androgen will effectively 
prevent cancer cell from proliferation and this is the mechanism base of hormone therapy. 
It is believed that androgens promote the 
cancer growth via binding to androgen 
receptor (AR), which is highly over-
expressed in PCa cells. AR belongs to the 
steroid and nuclear receptor superfamily,32 
and is similar to other members such as 
estrogen receptor (ER), mineralocorticoid 
receptor (MR) and progesterone receptor 
(PgR) in structure (Figure 9) and function 
manner.34 AR is a soluble protein acting as 
an intracellular transcription factor. 
Unbound ARs floating in the cytoplasm are 
associated with heat shock proteins through 
interactions with the ligand binding 
domain.35 Once androgen binds to the AR, 
it triggers a series of sequential conformational changes of the receptor which affect receptor protein 
interactions and receptor DNA interactions. The AR first dissociates from the heat shock proteins, then 
dimerizes, been phosphorylated and consequently translocates into the nucleus. It is notable that 
phosphorylation or dephosphorylation of androgen receptor has been deemed as a determinant of androgen 
agonistic or antagonistic activity.36 The translocated receptor subsequently binds to the androgen response 
element located in the promoter or enhancer region of gene that AR targeting. Recruitment of other 
transcription co-regulators37 (for example: steroid receptor co-activator 3 (Figure 9)) and transcriptional 
machinery38 further initiates the transactivation of AR regulated gene expression, which exhibits various 
physiological or pathological function; for prostate cancer cells the mitogenic effects. Some evidences39 
indicate that the recruitment of different co-regulators (co-activator or co-repressor) is another switch of 
 
Figure 9. Crystal structure of DHT bounded androgen receptor in 
complex with the first motif of steroid receptor co-activator 3 (gold), 
PDB code: 3L3X.33
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agonistic or antagonistic activity. Moreover, besides the genomic effects, the nongenomic pathway of AR 
has also been observed in prostate,40,41 which is the direct interactions between AR and cytosolic proteins 
from various signaling pathways. These nongenomic actions rapidly activates kinase signaling cascades or 
modulates intracellular calcium levels, which possibly contribute to the survival and proliferation of PCa 
cells.42 
Central Role of CYP17 in Androgen Biosynthesis. Two major androgens are produced endogenously as 
substrates of AR: testosterone and 5α-dihydrotestosterone (5α-DHT). The biosyntheses of androgen starts 
from cholesterol, which is produced in the metabolism process of fatty acid. After the side chain of 
cholesterol is cleaved by CYP11A1, which is the rate limiting step of the whole procedure, pregnenolone and 
progesterone (after further dehydrogenation catalyzed by 3β-hydroxysteroid dehydrogenase (3β-HSD)) are 
obtained. These two steroids are firstly hydroxylated at the 17 position and then the C17–20 bond is cleaved 
catalyzing by CYP17 to yield DHEA and androstenedione, which are subsequently converted to testosterone 
(Figure 5). More than 90% of the circulating testosterone is produced in the Leydig cells in the testes, 
whereas the rest is synthesized in adrenals. It has also been reported that minor portion of testosterone 
originates from prostate cancer cell in a paracrine or autocrine manner.43–45 Circulating testosterone is 
predominately sequestered to sex hormone-binding globulin and albumin, with only approximately 2% as 
free unbound hormone. After testosterone fluxes into the prostate, it is then converted to the most potent 
androgen DHT catalyzed by 5α-reductase (5α-R). These two androgens consequently bind to the AR of 
prostate cancer cells and stimulate them to proliferate. 
Regulation of Androgen Biosynthesis. The androgen 
biosyntheses is regulated by hypothalamic – pituitary –
gonadal / adrenal axes. Hypothalamus is a basic modulator 
controlling body temperature, immune responses and 
blood pressure. It secretes many hormones which take 
effect after being distributed to the pituitary via 
hypophyseal portal system, for example: gonadotropin-
releasing hormone (GnRH, also known as LHRH, 
hypothalamic luteinizing hormone-releasing hormone) and 
corticotropin-releasing hormone (CRH) (Figure 10). 
GnRH and CRH stimulate the release of gonadotropins 
(Gn, including follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH)) and adrenocortico-tropic 
hormone (ACTH) from anterior pituitary, respectively. 
Consequently, gonadotropins and ACTH trigger the 
production of androgens in testes and adrenals after 
binding to the corresponding receptor. When the 
concentration of testosterone is high enough, it will hold 
back the release of GnRH and CRH via negative feedback 
mechanism. 
CYP17
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Figure 10. Regulation of androgen biosyntheses by 
hypothalamic – pituitary – gonadal / adrenal axes, 
negative feedback loop and drug targets in hormone 
therapy.
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Figure 12. Typical AR antagonists. 
Potential Targets regarding Androgen Stimulation. As mentioned above, the segregation of tumor cells 
from androgen will be effective treatments for PCa. Two approaches are possible to achieve this goal: 
blocking AR, by which AR antagonists have been applied in clinic for many years; or interrupting the 
biosyntheses and release of androgen (Figure 10). For the latter, several nodes in androgen production 
system are important, yet not all of them are suitable targets. As inhibitors of 5α-R reduce the intracellular 
prostatic DHT concentration, they are exploited in the treatment of benign prostatic hyperplasia. However, 
due to testosterone stimulates cancer cell growth as well, 5α-R inhibitors did not show response in PCa 
patients. Moreover, ACTH controls the biosyntheses of glucocorticoids and mineralocorticoids besides 
androgen, therefore ACTH and CRH are not feasible targets either. Still there are some methods that have 
once been employed in clinic but dropped because of obvious drawback or more and more replaced by some 
other emerging therapies. 
Estrogen and Progestin. Early attempts to suppress androgens production by estrogen and progestin 
application46 were soon abandoned because of gynecomastia and elevated cholesterol level resulting in 
higher risk of cardiovascular diseases. 
Orchidectomy. The fact that more than 90% of androgen is produced in testes makes castration an easy 
and reasonable therapy. It is also inexpensive compared to other lang-term therapies. However, not everyone 
is willing to take permanent impotency as a consequence. 
GnRH Analogues (Agonists and Antagonists). 
This therapy is also known as “chemical castration”. 
The initial application of GnRH agonists leads to a 
surge of FSH and LH secretion after binding to the 
corresponding receptor in gonadotrope cells in pituitary. 
This surge causes a large amount of testosterone 
produced in testes, and tumor growth spurt (termed 
tumor flare). Nevertheless, after around ten days, these 
gonadotrope cells are no longer sensitive to 
endogenous GnRH and GnRH agonists resulting in the 
decline of testosterone levels comparative to that after 
castration. This reduction lasts as long as GnRH 
agonists consecutively administrated.47 On the contrary, 
GnRH antagonists competitively bind to the GnRH receptor and consequently block the gonadotropins 
release directly. GnRH analogues, such as leuprolide, goserelin, and buserelin (Figure 11), annihilate 
androgen produced in testes, however, 
have no effect on adrenals. Although more 
than 90% of androgen is no longer 
produced and the plasma testosterone 
concentration is reduced to less than 50 
ng/dL, the concentrations of androgen 
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Figure 11. Structures of GnRH analogues in clinical use.
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inside prostate are still high enough to enable the growth of cancer cells.48,49 Moreover, as side effects GnRH 
analogues cause testicular atrophy and loss of bone mineral density. 
AR antagonists (Antiandrogens). Since GnRH analogues are unable to block the androgen produced in 
adrenals, which continually stimulate cancer growth, AR antagonists (Figure 12) are exploited in 
combination. This is the current standard therapy, so-called combined androgen blockade (CAB, also 
known as androgen deprivation). Clinical trials demonstrate the effect of AR antagonists as mono-therapy is 
not satisfactory, which renders CAB as the best way to apply. Normally, antiandrogen is begun several days 
before GnRH analogues application in order to prevent the initial tumor flare resulting from the surge of 
testosterone. Since steroidal AR antagonists are less potent than non-steroidal ones and suppress other 
steroids produced in adrenals, steroidal AR antagonists are rarely employed. Although CAB achieves 
delayed disease progression and improved survival,50 it is also associated with cardiovascular death.51 
Furthermore, the long term application of antiandrogen induces AR mutations, such as T877A and W741C, 
which render the receptor’s capability to recognize some AR antagonists52,53 and glucocorticoids54 as 
agonists, thus resulting in the resistance to CAB. 
1.2.3 CYP17 Inhibition as Treatment for Prostate Cancer 
All these shortcomings of current therapies invoke CYP17 inhibition as a promising alternative because of 
its central role in androgen biosyntheses. Inhibition of CYP17 totally blocks the production of androgen not 
only in testes and adrenals, but also, and importantly, inside prostate cancer cells. This autocrine or paracrine 
of androgen inside prostate is at least partly responsible for the failure of CAB and the progression of the PC 
cell from androgen sensitive to “refractory”. 
CYP17 comprises 508 amino acids 
with an approximate molecular weight 
of 57 kDa and is coded by gene CYP17 
located in chromosome 10 q24.3.55 
Since this enzyme binds to the 
endoplasmic reticulum, its crystal 
structure is not solved yet. 
Nevertheless, several homology 
models have been built based on 
soluble bacterial CYPs56 or multi CYP 
templates (Figure 13).57 
CYP17 is the hinge in steroid 
biosyntheses route. In the adrenal zona 
glomerulosa where no CYP17 
expressed, steroidogenesis goes 
directly to the mineralocorticoid aldosterone. On the contrary, in the zona fasciculate and zona reticularis, the 
presence of CYP17 ensures the production of other steroids. Nevertheless, this enzyme still acts as a switch 
to control the syntheses of different steroids in different areas due to its bifunctionality in catalysis, namely 
 
Figure 13. Homology model of CYP17. 
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17α-hydroxylase and 17,20-lyase activities. In the zona fasciculate, 17α-hydroxylation is predominated 
leading to the favored glucocorticoids synthesis; whereas in the zona reticularis and gonads, these two 
activities both present promoting the production of sex hormones (Figure 5).58 Although the reason for this 
interesting phenomenon is still unclear, several regulators of 17,20-lyase activity have been identified, such 
as the abundance of osidoreductase59 and cytochrome b560 as well as the phosphorylation of serine and 
threonine residues.61  
The inhibition of CYP17 can be achieved via several approaches: 
1.2.3.I. Mechanism Based Inactivators 
In 1980s, scientists found that cyclopropyl group could irreversibly bind to the P450 enzymes.62,63 It is 
believed that the cyclopropyl compound was activated by enzymatic one-electron oxidation of nitrogen or 
oxygen atom, which connects directly to the cyclopropyl, thereby resulting in the cleavage of cyclopropyl 
ring and subsequent reactive radicals. These radicals covalently bind to CYP17 while still binding in the 
active site, and therefore inactivate the enzyme (Figure 14).62,63 This finding was soon applied in the design 
of CYP17 inhibitors.64 Besides cyclopropyl amino or ether, modifications were also created by introducing 
amino, amide or some other substitutents at the steroidal 4-position, thus rearranging the double bonds and 
inserting methylene to steroidal scalffold.65,66 These efforts led to some potent CYP17 inhibitors acting in a 
time dependent manner. Although these compounds arrested the growth of androgen dependent human 
prostatic tumor in mice, they were less effective than castration. 65,66 
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Figure 14. Reported mechanism based inactivators and the proposed action mechanism. 
1.2.3.II. Inhibition via Coordination between sp2 hybrid N and Heme Iron  
This reversible competitive inhibition mechanism was firstly identified for CYP19 inhibitors,67 but soon 
the application expanded to almost all CYPs inhibitors. Although using O69 or S68 as the coordination centre 
was also attempted, N is always the most common and effective one. 
Steroidal inhibitors. The early designed CYP17 inhibitors are simple combinations of steroidal scaffolds 
and various N containing heterocycles. It has been found that pregnenolone analogues are always more 
potent than the corresponding progesterone ones, which is consistent with the fact that pregnenolone shows 
higher affinity toward CYP17 compared to progesterone. A lot of heterocycles have been introduced onto the 
steroidal scaffold, such as pyridine, pyrimidine, imidazole, triazole, oxazole, thiazole, benzoimidazole and so 
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forth.70 Besides inhibition of CYP17, most of the steroidal inhibitors also show 5α-reductase inhibitors 
and/or affinity toward the androgen receptor. Nevertheless, good selectivity can still be achieved by some 
compounds, especially Abiraterone. 
Abiraterone (Figure 15) is a potent and selective CYP17 inhibitor showing Ki < 1 nM and no interference 
with CYP19 or 5α-reductase.71 The Δ16–17 double bond is believed to be crucial for the inhibitory potency,72 
and it is probably also responsible for the irreversible inhibition manner of Abiraterone. Although the short 
plasma half life (1.6 h) forces a high dose to be applicated (500 mg daily), Abiraterone reduces plasma 
testosterone concentration to less than 0.2 nM in 2 hours after oral administration.73 In the phase II/III 
clinical trials, patients diagnosed with castration resistant prostate cancer showed good responses to 
Abiraterone characterized by the reduce of PSA level and circulating tumor cells (CTC) counts.74 These 
successes further prove the conception of CYP17 inhibition as a treatment for PC and elucidate that PCs 
previously misapprehended as androgen independent are commonly remain hormone driven.74 
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Figure 15. Representative steroidal CYP17 inhibitors. 
Su4075 (Figure 15) and VN124-176 (Figure 15) are CYP17 inhibitors that are even more potent than 
Abiraterone in vitro and in vivo. Besides inhibiting CYP17, VN124-1 also acts as an AR antagonist, down-
regulates AR expression,77 and induces endoplasmic reticulum stress response,78 which are also thought to 
contribute its antitumor efficacy. 
Although many steroidal inhibitors are very potent, the potential drawbacks of these compounds should 
not be ignored: the relative short half life or poor bioavailability, the first pass effect when orally 
administered and the affinity toward steroid receptors which might result in side effects regardless acting as 
agonists or antagonists. 
Non-steroidal inhibitors. Due to the potential shortcomings of steroidal inhibitors described above, it is 
rational and promising to focus the interest on non-steroidal CYP17 inhibitors. Several classes of non-
steroidal compounds have been designed with potent inhibition in vitro or in vivo, and some of them also 
exhibit good pharmacokinetics properties.  
Ketoconazole (Figure 16), as an antimycotic agent showing 
non-selective inhibition toward CYP enzymes, is the first 
medication which has been clinically used in treatment of 
prostate carcinoma as a CYP17 inhibitor. Although withdrawn 
because of side-effects, Ketoconazole shows good curative 
effects,79 which elucidate the feasibility of prostate carcinoma 
treatment via CYP17 inhibition. 
Furthermore, 3-heterocycle substituted pyridines (Figure 17),80 heterocycle substituted carbazoles (Figure 
18),81,82 heterocycle substituted tetrahydronaphthalenes (Figure 19),83,84 pyridyl substituted esters (Figure  
Cl
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N
N
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N
N O
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Figure 16. Structure of Ketoconazole. 
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Figure 17. General structure of 3-heterocycle substituted pyridines and the representative compound. 
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Figure 18. General structure of 3-heterocycle substituted carbazoles and the representative compound. 
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Figure 19. General structure of heterocycle substituted tetrahydronaphthalenes and the representative compounds. 
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Figure 20. General structure of pyridyl substituted esters and the representative compounds. 
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Figure 21. General structure of substituted (1H-imidazol-4-yl)methanols and the representative compounds. 
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Figure 22. General structure of substituted butenyl imidazoles or pyridines and the representative compound. 
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Figure 23. General structure of substituted heterocycle methylene biphenyls and the representative compounds. 
20),85–87 substituted (1H-imidazol-4-yl)methanols (Figure 21),88–90 substituted butenyl imidazoles or 
pyridines (Figure 22)91,92 and substituted heterocycle methylene biphenyls (Figure 23)93–96 have been 
designed, synthesized and bio-evaluated. Although some compounds exhibit good pre-clinical results, no 
compound has been reported to enter into clinical trials. Therefore, more efforts are necessary for non-
steroidal CYP17 inhibitors to identify potential drug candidates. 
1.3 CYP11B2 Inhibition for Diseases related to High 
Aldosterone Levels 
1.3.1 Aldosterone: Physiology and Pathology 
1.3.1.I. Mineralocorticoid Regulating Electrolyte and Fluid Homeostasis 
Since its discovery in 1953, aldosterone has long been considered as the mineralocorticoid in circulation 
only to regulate electrolyte and fluid homeostasis for a long time.97 It is widely accepted that after the 
binding of aldosterone to mineralocorticoid receptor (MR) in epithelial cells of renal collecting ducts, a 
conformational change of MR is achieved. This renders MR to migrate into the cell nucleus and to ultimately 
activate gene transcription modulating the activity of amiloride-sensitive epithelial sodium channel (ENaC). 
As results, sodium and water are retained, thereby leading to the increase of blood volume and consequently 
elevated blood pressure. 
1.3.1.II. Deleterious Effects of High Aldosterone Levels to Heart, Vessels and Kidney 
Nevertheless, recent studies have revealed that aldosterone elicits some additional, non-classic effects on 
vessels, heart, kidney and central nervous system. Accordingly high aldosterone concentration exhibits 
various deleterious effects on its target organs, the severest being on the heart98 (Figure 24). Aldosterone is a 
potent pro-inflammation factor99,100 and is capable of inducing reactive oxygen species (ROS).101 These
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Figure 24. RAAS, regulation of aldosterone secretion and deleterious effects of high aldosterone levels on heart, vessels, kidney and CNS. 
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effects result in vascular fibrosis and vascular endothelium stiffening102 and are thought to be closely related 
to atherosclerosis,103,104 which is a high risk factor for stroke and ischemia related myocardial infarction (MI) 
leading to disability and death. Aldosterone also promotes calcium influx into smooth muscle cells,104 up-
regulates the expression of adrenomedullin and regulator of G protein signaling-2 (RGS2),105 and engenders 
excitatory sympathetic tone106 after acting on CNS. These effects lead to vasoconstriction and, together with 
the aforementioned blood volume increase, finally result into chronic hypertension. Furthermore, excessive 
aldosterone causes cardiac myocyte necrosis, collagen synthesis, and fibroblast proliferation, which results in 
cardiac fibrosis and increase of myocardial stiffness.107,108 These damages are mediated in part via the 
expression of  some genes closely related to cardiac fibrosis, for example: tenascin-X (TNX), urokinase 
plasminogen activator receptor (UPAR) and a disintegrin and metalloprotease with thrombospondin motifs 
(ADAMTS1).105 Consequently, cardiac hypertrophy and ventricular remodelling occur as the outcome of 
severe cardiac fibrosis. Inflammation, chronic hypertension, reperfusion injury, myocardial infarction and 
some other events stimulated by excessive aldosterone all contribute to this pathological process.109,110 The 
ventricular remodeling causes diastolic dysfunction, diminishes contractile capability, reduces stroke volume 
and ultimately results in congestive heart failure (CHF), which often leads to sudden death. Besides heart, 
high aldosterone levels also cause renal vascular fibrosis, glomerular injury, tubular damage and interstitial 
fibrosis.111   
1.3.1.III. Mechanisms of Action — Genomic and Non-genomic 
It is established that the binding of aldosterone frees MR from its chaperone proteins in the cytoplasm, 
such as heat shock protein. The aldosterone–MR complex subsequently translocates into the nuclei assisted 
by actin,112 where various transcriptional coregulators are recruited, such as the histone acetylase CBP/p300, 
the helicase RHA and the Pol II elongation factor ELL,113 to initiate the transcription via chromatin 
remodeling and histone acetylation or methylation.114,115 The targeted genes, such as serum and 
glucocorticoid-regulated kinase (SGK1), epithelial sodium channel (ENaC) and corticosteroid hormone-
induced factor (CHIF), are therefore expressed.116 However, there are some aldosterone effects, especially on 
cardiomyocytes, too rapid to be results of genomic actions.117,118 Thus, these effects are considered to be non-
genomic, including the activation of ERK1/2,119 as well as PKCɛ-mediated direct inhibition of Na+/K+-
ATPase activity and Na+–K+–2Cl− cotransporter activation resulting in [Na+] increase.117 It is intriguing that 
MR, although being a transcript factor, mediates most of the nongenotropic effects of aldosterone, whereas 
only small portion of the nongenotropic effects appear to be MR-independent.120 
1.3.2 CYP11B2, RAAS and Regulation of Aldosterone Biosyntheses 
The biosyntheses of aldosterone initiates from progesterone and involves CYP21 and CYP11B2. As the 
first step, the former converts progesterone into 11-deoxycorticosterone (DOC); whereas CYP11B2 as a 
mitochondrial cytochrome P450 enzyme is crucial due to the subsequently consecutive three steps from 
DOC to aldosterone depends on its catalysis. Aldosterone is mainly produced in adrenal zona glomerulosa, 
where the absence of CYP17 guarantees the abundance of progesterone. Nevertheless, recent studies have 
revealed that the biosyntheses of aldosterone also takes place in heart,121 vessels and some other target 
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tissues122 as well.  
Normally, the secretion of aldosterone is strictly regulated by the negative feedback loop of renin-
angiotesin-aldosterone system (RAAS), as well as the concentration of potassium and ACTH. Any 
disturbances of the balance will result in the abnormality of aldosterone level. Renin is a protease produced 
by juxtaglomerular cells in kidney. Increased renal perfusion pressure, β-adrenergic stimulation, 
prostaglandins, and deficiency of estrogen, all promote the secretion of rennin; whereas elevated levels of 
potassium and angiotensin II (Ang II), as well as α-adrenergic stimulation inhibit it. The circulating rennin 
tailors angiotensinogen into an inactive peptide angiotensin I, which is subsequently converted into Ang II 
catalyzed by angiotensin converting enzyme (ACE). A high concentration of Ang II blocks the rennin 
secretion directly as a small negative feedback loop. After Ang II binds to its receptor AT1R, the syntheses 
and release of aldosterone from the adrenal cortex are stimulated. Moreover, potassium stimulates 
aldosterone secretion directly, which is independent of the effects it casts on renin-angiotensin system.123 
Aldosterone promotes the excretion of potassium resulting in the decrease of alodterone as another negative 
feedback loop. Furthermore, ACTH is the most potent acute aldosterone secretagogue. However, in the long 
term, continuous stimulation leads to a paradoxical decrease of aldosterone secretion.124 
1.3.3 Treatment of High Aldosterone Related Diseases –– State of Art 
Due to the various deleterious effects aldosterone shows on the body, it is necessary and urgent to control 
the high aldosterone level for the patients with related diseases. Two approaches are feasible to prevent 
aldosterone from its deleterious effects: antagonism of MR and blocking aldosterone secretion. For the 
former, MR antagonists have been clinically implemented; while for the latter, targeting RAAS components 
or other regulators is reasonable. Since ACTH involves in the production and release of many other adrenal 
steroids, it is not suitable for this purpose. Two therapies targeting RAAS components are currently 
employed in clinic, namely renin inhibitors and ACE inhibitors; while another promising therapy is still 
under developement –– CYP11B2 inhibitors. 
1.3.3.I. Mineralocorticoid Receptor Antagonists 
As for MR antagonists, such as Spironolactone, Eplerenone, Canrenone and Mexrenone (Figure 25), 
although several clinical trails have demonstrated their improvement on morbidity and mortality of heart 
failure, adverse effects like gynaecomastia and hyperkalemia are common,125 and the severest is the 
possibility of carcinogenesis. Moreover, MR antagonists leave high level of aldosterone unaffected, which 
can leads to further exacerbation of heart dysfunction in a MR independent non-genomic manner.126 
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Figure 25. Typical MR antagonists: Spiromolactone, Eplerenone, Canrenone and Mexrenone. 
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1.3.3.II. Renin Inhibitors 
Early attempts to inhibit renin include monoclonal antibodies and peptide analogues; however, they have 
been discontinued because of immunogenesis and poor oral bioavailability. Aliskiren (Figure 26), as the first 
orally active renin inhibitor, was approved in 2007 for the treatment of hypertension. It is a potent and 
specific human renin inhibitor with a plasma half-life around 24 hours, which is due to its resistance to 
biodegradation by peptidases in intestine and blood.127–129 Later on, some more rennin inhibitors were 
designed with less chiral centers within the cores of piperidine,130–132,136 ketopiperazine133,134 and 3,9-
diazabicyclo[3.3.1] nonene135 (Figure 26). 
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Figure 26. Typical rennin inhibitors. 
1.3.3.III. Angiotensin Converting Enzyme Inhibitors 
Since ACE inhibitors relieve the vasoconstriction irrigated by both Ang II and aldosterone, they are 
exploited in the treatment of hypertension and CHF. Moreover, ACE inhibitors arrest the progress of diabetic 
nephropathy independently from the anti-hypertension effects,137 and therefore are implemented in the 
prevention of diabetic renal failure. The first orally active ACE inhibitor Captopril was approved in 1981. 
Two years later, the first non-mercapto-containing ACE inhibitor enalapril was launched. Despite the huge 
success of ACE inhibitors in the treatment of hypertension, the long-term plasma aldosterone level is only  
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Figure 27. Typical ACE inhibitors. 
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slightly influenced, which is known as “aldosterone escape”,138 probably due to the complicated regulation 
mechanism of aldosterone biosyntheses. The remaining abnormally high aldosterone levels continue to 
impaire many organs. Moreover, renal damage is commonly observed for all ACE inhibitors as a significant 
adverse effect. The reason behind this remains unclear. 
1.3.4 CYP11B2 Inhibition as Treatment for Hypertension, Primary 
Aldosteronism and Congestive Heart Failure  
Since primary aldosteronism, hypertension and congestive heart failure are the most severe diseases 
caused by high aldosterone levels, they are therefore the main indication of CYP11B2 inhibitors. Besides the 
inhibitory potency toward CYP11B2, another important issue in need of being addressed for CYP11B2 
inhibitors is the selectivity against 11β-hydroxylase (CYP11B1), which is the crucial enzyme in the 
production of glucocorticoids, especially cortisol. Since the interruption of cortisol biosyntheses leads to 
severe side effects, the selectivity is therefore considered as an important safety criterion. However, this task 
is indeed challenging due to more than 93% homology between these two enzymes.  
1.3.4.I. Fadrozole, Etomidate, Metyrapone and their Derivatives 
Early identified CYP11B2 inhibitors such as Fadrozole, Etomidate and Metyrpone (Figure 28) are very 
potent (IC50 < 10 nM), but lack of selectivity. Some of them even favor CYP11B1. As for compounds with 
chiral center, R- and S-enantiomers are proven to show different selectivity, for example: R-enantiomer of 
Fadrozole (FAD286) shows a selectivity factor (SF, IC50 CYP11B1 / IC50 CYP11B2) of 20, whereas that of S-
enantiomer is only 0.23. Moreover, recent in vivo studies elucidate that FAD286 can significantly reduce 
plasma aldosterone level,139 and thus improve cardiac haemodynamics, as well as cardiac function in rats 
with heart failure.140 Encouraged by the proof of conception, enormous modifications were carried out 
sustaining 1-benzyl-1H-imidazole –– the common sub-structure of Fadrozole and Etomidate –– as the 
fundamental scaffold. Four optimizing approaches were implemented: a) directly introducing substituents 
onto phenyl and / or imidazolyl moieties; b) replacing phenyl and / or imidazolyl with other aryl or N-
containing heterocycle, respectively; c) fusing various cycles (aliphatic, aromatic or heterocycle) onto 
imidazolyl; d) inserting substituents onto the methylene bridge, which can further annulate with each other or 
phenyl group to yield spiral compounds. These approaches, which were employed solely or in combination 
lead to many potent CYP11B2 inhibitors.141,142 
1.3.4.II. Heterocycle Substituted Methylene Tetrahydronaphthalene or Dihydroindene 
This is a series of potent (IC50 < 10 nM) and selective (SF > 100) CYP11B2 inhibitors originally identified 
by screening the focus library of inhibitors for other CYP enzymes (Figure 29). It is interesting that Z-
isomers are more potent than corresponding E-isomer.143,144 
1.3.4.III. Pyridyl Naphthalenes and Indenes: Semi-unsaturation and Heteratom Inserting 
Annulating the exocyclic double bond of pyridyl methylene dihydroindene into a new cycle condensing to 
the phenyl ring and removing the original aliphatic ring lead to pyridyl naphthalenes (Figure 30).145,146  
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Figure 28. Fadrozole, Etomidate, Metyrapone and their derivatives. 
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Figure 29. Heterocycle substituted methylene tetrahydronaphthalene or dihydroindene 
Although the resulting compounds are very potent and selective, they interfere with CYP1A2, which is an 
important hepatic CYP enzyme involved in the metabolism of many drugs. Since planer structure is an 
important feature of CYP1A2 substrates, it is feasible to reduce CYP1A2 inhibition of these compounds by 
increasing the flexibility of the whole molecule. Therefore, the naphthalene core was semi-unsaturated either 
at the left or the right side. Simultaneously, a ring size shrinkage was performed leading to indenes (Figure 
31). 145,146 After careful optimization, the CYP1A2 inhibition of synthesized compounds is significantly 
reduced, whereas the potency and selectivity are increased at the same time.147 Further modification by 
inserting heteratom into the molecule resulting in pyridyl indoles148 and dihydroquinolinones149,150 not only 
benefits inhibitory potency and selectivity, but also increases the water solubility and improves the  
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Figure 30. Design conception of pyridyl naphthalenes. 
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Figure 31. Optimization of pyridyl naphthalenes and indenes: semi-unsaturation and heteratom inserting. 
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Figure 32. Optimization of pyridyl naphthalenes: benzyl substitution on naphthalene core, substituents on pyridine and 
replacement of pyridyl by isoquinolinyl. 
pharmacokinetic properties.149 The optimizations also provide information pertaining to the enzyme 
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hydrophobic pocket. It has been found there is an extra pocket near where the core placed, which can be 
utilized by a benzyl group (Figure 32).150 Moreover, spar space is also identified around pyridyl, which is 
large enough to tolerate an additional direct connected or fused phenyl moiety.147,149,150 After such 
optimizations are applied, potent and selective CYP11B2 inhibitors with good pharmacokenitic properties 
are obtained, which are promising drug candidates for the treatment of diseases related to high aldosterone 
levels. 
1.4 Dual Inhibition 
The use of selective multi-target-directed ligands has already been proposed for the treatment of 
complicated diseases in order to enhance efficacy and to improve safety, for example, agents inhibiting 
angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) in the treatment of hypertension, 
multi-kinase inhibitors (MKI) with combined inhibition of vascular endothelial growth factor (VEGF), and 
platelet-derived growth factor (PDGF) for cancer therapy and dual binding site acetylcholinesterase 
inhibitors (AChEI) for Alzheimer’s disease.151–154 Compared to the traditional combinational application of 
two or more drugs, multi-target-directed agents can reduce the risk of drug–drug interactions and achieve 
better compliance. 
1.4.1 Dual CYP17 / CYP11B1 Inhibition for Prostate Cancer Treatment 
After the application of CAB, a major portion of patients becomes “castration resistant”, which might be 
caused by androgen receptor mutations, such as T877A and W741C.52 These mutated androgen receptor can 
be activated by glucocorticoids, especially cortisol, and thus continue to stimulate cancer cell proliferation53 
thereby resulting in the collapse of CAB.  
Moreover, since small cell anaplastic prostate carcinoma, which is usually concurrent with normal prostate 
adenocarcinoma, originates from neuro-endocrine cells, it is capable of ectopic ACTH production.155 The 
elevated ACTH levels promote adrenals to synthesize and release high concentrations of cortisol leading to 
Cushing’s syndrome,156–158 diabetes mellitus, osteoporosis, hypertension and obesity. For patients under 
CAB therapy, high cortisol levels, yet with a low concentration of androgen, probably induces the AR 
mutation exploiting cortisol as substrate; the high cortisol levels are therefore considered as a sign of PC 
progression in clinc.156 Importantly, some patients die of severe infections largely due to the immuno-
suppression caused by the glucocorticoid.157,158  
Hence, for these patients the control of cortisol concentration is urgently needed. As the key step in the 
biosynthesis of this hormone is catalyzed by CYP11B1 (Figure 5), additional inhibition of this enzyme could 
be a substantial way to improve curative effects, relieve symptoms, and increase survival of prostate cancer 
patients.  
Antimycotic Ketoconazole (Figure 16) has already been employed to treat prostate cancer patients with 
ectopic adrenocorticotropic hormone syndrome158 because it inhibits both androgen and corticosteroid –– not 
only glucocorticoid but also mineralocorticoid –– biosynthesis. However, the response was not satisfactory 
due to the weak potency of Ketoconazole (CYP17 IC50 = 2780 nM). Metyrapone (Figure 28) as the 
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medication being employed in clinic for the treatment of Cushing’s syndrome does not show enough 
selectivity over other steroidogenic CYP enzymes and therefore exhibits severe side effects. Accordingly it is 
not an appropriate candidate for combined application with CYP17 inhibitors. Therefore, it is necessary and 
urgent to design dual CYP17 / 11B1 inhibitors.  
The application of CYP17 inhibitors with different selectivity profiles should adhere to the status of the 
patients. For normal patients, selective CYP17 inhibitors that do not interfere with other steroidogentic CYPs 
should be used to avoid side effects, whereas for patients with mutated androgen receptors or ectopic 
adrenocorticotropic hormone syndrome, dual inhibitors of CYP17 and CYP11B1 are the best choice in the 
view of a personalized medicine. 
1.4.2 Dual CYP19 / CYP11B2 Inhibition to Cure Cardiovascular Diseases in 
Breast Cancer Patients 
In the western countries, breast cancer (BC) is the carcinoma with the highest morbidity in female. 
Although BC is still the second leading cause of death, the mortality is significantly reduced because of the 
cancer screening to identify cases in early stages159 and, more importantly,  the employment of adjuvant 
endocrine therapy. Endocrine therapy is based on the fact that estrogen stimulates the growth of “hormone 
sensitive” breast cancer, in which estrogen receptor (ER) and / or progesterone receptor (PgR) are 
expressed.160 Therefore, deprivation of estrogen is a feasible treatment for the hormone sensitive BC, which 
accounts for more than 60% of all cases. Several decades ago, selective estrogen receptor modulators 
(SERM),161 such as Tamoxifen and Raloxifen (Figure 33), were introduced into the clinic. These SERMs 
competitively bind to ER antagonizing transcription and the subsequently mitogenic effects. However, the 
poor risk / benefit profiles prevented Tamoxifen from continuous application for more than five years. 
Moreover, severe toxicities such as endometrial cancer and thrombosis were observed.162 On the contrary, 
the third generation aromatase inhibitors (AI), such as, Anastrozole, Letrozole and Exemestane (Figure 33), 
exhibited better efficacy and tolerability compared to Tamoxifen, which rendered AIs to become the first 
choice as first-line and adjuvant therapy for postmenopausal women –– the majority of breast cancer patients. 
Aromatase (CYP19) is the crucial enzyme catalyzing the final aromatization of steroidal A-ring in the 
biosynthesis of estrogen from corresponding androgen precursors: testosterone and androstenedione. 
Inhibition of CYP19 can totally block estrogen production and consequently prevent BC cells from 
proliferation. After the administration of the third generation AIs, the plasma estrogen concentration can 
even be reduced to an undetectable level.163,164 Several clinic trials demonstrated AIs as an adjuvant therapy 
significantly improved disease-free survival and relapse-free survival with the overall survival rate increased 
accordingly.165–168  
However, it has been revealed that only around 40% of the patients, who did not survive, eventually died 
of BC,169 which means a lot of people survive BC, yet perish of other diseases, especially patients older than 
70 years old, among whom non-BC specific deaths accounted for 72% of total deaths.169 Since 
cardiovascular diseases (CVD) have been identified as a statistically significant risk factor and a major cause 
of non-BC specific deaths,169 it is necessary and urgent to manage CVD to prolong longevity of BC patients  
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Figure 33. Structures of selective estrogen receptor modulators: Tamoxifen and Raloxifen; and aromatase inhibitors: Anastrozole, 
Letrozole, Fadrozole and Exemestane. 
and to improve the overall survival.  
Recently, estrogen has been proven to exhibit some protective effects on heart170–176 and kidney.177 The 
administration of estrogen prevents the development of heart failure post-myocardial infarction174 and 
attenuates ventricular hypertrophy and remodelling.175,176 Moreover, the fact that the incidences of CVD in 
post-menopausal women triple those of premenopausal women at the same age178,179 indicates the deficiency 
of estrogen is closely correlated with CVD. For post-menopausal BC patients under endocrine therapy, AIs 
further decrease the estrogen production to rather low levels leading to an even higher risk of CVD. The 
ischemic side effects observed in AIs clinic trials were considered as results of lipid metabolism dysfunction 
due to estrogen deficiency.180–185 This disturbance of lipid metabolism by AIs has been noticed and can be 
managed with antihyperlipidemic agents.182,183 However, the up-regulation of RAAS, especially aldosterone 
–– another severe aftermath of estrogen deficiency186,187 and an important cause of CVD simultaneously –– 
was still neglected. It has been established that the depletion of estrogen not only directly increases the 
circulating aldosterone level, but also augments the concentrations of other RAAS components, such as 
rennin, Ang II, ACE and the angiotensin type 1 receptor (AT1R), which further elevate aldosterone 
biosynthesis.188–193 Moreover, estrogen deficiency also increases the potassium plasma concentration 
resulting in promotion of aldosterone secretion in return.194,195 The consequent abnormity of high aldosterone 
level exhibits deleterious effects on kidney, vessels, brain and heart (Figure 24).  
Therefore, reducing the high plasma aldosterone concentration rendered by estrogen deficiency is an 
effective treatment for the cardiovascular diseases in BC patients. Because aldosterone synthase (CYP11B2) 
catalyzing the conversion of 11-deoxycorticosterone to aldosterone is the key enzyme in aldosteron 
biosynthesis, the inhibition of CYP11B2 is a superior means to reduce the aldosterone levels. Since AIs as an 
adjuvant therapy have to be applied for at least 5 years and there are no selective CYP11B2 inhibitors in 
clinic use, it is therefore necessary to design selective dual inhibitors of CYP19 / 11B2.  
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2 Work Strategy 
As described above, various steroidogenic CYP enzymes are promising targets for the treatment of some 
complicated diseases: CYP17 inhibition for prostates cancer, CYP19 inhibition for breast cancer, CYP11B2 
inhibition for diseases related to high aldosterone levels, and CYP11B1 inhibition for Cushing’s syndrome. 
2.1 Inhibitors Design 
2.1.1 General 
2.1.1.I. Mechanism Inactivator or Reversible Inhibition via N–Fe Coordination 
Although mechanism inactivators only inhibit the enzymes after being metabolized to give the reactive 
intermediates, which might be advantageous for the selectivity, the in vivo tests and clinical studies revealed 
that they are not effective enough.66 On the contrary, reversible inhibition via N–Fe coordination is proven to 
be much more potent in vitro and vivo in blocking the production of corresponding steroidal hormanes, 
especially some CYP19 inhibitors currently in clinical use, which could thus reduce the estrogen levels to 
under detectable limits. Therefore, the N–Fe coordination is implemtented to design steroidogenic CYP 
enzymes inhibitors. 
2.1.1.II. Steroidal or Non-steroidal 
Although lots of steroidal inhibitors are very potent, especially Abiraterone for CYP17 inhibition, the 
potential drawback of these compounds can not be neglected: the relative short half life or poor 
bioavailability, the first pass effect when orally administered  and the affinity toward steroid receptors which 
might result in side effect regardless acting as agonists or antagonists. These shortcomings render non-
steroidal inhibitors more promising. 
2.1.1.III. Multi-targeting and Selectivity 
It has been found that almost all CYP enzymes inhibitors comprise two parts: N-containing heterocycle to 
interfere with the heme iron and hydrophobic core. This common feature provides the possibility of multi-
targeting, but also denotes the selectivity as a challenging goal.  
2.1.2 Combination of Ligand and Structure Approaches 
The design of CYPs inhibitors mainly bases on the previously identified leads via the ligand approach. The 
SARs obatained in the early studies are employed as good guides. Systematic optimizations on all 
topological directions are performed to improve inhibitory potency and selectivity and also with the aim to 
probe amino acid residues surrounding. Moreover, since almost no crystal structures of human steroidogenic 
CYP enzymes are available (the first and only one solved is CYP192), homology models of CYP17 and 
CYP11B2 are built based on multi-templates of CYP enzymes. After docking the synthesized compounds 
into the model, information of interactions between inhibitors and amino acids comprising the pocket is 
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obtained, which provide clues in further drug design.  
2.1.3 Other Considerations: Drug-Like Properties, Solubility and Metabolic 
Stability 
Besides pursuing the maximization of inhibitory potency, the drug-like properties are also considered 
when designing inhibitors. A principle on drug-like properties is known as “Lipinski's Rule of Five”, which 
is summarized from many orally active drugs and is an important guideline to design compounds with good 
pharmacokinetic properties, including absorption, distribution, metabolism and excretion. As a orally active 
compound, it contains no more than 5 hydrogen bond donors and no more than 10 hydrogen bond acceptors; 
the molecular weight is usually under 500 dalton and the octanol-water partition coefficient (log P) is less 
than 5. Furthermore, the water solubility is also taken into consideration due to it is important in drug 
formulation and absorption. Moieties or substituents might vulnerable to metabolism are concealed as well. 
2.2 Syntheses 
The design of synthetic routes follows “EOS” (easy of syntheses) principle trying to facilitate the future 
industrial production and reduce costs. For series of derivatives, common building blocks are used as 
frequently as possible, and diversification is attempted to achieve only in the last step. 
2.3 Biological evaluation 
The synthesized compounds are firstly tested for the inhibition of their targeting CYP enzyme(s). Only 
potent inhibitors (IC50 < 100 nM) will be further tested for the selectivity over other steroidogenic CYP 
enzymes (CYP17, CYP19, CYP11B1 and CYP11B2; sometimes CYP11A1 as well) and hepatic CYP 
enzymes (most frequently for CYP3A4, but CYP1A2, CYP2C9, CYP2D6, CYP2C19 as well). Subsequently, 
inhibition against enzymes from rat or other species is evaluated as the basis of in vivo test. As for in vivo 
studies, besides pharmacokinetic data obtained in health animals, the promising drug candidates are also 
evaluated in further disease models.   
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3 Results and Discussions 
The design, syntheses and bio-evaluation of CYP17 inhibitors, CYP11B2 inhibitors as well as dual 
inhibitors of CYP17 / 11B1 and CYP19 / 11B2 are described in detail as following: 
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Paper I 
 
Abstract: Thirty-five novel substituted imidazolyl methylene biphenyls have been synthesised as CYP17 
inhibitors for the potential treatment of prostate cancer. Their activities have been tested with recombinant 
human CYP17 expressed in E. coli. Promising compounds were tested for selectivity against CYP11B1, 
CYP11B2 and hepatic CYP enzymes 3A4, 1A2, 2B6, and 2D6. The core rigidified compounds (30–35) were 
the most active ones, being much more potent than Ketoconazole and reaching the activity of Abiraterone. 
However, they were not very selective. Another rather potent and more selective inhibitor (compound 23, 
IC50 = 345 nM) was further examined in rats regarding plasma testosterone levels and pharmacokinetic 
properties. Compared to the reference Abiraterone, 23 was more active in vivo, showed a longer plasma half-
life (10 hours) and a higher bioavailability. Using our CYP17 homology protein model, docking studies with 
selected compounds were performed to study possible interactions between inhibitors and amino acid 
residues of the active site. 
 
Keywords: prostate cancer, 17α-hydroxylase-17,20-lyase (CYP17) inhibitors, pharmacokinetic studies, 
testosterone plasma concentrations. 
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1. Introduction 
It has been illuminated that the growth of up to 80% of prostate carcinoma, the most common malignancy 
and cause of death for male elders, depends on androgen stimulation. Thus, inhibition of androgen formation 
or prevention of androgens unfolding activity will effectively prevent cancer cell proliferation. Currently the 
standard therapy for prostate carcinoma is the so called “combined androgen blockade” (CAB), which means 
orchidectomy or treatment with gonadotropin-releasing hormone (GnRH) analogues (chemical castration) 
combined with androgen receptor antagonists.1 Anti-androgens are used to prevent adrenal androgens which 
are not affected by the former strategies from unfolding stimulatory effects. However, CAB often leads to 
resistance which can be associated with androgen receptor mutations. The mutated androgen receptor 
recognizes antagonists as agonists, and the efficiency of this therapy is whittled away. Total blockage of the 
androgen biosynthesis could be a more promising alternative, which brings CYP17 and its central role in the 
androgen biosynthesis into focus. CYP17, located in both testicular and adrenal tissue,2 is the key enzyme 
catalyzing 17α-hydroxylation and subsequent C17–C20 bond cleavage of pregnenolone and progesterone to 
form DHEA and androstenedione, which are then converted to testosterone and DHT.3 
Chart 1. Structures of typical CYP17 inhibitors. 
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From Ketoconazole, the first medication which has been used clinically as CYP17 inhibitor, to 
Abiraterone which entered into phase II clinical trial very recently, several types of CYP17 inhibitors have 
been synthesised and tested (representative structures are shown in Chart 1). Almost all the inhibitors, 
steroidal or non-steroidal, are mimics of the natural substrates pregnenolone and progesterone. Although lots 
of steroidal inhibitors are very potent,4 especially Abiraterone,5 the potential drawback of these compounds 
should not be ignored: the relative short half-life or poor bioavailability,6 the first pass effect when orally 
administered7 and the affinity toward steroid receptors which might result in side effect no matter acting as 
agonists or antagonists. All of these shortcomings indicated the necessity to develop non-steroidal CYP17 
inhibitors. In the past decade, a wide variety of non-steroidal compounds has been described, the most 
important of these were tetrahydronaphthalenes (A),8 m-pyridinyl substituted esters (CB7645 and C),9 1H-
imidazol-4-yl substituted alcohols (D and E)10 and 1-(m-pyridinyl)-3-phenyl substituted heterocycles (B).11 
Our group has reported a series of imidazolyl and triazolyl substituted biphenyls as potent CYP17 
inhibitors.12 Recently heterocyclic modifications of the core structure were performed with the more 
promising biphenyl methylene imidazoles. They have been published recently as part I of a study to further 
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improve biological properties.13 In the present paper modifications such as the introduction of different 
substituents at the methylene bridge as well as the A-ring and core rigidifications have been made leading to 
compounds 1–35 (general structures shown in Chart 2). Besides the syntheses and the determination of 
inhibitory activities toward human CYP17, the inhibitions of selected compounds against CYP11B1, 
CYP11B2 and hepatic CYP enzymes 3A4, 1A2, 2B6 and 2D6 are described. Furthermore, compound 23, as 
the most selective inhibitor, was examined for its potency of reducing plasma testosterone concentration and 
its pharmacokinetic properties in rats. Moreover, molecular docking studies with both enantiomers of 
selected compounds, if existing, were carried out using our homology model of CYP1713 for getting a closer 
insight into the interaction between active site amino acids and the ligands. 
Chart 2. General structures of synthesised compounds 1–35. 
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2. Chemistry 
For the synthesis of compounds 1–10 and 12–35 (Scheme 1–7), basically the following strategy was used: 
the corresponding ketone or aldehyde intermediates were obtained commercially or synthesised by Suzuki 
coupling (Method C) from the corresponding bromides and boronic acids.14 Subsequently they were 
converted to the alcohols by reduction with NaBH4 (Method D) or Grignard reaction (Method B). The 
Scheme 1.a  
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a Reagents and conditions: (i) Method C: Pd(PPh3)4, Na2CO3, toluene/ EtOH/ H2O, reflux, 16h. 
 
Scheme 2. a 
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23a-25a, 28a-29a
1b, 12b-20b,
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Compd. R1 R2 R3 R4
9 H phenyl H H
10 H biphenyl H H
12 OCF3 Et H H
13 SMe Et H H
14 CN Et H H
15 Me Et H Et
16 Et Et H Et
17 N(Me)2 Et H H
Compd. R1 R2 R3 R4
18 N(Et)2 Et H H
19 morpholino Et H H
20 NHBoc Et H H
23 F Et H Et
24 F Me Me Me
25 F Et Et Et
28 F CH=CH2 H H
29 H CH=CH2 H H
Compd. R1 R2 R3 R4
1 H Et H H
2 H n-Pr H H
3 H i-Pr H H
4 H n-Bu H H
5 H i-Pr H H
6 H t -Bu H H
7 H cyclohexy H H
8 H benzyl H H
OR or (iii)
 
a Reagents and conditions: (i) Method C: Pd(PPh3)4, Na2CO3, toluene, reflux 6h. (ii) Method D, 15b-16b, 23b: NaBH4, MeOH. (iii) 
Method B, 1b, 12b-14b, 17b-20b, 24b, 25b, 28b, 29b: corresponding Grignard reagent, THF. (iv) Method A: CDI, NMP. 
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Scheme 3. a 
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a Reagents and conditions: (i) TBSCl, Imidazole. (ii) Method C: 4-formylphenylboronic acid, Pd(PPh3)4, Na2CO3, toluene, reflux 6h. 
(iii) Method B: EtMgBr, THF. (iv) Method A: CDI, NMP. (v) TBAF, THF, room temp. 
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a Reagents and conditions: (i) Method C: Pd(PPh3)4, Na2CO3, toluene, reflux 6h. (ii) Method D: NaBH4, MeOH. (iii) Method A: CDI, 
NMP, reflux, 3h. (iv) TBAF, THF (v) SOCl2, DCM. 
 
Scheme 6. a 
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a Reagents and conditions: (i) Method D: NaBH4, MeOH. (ii) Method A: CDI, NMP, reflux, 3h. (iii) TBSCl, imidazole.  (iv) TBAF, 
THF. 
alcohol intermediates were reacted with 1,1-carbonyl diimidazole (CDI) (Method A), in a SNt reaction, to 
give the racemic mixtures of the desired products,15 which were tested for their inhibitory potencies without 
further separation. In the case of some sensitive intermediates, certain protecting groups were employed and 
subsequently removed: tert-butyldimethylsilyl (TBDMS) or tert-butyldiphenylsilyl (TBDPS) for hydroxy 
groups and tert-butoxycarbonyl (Boc) for amino groups. The conversion of the hydroxy compound 26 to the 
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chloro compound 27 was achieved using SOCl2 (Scheme 5). In some cases, the carbazole core was 
constructed by ring closure of the o-nitro substituted biphenyl refluxed with phosphorous acid triethyl ester 
(Scheme 7). The only exception from this strategy was the synthesis of compound 11 (Scheme 1). This 
compound was simply prepared from 1-(4-bromobenzyl)-1H-imidazole and 4-trifluoromethylphenylboronic 
acid by means of Suzuki coupling (Method C). 
Scheme 7. a 
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a Reagents and conditions: (i) Method C: Pd(PPh3)4, Na2CO3, toluene, reflux 6h. (ii) P(OEt)3, reflux. (iii) Method D: NaBH4, THF, 
MeOH. (iv) Method A: CDI, NMP, reflux, 3h. 
3. Biological Results, Modelling Studies and Discussion 
CYP17 inhibition of all compounds was evaluated using the 50,000 sediment after homogenation of E.coli 
expressing human CYP17 as well as cytochrome P450 reductase.12d The assay was run with progesterone (25 
µM) as substrate and NADPH as cofactor. Separation of substrate and product was accomplished by HPLC 
using UV detection.16a IC50 values are presented in comparison to Ketoconazole and Abiraterone in Tables 
1–4. 
Table 1. Inhibition of CYP17 by compounds 1–10 
N
R2
N
1 - 10  
Compd R2 CYP17 IC50 [nM]b  Compd R2 CYP17 IC50 [nM]b 
Ref. 1 Me 910  6 t-Bu 460 
1 Et 450  7 Cyclohexyl 1050 
2 n-Pr 580  8 Benzyl 780 
3 i-Pr 310  9 Phenyl 790 
4 n-Bu 300  10 Biphenyl 2300 
5 i-Bu 2100     
KTZa  2780  ABTa  72 
a KTZ: Ketoconazole; ABT: Abiraterone. 
b Concentration of inhibitors required to give 50% inhibition. The given values are mean values of at least three experiments. The 
deviations were within ±10%. 
Inheriting from Ref. 1,12b the influence of different substituents on the methylene bridge was investigated 
(Table 1). From the inhibitory activity values, it becomes apparent that increasing the length of R2 would 
largely influence the potency. The introduction of two-carbon alkyl substituents, like Et (1), and even more 
bulky ones like i-Pr (3) and t-Bu (6), increased the potency of the compounds compared to Ref. 1 (IC50 = 910 
nM), resulting in inhibitors with IC50 values in a range from 300 to 450 nM. Interestingly, the further 
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prolongation of the alkyl chain by another carbon atom led to moderate (2, R2: n-Pr, IC50 = 580 nM) or low 
active inhibitors (5, R2: i-Bu, IC50 = 2100 nM).  However, adding another C atom to the alkyl R2 gave again 
a very potent compound (4, R2: n-Bu, IC50 = 300 nM). Furthermore, it could be observed that the activity of 
the compounds with a bulky group was reduced dramatically as expected, like benzyl, phenyl (8 and 9 with 
IC50 values around 800 nM), cyclohexyl (7, IC50 = 1050 nM) and biphenyl (10, IC50 = 2300 nM). 
In the modelling studies, it was observed that all docked compounds showed two binding modes, named 
BM1 and BM2, which were identified previously for other biaryl type inhibitors.13,17 These binding modes 
are different from the proposed substrate binding mode.18–19 In BM1 the biaryl plane is oriented almost 
parallel to the I-helix and principally ligands bearing a R1-substitutent were found in this mode (in Figure 1 
compound 22 is taken as an example). The substituted A-ring is located next to a polar pocket18 delimitated 
by Arg109, Lys231, His235 and Asp298 which tolerates different substitution patterns. On the other hand, in 
BM2 the biaryl plane crosses the I-helix, avoiding the interaction with the polar pocket. It is a less 
permissive binding mode, which tolerates only planar ligands with an un- or fluorine substituted A-ring 
(compound 2 in Figure 1). 
Nonetheless, for both binding orientations similar hydrophobic and π-π interactions can be observed,13,17 
namely between the biphenyl core and Phe114 as well as between the biphenyl moiety and apolar parts of 
amino acids of the F-helix (Asn 202, Ile206) and I-helix (Gly301, Ala302, Val304, Glu305) (Figure 1). 
 
Figure 1. Presentation of the two found binding modes BM1 and BM2, exemplified by compounds 22 (magenta, BM1) and 2 
(yellow, BM2). Furthermore, heme, interacting residues and ribbon rendered tertiary structure of the active site are shown. Figures 
were generated with Pymol (http://www.pymol.org). 
Compounds 1, 2, 4, 5, 6 and Ref. 1 were docked into our CYP17 model with the aim of explaining the 
influence of the different R2 substituents. For all R-enantiomers bearing a short alkyl substituent (Et, i-Pr, t-
Bu or Me) at the methylene bridge, the preferred binding mode was BM1; whereas for the corresponding S-
enantiomers, BM2 seemed to be the most probable. Based on the requisites for each binding mode,13,17 both 
orientations seem to be possible for compounds 1, 6 and Ref. 1. On the other hand, although poses in BM2 
could also be observed, the preferred orientations for compounds 2, 4 and 5 seems to be BM1, regardless 
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which enantiomer was considered. This might be caused by the presence of a longer and bulkier substituent 
on the methylene bridge. 
The results revealed an orientation of the R2 group toward a tiny hydrophobic pocket, formed by amino 
acids Ala367-Pro368-Met369-Leu370-Ile371 (Figure 2A). Et, i-Pr and t-Bu substituents can undergo 
hydrophobic interactions with this apolar environment close to the heme without steric clashes due to their 
reduced length. However, for compounds 2 (n-Pr) and 5 (i-Bu) steric hindrance and hydrophobic repulsion 
perish the possibility of additional hydrophobic interactions, thus reducing their inhibitory potencies. As for 
compound 4, the results indicate that the n-Bu group can interact not only with amino acids Ile371 and 
Ala367, like n-Pr does, but also with Val366, Pro368 and Val382 as additional contacts. This leads to the 
stabilization of its orientation, and makes it a potent inhibitor (Figure 2A). 
 
Figure 2. A cross-section of the solvent accessible surface of the active site is given with a A) closer look to the orientation of the R2 
methylene linker substituents (compounds 2 (light blue), 4 (green), 5 (magenta), 6 (violet), 23 (orange) and 27 (yellow)) with their 
surrounding amino acids and a B) more in-depth view of the A-ring substituents (compounds 30 (cyan), S-23 (yellow), R-22 
(magenta) and ref. 1 (R; green) and interacting residues. 
It can also be observed that different R1 substituents on the A-ring show a strong influence on the activity 
of the imidazole substituted biphenyls. Exhibiting the same ethyl group at the methylene bridge, the A-ring 
substi tut ion dispersed the inhibitory potency of the corresponding compounds strongly 
ranging from no to strong inhibition (Table 2). It becomes apparent that hydrophobic and electronegative 
groups in R1 led to almost inactive compounds. However, when R1 is a small polar substituent, capable of H-
bond formation, the compounds turned out to be very active (22, R1 = OH, IC50 = 375 nM; 23, R1 = F, IC50 = 
345 nM). 
Docking of both enantiomers of ligands 22 and 23 into the active site of our CYP17 model revealed BM1 
is preferred for S-22, R-22 and R-23. There is obviously hydrogen bond formation between R1 and the polar 
surrounding of Arg109, Asp298, Lys231 and His235 (Figure 2B). However, the S-enantiomer of compound 
23 was found to bind in BM2 as long as the small H-bond accepting fluorine group can interact with Gln199 
and Asn202 (Figure 2B). 
As it is known that fluorine compounds are more stable in vivo than hydroxy compounds, R1 was 
sustained to be fluorine and the influence of substituents at the methylene bridge was further investigated 
(Table 3). Interestingly, the single ethyl group turned out to be the best, while twin alkyl substituted 
analogues (24–25) showed lower inhibitory potency than their single substituted analogues (23, Ref. 2). This 
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is obviously due to the steric clashes with amino acids of the I-helix kink and the reduced flexibility of these 
ligands. Moreover, the similar activity of compound 27 (2-chloroethyl, IC50 = 756 nM) and compound 2 (n-
Pr) and the total loss of activity for the 2-hydroxylethyl analogue (26) demonstrate the necessity of a 
hydrophobic side chain on the methylene bridge. 
Table 2. Inhibition of CYP17 by compounds 11–23 
N
R2
N
11 - 23R
1
 
Compd R1 R2 CYP17 IC50 [nM]b  Compd R1 R2 CYP17 IC50 [nM]b 
11 CF3 H >5000  18 N(Et)2 Et >>5000 
12 OCF3 Et >5000  19 morpholino Et 2200 
13 SMe Et 3100  20 NHBoc Et 1700 
14 CN Et >5000  21 NHAc Et >5000 
15 Me Et >5000  22 OH Et 375 
16 Et Et 2000  23 F Et 345 
17 N(Me)2 Et >>5000      
KTZa   2780  ABTa   72 
a KTZ: Ketoconazole; ABT: Abiraterone. 
b Concentration of inhibitors required to give 50% inhibition. The given values are mean values of at least three experiments. The 
deviations were within ±10%. 
Table 3. Inhibition of CYP17 by compounds 23–29 
N
R2
N
R1
R3
23 - 29
 
Compd R1 R2 R3 CYP17 IC50 [nM]b  Compd R1 R2 R3 CYP17 IC50 [nM]b 
Ref. 2 F Me H 1100  26 F (CH2)2OH H >5000 
23 F Et H 345  27 F (CH2)2Cl H 756 
24 F Me Me 3800  28 F CH=CH2 H >5000 
25 F Et Et 1300  29 H CH=CH2 H 1400 
KTZa    2780  ABTa    72 
a KTZ: Ketoconazole; ABT: Abiraterone. 
b Concentration of inhibitors required to give 50% inhibition. The given values are mean values of at least three experiments. The 
deviations were within ±10%. 
Rigidification of the biphenyl core to form a carbazole or 9H-fluorene ring (Table 4) led to the most potent 
series of compounds (30–35). The planar conjugated scaffolds apparently contributed most to the inhibitory 
potency, probably due to the reduced degrees of freedom. Once again, inhibitors furnished with groups 
capable of forming hydrogen bonds turned out to be more active, with the hydroxy substituted 9H-fluorene 
analogue (30) being the most potent compound of this study (IC50 = 99 nM, 28 fold more potent than 
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Ketoconazole). Moreover, the importance of an alkyl substituent on the spacer has been demonstrated again, 
as can be seen from the higher activity of the methyl compound 32 showing IC50 of 112 nM (for this 
compound IC50 of 4 nM is reported23) compared to the corresponding non-substituted analogue 31 (IC50 = 
388 nM).  
Table 4. Inhibition of CYP17 by compounds 30–35 
N
R5
N
R4
X
30 - 35  
Compd R4 R5 X CYP17 IC50 [nM]b  Compd R4 R5 X CYP17 IC50 [nM]b 
30 OH Me CH2 99  33 F Me CH2 168 
31 H H CH2 388  34 H Me NH 282 
32 H Me CH2 112c  35 F Me NH 118 
KTZa    2780  ABTa    72 
a KTZ: Ketoconazole; ABT: Abiraterone. 
b Concentration of inhibitors required to give 50% inhibition. The given values are mean values of at least three experiments. The 
deviations were within ±10%. 
c IC50 = 4 nM, reported in reference 23. 
 
Figure 3. Docking complex between CYP17 and compounds 30 (cyan), S-23 (yellow), R-22 (magenta) and ref. comp. 1 (R; green). 
Heme, interacting residues and ribbon rendered tertiary structure of the active site are shown. 
For the docking studies of selected compounds from Table 4 (30, 32 and 35), similar results were achieved 
as obtained for the non-rigidified compounds. Two binding modes, BM1 and BM2, were identified. The 
former seemed to be preferred,  based on the internal  energies of the docked inhibitors  
and the visual inspection of possible interactions, regardless which enantiomer was considered. The same H-
bond interactions were found as described above (Figure 1, Figure 2B). Moreover, the poses were also 
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stabilized by the electrostatic interactions with carbon chain of Glu305 (Figure3). 
The inhibition of selected compounds toward hepatic CYP enzymes was determined (Table 5), because of 
their important role in drug metabolism and drug-drug interaction. Although the compounds tested showed 
inhibition of CYP3A4, it was lower than that of Ketoconazole. Interestingly, compound 20 showed only little 
inhibition (52% at 1 µM), possibly due to the bulky t-Boc amino group it bears. However, CYP1A2 
inhibition shown by the test compounds was much higher than that of Ketoconazole. Compounds 23 and 27 
showed good selectivity toward CYP2B6 and 2D6. 
Table 5. Inhibition of hepatic CYP enzymes by selected compounds. 
CYP % Inhibitionb CYP % Inhibitionb 
Compd 
3A4 1A2 2B6 2D6 
 Compd
3A4 1A2 2B6 2D6 
20 52 n.d.a n.d.a n.d.a  30 89 93 n.d.a n.d.a 
23 88 97 46 54  32 89 98 n.d.a n.d.a 
25 95 51 n.d. n.d.  34 88 99 n.d.a n.d.a 
27 86 96 34 32  35 75 n.d. n.d.a n.d.a 
KTZa 96 8 11 1  ABTa 27 36 2 7 
a KTZ: Ketoconazole; ABT: Abiraterone; n.d.: not determined. 
b Inhibition at a concentration of 1 μM; standard deviations were within < ±5%; All the data are the mean values of at least 3 
independent tests. 
 Furthermore, selectivity toward CYP11B1 and CYP11B2 –– the most important steroidogenic enzymes 
being responsible for adrenal corticoid biosynthesis –– has been determined as another criterion to decide 
which compound should be tested further in vivo. CYP11B1 catalyzes 11β-hydroxylation in cortisol 
biosynthesis, whereas CYP11B2 is responsible for the final three steps (11β-hydroxylation, 18-
hydroxylation, and 18-oxidation) in aldosterone biosynthesis. Inhibition of these two enzymes could cause 
hyponatremia, hyperkalemia and a series of recessive disorders, such as adrenal hyperplasia and 
hypovolemic shock.20 The most interesting compound of this series, 23 and 30, were tested at a concentration 
of 0.2 μM. As compound 23 showed less inhibition on both enzymes (11B2: 66%; 11B1: 66%, compound 30: 
11B1: 96%; 11B2: 98%), it was further tested in rats.  
Table 6. Reduction of the plasma testosterone concentrations in rats by compound 23a 
Relative plasma testosterone level (%)b 
Compd 
1h 2h 4h 6h 8h 24h 
Control 143.1 ± 13.3 76.4 ±13.3 81.4 ± 24.6 109.6 ± 31.7 90.6 ± 22.8 80.6 ± 21.0 
23 16.5 ± 5.7d 11.7 ± 5.0d 13.9 ± 8.0d 13.9 ± 7.1d 13.4 ± 6.2d 36.7 ± 27.4d 
ABTe 92.5 ± 43.1d 44.0 ± 14.7d 43.5 ± 12.4d 43.3 ±12.8c 35.6 ± 9.7d 476.0 ± 238.6 
a Compound 23 was applied at a dose of 50 mg / kg body weight; Abiraterone was administrated as Abiraterone acetate (56 mg / kg 
body weight, equivalent to Abiraterone 50 mg / kg body weight). 5 to 6 intact adult male Wistar rats were employed for each 
treatment group; each sample was tested for 3 times. 
b The average plasma testosterone concentrations (1.81 ng / mL) at pre-treatment time points (-1, -0.5 and 0 h) were set to 100%. The 
values shown are the relative levels compared to the pre-treatment value. 
c P < 0.05. d P < 0.01. e ABT: Abiraterone. 
The in vivo evaluation of compound 23, including the ability of reducing plasma testosterone 
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concentration (Table 6) and the determination of pharmacokinetic properties (Table 7), was performed in 
male Wistar rats after oral application using Abiraterone as reference compound. The plasma concentrations 
of testosterone were determined by ELISA assay and plasma drug concentrations were measured using LC-
MS. Although applied as acetate, only the signals of the free Abiraterone were monitored. It is obvious that 
both compounds significantly reduced the plasma testosterone concentration. It is striking that compound 23, 
which was less active in vitro, was much more active in vivo than Abiraterone at each time point checked. 
Importantly, after 24 hours compound 23 still showed strong inhibitory activity, while Abiraterone exhibited 
at this time point plasma testosterone concentrations 6 fold higher than that of the untreated control. This 
activity profile can be explained by the pharmacokinetic properties of the compounds. Compound 23 
exhibited a plasma half-life of 10 hours, while Abiraterone only showed 1.6 hours. The fact that Abiraterone 
had to be administrated as acetate prodrug, which is inactive as CYP17 inhibitor, could explain the reduced 
inhibitory activity of the steroidal compound. However, application of the acetate should prolong the plasma 
half-life having no influence on the AUC of the parent compound. The superiority of compound 23 becomes 
apparent by comparing the AUCs of the two compounds, leading to the conclusion that the bioavailability of 
compound 23 is much better. 
Table 7. Pharmacokinetic properties of compound 23a 
Compd t1/2 z(h)b t max (h)b C max (ng / mL)b AUC0-∞ (ng x h / mL)b Clint (l / kg / h)b 
23 10.0 6.0 3288 70729 0.7 
Abiraterone  1.6 2.0 592 4015 11.2 
a Compound 23 was applied at a dose of 50 mg / kg body weight; Abiraterone was administrated as Abiraterone acetate (56 mg / kg 
body weight, equivalent to Abiraterone 50 mg / kg body weight). 5 to 6 intact adult male Wistar rats were employed for each 
treatment group; each sample was tested for 3 times. 
b t ½ z: terminal half-life; t max: time of maximal concentration; C max: maximal concentration; AUC0-∞: area under the curve; Clint: 
intrinsic hepatic clearance. 
4. Conclusion 
Herein, we reported the synthesis and evaluation of bioactivity of a series of substituted and core rigidified 
biphenyl methylene imidazoles as CYP17 inhibitors. We found clearer SAR for biphenyl type CYP17 
inhibitors, comparing to previous work,12–13 that alkyl groups at the methylene bridge, if in suitable length, 
can strongly improve the inhibitory potency. Analogues substituted with polar substituents at the A-ring, 
capable of H-bond formation, always led to potent inhibitors. Besides, rigidification of the biphenyl core to 
form a carbazole or 9H-fluorene ring also significantly elevated the activity to give a series of CYP17 
inhibitors more potent than previously reported,12–13 probably due to their planar conjugated scaffolds. 
Moreover, one of the best compounds in vitro, compound 23 showed potent activity in vivo, a long plasma 
half-life and a high bioavailability. 
However, further structure modifications have to be performed with the aim of reducing the CYP1A2 
inhibition –– the enzyme responsible for the metabolism of approximately 10% of the prescription drugs –– 
before a candidate for the treatment of prostate cancer can be propagated. Furthermore, because of being 
tested as racemic mixtures, it is likely that one enantiomer of compound 23 would be more potent and 
selective than the other. A separation of the enantiomers is presently being performed.  
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5. Experimental Section 
5.1 CYP17 preparation and assay 
Human CYP17 was expressed in E. coli (coexpressing human CYP17 and cytochrome P450 reductase) 
and the assay was performed as previously described.12d,16a 
5.2 Inhibition of hepatic CYP enzymes 
The recombinantly expressed enzymes from baculovirus-infected insect microsomes (Supersomes) were 
used and the manufacturer’s instructions (www.gentest.com) were followed. 
5.3 Inhibition of CYP11B1 and CYP11B2 
V79MZh cells expressing human CYP11B1 or CYP11B2 were incubated with [4-14C]-11-
deoxycorticosterone as substrate. The assay was performed as previously described.16c–d 
5.4 In vivo study 
The in vivo tests were performed with intact adult male Wistar rats (Harlan Winkelmann, Germany), 5 to 6 
for each treatment group. These rats were cannulated with silicone tubing via the right jugular vein. 
Compound 23 was applied p.o. at 50 mg/kg body weight, while Abiraterone was administrated as acetate at 
56 mg/kg body weight (equivalent to Abiraterone at 50 mg/kg body weight). The concentrations of 
testosterone in the rat plasma were determined using the Testosterone ELISA (EIA - 1559) from DRG 
Instruments according to the manufacturer’s instructions. The plasma drug levels were measured by LC-MS. 
Non-compartmental pharmacokinetic analysis of concentration vs time data was performed for each 
compound on the mean plasma level using a validated computer program (PK solution 2 software; Summit 
Research Services, Montrose, USA). Plasma concentrations below the limit of detection were assigned a 
value of zero. 
5.5 Chemistry Section 
General 
Melting points were determined on a Mettler FP1 melting point apparatus and are uncorrected. IR spectra 
were recorded neat on a Bruker Vector 33FT-infrared spectrometer. 1H and 13C NMR spectra were measured 
on a Bruker DRX-500 (500 MHz). Chemical shifts are given in parts per million (ppm), and TMS was used 
as an internal standard for spectra obtained. All coupling constants (J) are given in Hz. ESI (electrospray 
ionization) mass spectra were determined on a TSQ quantum (Thermo Electron Corporation) instrument. 
Elemental analyses were performed at the Department of Instrumental Analysis and Bioanalysis, Saarland 
University. The purities of the final compounds were controlled by Surveyor®-LC-system. Purities were 
greater than 98%. Column chromatography was performed using silica-gel 60 (50–200 µm), and reaction 
progress was determined by TLC analysis on Alugram® SIL G/UV254 (Macherey-Nagel). Boronic acids and 
bromoaryls used as starting materials were commercially obtained (CombiBlocks, Chempur, Aldrich, 
Acros). 
Method A: CDI reaction 
To a solution of the corresponding alcohol (1 eq) in N-methylpyrrolidone (NMP) or acetonitrile (10 mL / 
mmol) was added CDI (5 eq). Then the solution was heated to reflux for 4 to 18 h. After cooling to ambient 
temperature, it was diluted with water (30 mL) and extracted with ethyl acetate (3 x 10 mL). The combined 
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organic phases were washed with brine, dried over MgSO4 and evaporated under reduced pressure. Then the 
desired product was purified by chromatography on silica gel. 
1-(1-Biphenyl-4-yl-propyl)-1H-imidazole, 1. Synthesised according to Method A using 1a (0.50 g, 2.36 
mmol) and CDI (1.91 g, 11.78 mmol); yield: 0.13 g (21%); yellow solid: mp 75–77 °C; Rf = 0.31 (DCM / 
MeOH, 10:1); δH (CDCl3, 500 MHz) 0.99 (t, J = 7.5 Hz, 3H, CH3), 2.26–2.32 (m, 2H, CH2), 5.09 (t, J = 7.5 
Hz, 1H, CH), 6.99 (s, 1H), 7.11 (s, 1H), 7.25 (d, J = 8.4 Hz, 2H), 7.33–7.37 (m, 1H), 7.42–7.46 (m, 2H), 
7.56 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 8.4 Hz, 2H), 7.69 (s, 1H); MS (ESI): m/z = 263 [M++H]. 
1-(1-Biphenyl-4-yl-butyl)-1H-imidazole, 2. Synthesised according to Method A using 2a (0.50 g, 2.21 
mmol) and CDI (1.79 g, 11.05 mmol); yield: 0.16 g (27%); brownish oil; Rf = 0.29 (DCM / MeOH, 10:1); δH 
(CDCl3, 500 MHz) 0.98 (t, J = 7.5 Hz, 3H, CH3), 1.31–1.39 (m, 2H, CH2), 2.14–2.28 (m, 2H, CH2), 5.17 (t, J 
= 7.5 Hz, 1H, CH), 6.99 (s, 1H), 7.10 (s, 1H), 7.26 (d, J = 8.0 Hz, 1H), 7.34 (t, J = 7.5 Hz, 2H), 7.45 (dd, J = 
7.5, 8.4 Hz, 2H), 7.54–7.57 (m, 4H), 7.66 (s, 1H); MS (ESI): m/z = 277 [M++H]. 
1-(1-Biphenyl-4-yl-2-methyl-propyl)-1H-imidazole, 3. Synthesised according to Method A using 3a 
(0.50 g, 2.36 mmol) and CDI (1.91 g, 11.78 mmol); yield: 0.20 g (33%); white solid: mp 124–125 °C; Rf = 
0.31 (DCM / MeOH, 10:1); δH (CDCl3, 500 MHz) 0.95 (t, J = 7.5 Hz, 6H, (CH3)2), 2.56–2.65 (m, 1H, 
CH(Me)2), 4.67 (d, J = 7.5 Hz, 1H, CH), 7.05 (s, 1H), 7.07 (s, 1H), 7.32–7.38 (m, 3H), 7.42–7.45 (m, 2H), 
7.55–7.58 (m, 4H), 7.67 (s, 1H); MS (ESI): m/z = 277 [M++H]. 
1-(1-Biphenyl-4-yl-pentyl)-1H-imidazole, 4. Synthesised according to Method A using 4a (0.50 g, 2.08 
mmol) and CDI (1.69 g, 10.40 mmol); yield: 0.15 g (25%); brownish oil; Rf = 0.30 (DCM / MeOH, 10:1); δH 
(CDCl3, 500 MHz) 0.89 (t, J = 7.5 Hz, 3H, CH3), 1.28–1.37 (m, 2H, CH2), 1.39–1.43 (m, 2H, CH2), 2.20–
2.26 (m, 2H, CH2), 5.14 (t, J = 7.7 Hz, 1H, CH), 6.99 (s, 1H), 7.12 (s, 1H), 7.26 (d, J = 8.4 Hz, 2H), 7.35–
7.37 (m, 1H), 7.43 (dd, J = 7.9, 8.4 Hz, 2H), 7.54–7.57 (m, 4H), 7.68 (s, 1H); MS (ESI): m/z = 291 [M++H]. 
1-(1-Biphenyl-4-yl-3-methyl-butyl)-1H-imidazole, 5. Synthesised according to Method A using 5a (0.50 
g, 2.08 mmol) and CDI (1.69 g, 10.40 mmol); yield: 0.16 g (27%); brownish oil; Rf = 0.30 (DCM / MeOH, 
10:1); δH (CDCl3, 500 MHz) 0.96 (d, J = 7.5 Hz, 6H, C(CH3)2), 1.46–1.53 (m, 1H, CH(Me)2), 1.99–2.20 (m, 
2H, CH2), 5.14 (t, J = 9.5 Hz, 1H, CH), 6.99 (s, 1H), 7.09 (s, 1H), 7.25 (d, J = 8.0 Hz, 2H), 7.35–7.36 (m, 
1H), 7.43 (dd, J = 7.9, 8.4 Hz, 2H), 7.54–7.57 (m, 4H), 7.65 (s, 1H); MS (ESI): m/z = 291 [M++H]. 
1-(1-Biphenyl-4-yl-2,2-dimethyl-propyl)-1H-imidazole, 6. Synthesised according to Method A using 6a 
(0.50 g, 2.08 mmol) and CDI (1.69 g, 10.40 mmol); yield: 0.15 g (25%); white solid: mp 150–151 °C; Rf = 
0.30 (DCM / MeOH, 10:1); δH (CDCl3, 500 MHz) 1.07 (s, 9H, C(CH3)3), 4.92 (s, 1H, CH), 7.08 (s, 1H), 7.24 
(s, 1H), 7.32–7.36 (m, 1H), 7.41–7.45 (m, 4H), 7.55–7.57 (m, 4H), 7.72 (s, 1H); MS (ESI): m/z = 291 
[M++H]. 
1-(1-Biphenyl-4-yl-cyclohexyl-methyl)-1H-imidazole, 7. Synthesised according to Method A using 7a 
(0.50 g, 1.87 mmol) and CDI (1.52 g, 9.34 mmol); yield: 0.19 g (32%); white solid: mp 118–121 °C; Rf = 
0.32 (DCM / MeOH, 10:1); δH (CDCl3, 500 MHz) 0.89–1.03 (m, 2H, cyclohexyl), 1.15–1.28 (m, 3H, 
cyclohexyl), 1.52–1.60 (m, 2H, cyclohexyl), 1.71–1.77 (m, 3H, cyclohexyl), 2.22–2.23 (m, 1H, cyclohexyl), 
4.72 (t, J = 10.1 Hz, 1H, CH), 7.04 (s, 1H), 7.06 (s, 1H), 7.32–7.37 (m, 3H), 7.43 (dd, J = 7.5, 8.8 Hz, 2H), 
7.54–7.57 (m, 4H), 7.63 (s, 1H); MS (ESI): m/z = 317 [M++H]. 
1-(1-Biphenyl-4-yl-2-phenyl-ethyl)-1H-imidazole, 8. Synthesised according to Method A using 8a (0.50 
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g, 1.82 mmol) and CDI (1.48 g, 9.11 mmol); yield: 0.14 g (23%); yellow solid: mp 99–101 °C [Ref: 98–100 
°C21]; Rf = 0.29 (DCM / MeOH, 10:1); δH (CDCl3, 500 MHz) 3.50 (d, J = 7.5 Hz, 2H, CH2), 5.09 (t, J = 7.5 
Hz, 1H, CH), 6.95 (s, 1H), 7.01 (d, J = 8.0 Hz, 2H), 7.06 (s, 1H), 7.22–7.24 (m, 3H), 7.28 (d, J = 8.4 Hz, 2H), 
7.35–7.37 (m, 1H), 7.42–7.45 (m, 2H), 7.48 (s, 1H), 7.56–7.58 (m, 4H); MS (ESI): m/z = 325 [M++H]. 
1-(1-Biphenyl-4-yl-2-phenyl-methyl)-1H-imidazole, 9. Synthesised according to Method A using 9a 
(0.50 g, 1.92 mmol) and CDI (1.56 g, 9.60 mmol); yield: 0.07 g (12%); yellow oil; [Ref: mp 142 °C22]; Rf = 
0.35 (DCM / MeOH, 10:1); δH (CDCl3, 500 MHz) 6.57 (s, 1H, CH), 6.89(s, 1H), 7.13–7.19 (m, 5H), 7.35–
7.38 (m, 4H), 7.42–7.47 (m, 3H), 7.56–7.59 (m, 4H); MS (ESI): m/z = 311 [M++H]. 
1-(Bis-biphenyl-4-yl-methyl)-1H-imidazole, 10. Synthesised according to Method A using 10a (0.50 g, 
1.49 mmol) and CDI (1.21 g, 7.43 mmol); yield: 0.07 g (13%); yellow oil; [Ref: mp 120 °C22]; Rf = 0.37 
(DCM / MeOH, 10:1); δH (CDCl3, 500 MHz) 6.95 (s, 1H), 7.16 (s, 1H), 7.21–7.23 (m, 4H), 7.35–7.38 (m, 
2H), 7.43–7.47 (m, 4H), 7.55–7.61 (m, 10H); MS (ESI): m/z = 387 [M++H]. 
1-(1-(4'-(Trifluoromethoxy)biphenyl-4-yl)propyl)-1H-imidazole, 12. Synthesised according to Method 
A using 12a (0.50 g, 2.10 mmol) and CDI (2.00 g, 12.40 mmol); yield: 0.16 g (21%); brownish oil; Rf = 0.51 
(DCM / MeOH, 95:5); δH (CDCl3, 500 MHz) 0.99 (t, J = 7.5 Hz, 3H, CH3), 2.26–2.32 (m, 2H, CH2), 5.09 (t, 
J = 7.5 Hz, 1H, CH), 7.00 (s, 1H), 7.13 (s, 1H), 7.28–7.31 (m, 4H), 7.54–7.59 (m, 4H), 7.66 (s, 1H); δC 
(CDCl3, 125 MHz) 11.1 (CH3), 28.6 (CH2), 63.0 (CH), 117.6 (CH), 119.5(CF3), 121.2 (CH), 127.0 (Im-C5), 
127.5 (CH) 127.6 (CH), 128.4 (CH), 129.5 (Cq), 136.4 (Cq), 139.1 (Cq), 139.7, 139.8 (Cq) 148.8 (Cq); MS 
(ESI): m/z = 347 [M++H]. 
1-(1-(4'-(Methylsulfanyl)biphenyl-4-yl)propyl)-1H-imidazole, 13. Synthesised according to Method A 
using 13a (0.67 g, 2.6 mmol) and CDI (2.00 g, 12.40 mmol); yield: 0.12 g (15%); beige solid; Rf  = 0.44 
(DCM / MeOH, 95:5); δH (CDCl3, 500 MHz) 0.96 (t, J = 7.0 Hz, 3H, CH3), 2.24–2.28 (m, 2H, CH2), 2.52 (s, 
3H, SCH3), 5.04 (t, J = 7.0 Hz, 1H, CH), 6.97 (s, 1H), 7.10 (s, 1H), 7.23–7.26 (m, 2H), 7.30–7.33 (m, 2H), 
7.47–7.50 (m, 2H), 7.52–7.54 (m, 2H), 7.63 (s, 1H); δC (CDCl3, 125 MHz) 11.1 (CH3), 15.8 (SCH3), 28.6 
(CH2), 63.0 (CH), 117.7 (Im-C4), 126.9 (CH), 127.0 (CH), 127.2 (CH), 127.4 (CH), 129.5 (Cq), 136.4 (Cq), 
137.1 (Cq), 138.0 (Cq), 139.2 (CH), 140.4 (CH); MS (ESI): m/z = 309 [M++H]. 
4'-(1-(1H-Imidazol-1-yl)propyl)biphenyl-4-carbonitrile, 14. Synthesised according to Method A using 
14a (0.46 g, 1.93 mmol) and CDI (1.5 g, 9.30 mmol); yield: 0.14 g (25%); brown oil; Rf = 0.40 
(DCM/MeOH, 95:5); δH (CDCl3, 500 MHz) 0.98 (t, J = 7.0 Hz, 3H, CH3), 2.22–2.30 (m, 2H, CH2), 5.08 (t, J 
= 7.0 Hz, 1H, CH), 6.97 (s, 1H), 7.10 (s, 1H), 7.29 (d, J = 8.5 Hz, 2H), 7.56 (d, J = 8.5 Hz, 2H), 7.61–7.68 
(m, 3H), 7.73 (d, J = 8.0 Hz, 2H); δC (CDCl3, 125 MHz) 11.1 (CH3), 28.5 (CH2), 62.9 (CH), 111.2 (C-4´), 
117.6 (C-N), 118.7 (Im-C4), 127.2 (CH), 127.6 (CH), 129.6 (Cq), 132.6 (CH), 136.3 (Cq),  139.0 (CH), 140.9 
(Cq), 144.7 (Cq); MS (ESI): m/z = 288 [M++H]. 
1-(1-(4'-Methylbiphenyl-4-yl)propyl)-1H-imidazole, 15. Synthesised according to Method A using 15a 
(0.57 g, 2.5 mmol) and CDI (2.0 g, 12.50 mmol); yield: 0.20 g (29%); yellow solid: mp 71–72 °C; Rf  = 0.26 
(EtOAc); δH (CDCl3, 500 MHz) 0.88 (t, J = 7.3 Hz, 3H, CH3), 2.16 (q, J = 7.3 Hz, 2H, CH2), 2.30 (s, 3H, 
PhCH3), 4.95 (t, J = 7.3 Hz, 1H, CH), 6.89 (s, 1H), 7.00 (s, 1H), 7.12–7.18 (m, 4H), 7.37 (d, J = 8.2 Hz, 2H), 
7.45 (d, J = 8.2 Hz, 2H), 7.54 (s, 1H); δC (CDCl3, 125 MHz) 11.1 (CH3), 21.0 (PhCH3), 28.5 (CH2), 63.0 
(CH), 117.6, 126.81, 126.86, 127.3, 129.5, 136.3, 137.3, 138.9, 140.9, 142.1; MS (ESI): m/z = 277 [M++H]. 
3 Results and Discussions 
胡庆忠博士论文 
- 46 - 
1-(1-(4'-Ethylbiphenyl-4-yl)propyl)-1H-imidazole, 16. Synthesised according to Method A using 16a 
(0.64 g, 2.6 mmol) and CDI (2.1 g, 13.12 mmol); yield: 0.14 g (18%); yellowish oil; Rf  = 0.30 (EtOAc); δH 
(CDCl3, 500 MHz) 0.89 (t, J = 7.3 Hz, 3H, CH3), 1.20 (t, J = 7.6 Hz, 3H, CH3), 2.18 (quint, J = 7.3 Hz, 2H, 
CH2), 2.61 (q, J = 7.6 Hz, 2H, CH2), 4.97 (t, J = 7.3 Hz, 1H, CH), 6.90 (s, 1H), 7.02 (s, 1H), 7.14–7.21 (m, 
4H), 7.41 (d, J = 8.2 Hz, 2H), 7.47 (d, J = 8.5 Hz, 2H), 7.57 (s, 1H); δC (CDCl3, 125 MHz) 10.1 (CH3), 14.5 
(CH3), 27.5 (CH2), 27.6 (CH2), 62.1 (CH), 116.7, 125.9, 126.0, 126.4, 127.3, 128.3, 135.3, 136.7, 137.8, 
140.0, 142.1; MS (ESI): m/z = 291 [M++H]. 
[4'-(1H-Imidazol-1-yl-propyl)-biphenyl-4-yl]-dimethyl-amine, 17. Synthesised according to Method A 
using 17a (0.59 g, 2.31 mmol) and CDI (0.56 g, 3.47 mmol); yield: 0.18 g (25%); white solid: mp 117–119 
°C; Rf = 0.33 (DCM / MeOH, 20:1); δH (CDCl3, 500 MHz) 0.95 (t, J = 7.3 Hz, 3H, CH3), 2.24 (q, J = 7.3, 7.6 
Hz, 2H, CH2), 2.99 (s, 6H, N-CH3), 5.01 (t, J = 7.6 Hz, 1H, CH), 6.78 (d, J = 9.1 Hz, 2H), 6.97 (s, 1H), 7.09 
(s, 1H), 7.20 (d, J = 8.5 Hz, 2H), 7.47 (d, J = 8.8 Hz, 2H), 7.51 (d, J = 8.2 Hz, 2H), 7.62 (s, 1H); δC (CDCl3, 
125 MHz) 11.1 (CH3), 28. 6 (CH2), 40.4 (N-CH3), 63.0 (CH), 112.6, 117.6, 126.5, 126.8, 127.6, 129.4, 
136.4, 137.7, 141.0, 150.1; MS (ESI): m/z = 306 [M++H]. 
Diethyl-[4'-(1H-imidazol-1-yl-propyl)-biphenyl-4-yl]-amine, 18. Synthesised according to Method A 
using 18a (0.70 g, 2.47 mmol) and CDI (0.61 g, 3.70 mmol); yield: 0.16 g (19%); white solid: mp 109–111 
°C; Rf = 0.33 (DCM / MeOH, 20:1); δH (CDCl3, 500 MHz) 0.95 (t, J = 7.3 Hz, 3H, CH3), 1.19 (t, J = 6.9 Hz, 
6H, NCH3), 2.24 (q, J = 7.3, 7.6 Hz, 2H, CH2), 3.39 (q, J = 6.9 Hz, 4H, NCH2), 5.01 (t, J = 7.6 Hz, 1H, CH), 
6.73 (d, J = 9.1 Hz, 2H), 6.97 (s, 1H), 7.09 (s, 1H), 7.19 (d, J = 8.5 Hz, 2H), 7.45 (d, J = 8.8 Hz, 2H), 7.50 
(d, J = 8.2 Hz, 2H), 7.62 (s, 1H); δC (CDCl3, 125 MHz) 11.1 (CH3), 12.6 (NCH3), 28.6 (CH2), 44.3 (N-CH2), 
63.0 (CH), 111.8, 117.6, 126.3, 126.8, 127.7, 129.4, 136.4, 137.5, 141.1, 147.3; MS (ESI): m/z = 334 
[M++H]. 
4-[4'-(1H-Imidazol-1-yl-propyl)-biphenyl-4-yl]-morpholine, 19. Synthesised according to Method A 
using 19a (0.70 g, 2.37 mmol) and CDI (0.58 g, 3.55 mmol); yield: 0.27 g (33%); white solid: mp 119–121 
°C; Rf = 0.17 (DCM / MeOH, 20:1); δH (CDCl3, 500 MHz) 0.95 (t, J = 7.3 Hz, 3H, CH3), 2.24 (q, J = 7.3, 7.6 
Hz, 2H, CH2), 3.20 (t, J = 4.7 Hz, 4H), 3.86 (t, J = 4.7 Hz, 4H), 5.02 (t, J = 7.6 Hz, 1H, CH), 6.92–6.95 (m, 
3H), 7.08 (s, 1H), 7.21 (d, J = 8.5 Hz, 2H), 7.49 (d, J = 8.8 Hz, 2H), 7.51 (d, J = 8.5 Hz, 2H), 7.61 (s, 1H); δC 
(CDCl3, 125 MHz) 11.1 (CH3), 28.5 (CH2), 48.9, 62.9 (CH), 66.7, 115.6, 117.6, 126.7, 126.8, 127.6, 129.4, 
131.5, 136.3, 138.3, 140.5, 150.6; MS (ESI): m/z = 348 [M++H]. 
[4'-(1H-Imidazol-1-yl-propyl)-biphenyl-4-yl]-carbamic acid tert-butyl ester, 20. Synthesised 
according to Method A using 20a (1.23 g, 3.75 mmol) and CDI (0.91 g, 5.63 mmol); yield: 0.33 g (23%); 
white solid: mp 204–206 °C; Rf = 0.29 (DCM / MeOH, 20:1); δH (CDCl3, 500 MHz) 0.97 (t, J = 7.3 Hz, 3H, 
CH3), 1.53 (s, 9H, t-Bu), 2.26 (q, J = 7.3, 7.6 Hz, 2H, CH2), 5.04 (t, J = 7.6 Hz, 1H, CH), 6.57 (s, 1H, 
CONH), 6.97 (s, 1H), 7.09 (s, 1H), 7.24 (d, J = 8.2 Hz, 2H), 7.42 (d, J = 8.5 Hz, 2H), 7.51–7.53 (m, 4H), 
7.62 (s, 1H); δC (CDCl3, 125 MHz) 11.1 (CH3), 28.3 (t-Bu), 28.6 (CH2), 63.0 (CH), 118.8, 126.9, 127.1, 
127.5, 129.5, 137.9, 138.8, 140.5; MS (ESI): m/z = 378 [M++H]. 
1-[1-(4'-Fluoro-biphenyl-4-yl)-propyl]-1H-imidazole, 23. Synthesised according to Method A using 23a 
(1.23 g, 5.34 mmol) and CDI (4.33 g, 26.70 mmol); yield: 0.52 g (35%); brown oil; Rf = 0.6 (DCM / MeOH, 
95:5); δH (CDCl3, 500 MHz) 0.97 (t, J = 7.3 Hz, 3H, CH3), 2.27 (q, J = 7.3, 7.6 Hz, 2H, CH2), 5.06 (t, J = 7.6 
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Hz, 1H, CH), 6.97 (s, 1H), 7.09–7.14 (m, 3H), 7.25 (d, J = 8.9 Hz, 2H), 7.51–7.53 (m, 4H), 7.62 (s, 1H); δC 
(CDCl3, 125 MHz) 11.1 (CH3), 28.6 (CH2), 63.0 (CH), 115.6, 115.7, 117.7, 127.0, 127.4, 128.6, 128.7, 129.5, 
136.4, 136.5, 139.3, 140.1, 161.6, 163.6; MS (ESI): m/z = 281 [M++H]. 
1-(2-(4'-Fluorobiphenyl-4-yl)propan-2-yl)-1H-imidazole, 24. Synthesised according to Method A using 
24a (0.23 g, 1.0 mmol) and CDI (0.36 g, 2.20 mmol); yield: 0.05 g (19%); Rf  = 0.27 (DCM / MeOH, 95:5); 
δH (CDCl3, 500 MHz) 1.94 (s, 6H, CH3), 6.94–6.96 (m, 1H), 7.10–7.15 ( m, 5H), 7.47–7.36 (m, 4H), 7.67–
7.69 (m, 1H); δC (CDCl3, 125 MHz) 31.5 (CH3), 60.3 (CH), 116.1, 117.0, 125.2, 127.3, 129.2, 132.6, 139.4, 
145.4, 163.7; MS (ESI): m/z = 281 [M++H]. 
1-(3-(4'-Fluorobiphenyl-4-yl)pentan-3-yl)-1H-imidazole, 25. Synthesised according to Method A using 
25a (0.26 g, 1.00 mmol) and CDI (0.36 g, 2.20 mmol); yield: 0.13 g (43%); Rf  = 0.33 (DCM / MeOH, 95:5); 
δH (CDCl3, 500 MHz) 0.75 (s, 6H, CH3), 2.26–2.30 (q, 4H, CH2),  6.84–6.86 (m, 1H), 7.08–7.09 (m, 1H), 
7.10–7.13 (m, 2H), 7.17–7.20 (m, 2H), 7.48–7.55 (m, 4H), 7.62–7.63 (m, 1H); δC (CDCl3, 125 MHz) 8.3 
(CH3), 30.5 (CH2), 66.1 (CH), 116.3, 119.7, 127.6, 129.9, 136.2, 139.1, 142.8; MS (ESI): m/z = 309 [M++H]. 
1-(1-(4'-Fluorobiphenyl-4-yl)allyl)-1H-imidazole, 28. Synthesised according to Method A  using 28a (1.14 
g, 5.00 mmol) and CDI (1.80 g, 10.10 mmol); yield: 0.57 g (41%); Rf  = 0.27 (DCM / MeOH, 95:5); δH (CDCl3, 
500 MHz) 4.73–4.74 (m, 2H, CH2), 6.30–6.35 (m, 1H, CH), 6.54–6.57 (m, 1H, CH), 6.98 (s, 1H), 7.10–7.12 
(m, 3H), 7.42–7.44 (m, 2H), 7.50–7. 56 (m, 5H); δC (CDCl3, 125 MHz) 49.3 (CH), 116.5, 124.9, 127.4, 
128.6, 130.8, 133.2, 135.2, 137.0, 140.3, 161.7; MS (ESI): m/z = 279 [M++H]. 
1-(1-(Biphenyl-4-yl)allyl)-1H-imidazole, 29. Synthesised according to Method A  using 29a (0.30 g, 1.00 
mmol) and CDI (0.36 g, 2.20 mmol); yield: 0.09 g (32%); Rf  = 0.21 (DCM / MeOH, 95:5); δH (CDCl3, 500 
MHz) 4.73–4.75 (m, 2H, CH2), 6.30–6.35 (m, 1H, CH), 6.56–6.57 (m, 1H, CH), 6.98 (s, 1H), 7.12–7.13 (m, 
1H), 7.34–7.37 (m, 1H), 7.43–7.46 (m, 4H), 7.56–7.60 (m, 5H); δC (CDCl3, 125 MHz) 49.3 (CH), 119.4 
(=CH2), 123.8, 127.0, 129.4, 133.2, 134.5, 137.7, 140.9; MS (ESI): m/z = 297 [M++H]. 
1-[(9H-Fluoren-2-yl)methyl]-1H-imidazole, 31. Synthesised according to Method A using 31a (0.32 g, 
1.63 mmol) and CDI (0.53 g, 3.26 mmol); yield: 0.16 g (40%); Rf = 0.31 (MeOH / EtOAc, 5:95); colourless 
solid: mp 183–185 °C; δH (CDCl3, 500 MHz) 3.87 (s, 2H, CH2), 5.18 (s, 2H), 6.94 (s, br, 1H), 7.11 (s, br, 
1H), 7.19 (d, J = 8.5 Hz, 1H), 7.30–7.33 (m, 2H), 7.38 (dd, J = 7.3, 7.6 Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H), 
7.59 (s, br, 1H), 7.75 (d, J = 7.9 Hz, 1H), 7.77 (d, J = 7.6 Hz, 1H); δC (CDCl3, 125 MHz) 36.8 (CH2), 51.0 
(CH2), 119.3 (CH), 120.0 (CH), 120.2 (CH), 124.0 (CH), 125.1 (CH), 126.1 (CH), 126.8 (CH), 127.1 (CH), 
129.7 (CH), 134.4 (Cq), 137.4 (CH), 140.9 (Cq), 141.9 (Cq), 143.3 (Cq), 144.1 (Cq); MS (ESI): m/z = 247 
[M++H]. 
1-((9H-Fluoren-2-yl)ethyl)-1H-imidazole, 32. Synthesised according to Method A using 32a (1.00 g, 
4.70 mmol) and CDI (1.53 g, 9.50 mmol); yield: 0.62 g (51%); Rf = 0.58 (MeOH / EtOAc, 5:95); light 
yellow solid: mp 109–110 °C [Ref: no mp reported23]; δH (CDCl3, 500 MHz) 1.90 (d, J = 6.9 Hz, 3H, CH3), 
3.86 (s, 2H, CH2), 5.41 (q, J = 6.9 Hz, 1H, CH), 6.96 (t, J = 1.3 Hz, 1H), 7.10 (s, br, 1H), 7.17–7.19 (m, 1H), 
7.29 (s, br, 1H), 7.31 (dd, J = 1.3, 7.6 Hz, 1H), 7.37 (t, J = 7.8 Hz, 1H), 7.53 (bd, J = 7.6 Hz, 1H), 7.63 (s, br, 
1H), 7.74 (d, J = 7.9 Hz, 1H), 7.76 (d, J = 7.6 Hz, 1H); δC (CDCl3, 125 MHz) 22.2 (CH3), 36.9 (CH2), 56.8 
(CH), 118.0 (CH), 120.0 (CH), 120.1 (CH), 122.6 (CH), 124.8 (CH), 125.0 (CH), 126.8 (CH), 127.0 (CH), 
129.2 (CH), 136.0 (CH), 139.9 (Cq), 140.9 (Cq), 141.8 (Cq), 143.3 (Cq), 144.0 (Cq); MS (ESI): m/z = 261 
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[M++H]. 
1-[1-(7-Fluoro-9H-fluoren-2-yl)-ethyl]-1H-imidazole, 33. Synthesised according to Method A using 33a 
(1.00 g, 4.38 mmol) and CDI (1.87 g, 1.16 mmol); yield: 0.44 g (36%); Rf = 0.24 (MeOH / EtOAc, 5:95); 
yellow oil; δH (CDCl3, 500 MHz) 1.90 (d, J = 6.9 Hz, 3H, CH3), 3.85 (s, 2H, CH2), 5.41 (q, J = 7.0 Hz, 1H, 
CH), 6.96 (s, 1H), 7.05–7.09 (m, 2H), 7.18 (d, J = 7.9 Hz, 1H), 7.22 (dd, J = 1.8, 8.6 Hz, 1H), 7.28 (s, br, 
1H), 7.63 (s, br, 1H), 7.67–7.70 (m, 2H); δC (CDCl3, 125 MHz) 22.2 (CH3), 36.9 (CH2), 56.8 (CH), 112.4 (d, 
CH), 114.1 (d, CH), 118.0 (CH), 119.8 (CH), 120.9 (CH), 122.6 (CH), 125.0 (CH), 129.2 (CH), 136.0 (CH), 
137.0 (Cq), 139.7 (Cq), 141.0 (Cq), 143.7 (Cq), 145.5 (Cq), 161.6 (Cq); MS (ESI): m/z = 279 [M++H]. 
2-(1-Imidazol-1-yl-ethyl)-9H-carbazole, 34. Synthesised according to Method A using 34a (0.22 g, 1.02 
mmol) and CDI (0.33 g, 2.04 mmol); yield: 0.08 g (29%); [Ref: 157–158 °C23]; Rf = 0.40 (MeOH / EtOAc, 
5:95); δH (CDCl3, 500 MHz) 1.90 (d, J = 6.9 Hz, 3H), 5.46 (q, J = 6.9 Hz, 1H), 6,97 (s, br, 1H), 7.05–7.07 
(m, 2H), 7.11 (s, br, 1H), 7.22 (ddd, J = 1.9, 6.4, 8.0 Hz, 1H), 7.38–7.43 (m, 2H), 7.65 (s, br, 1H), 8.02 (d, J 
= 8.5 Hz, 1H), 8.05 (d, J = 7.9 Hz, 1H); δC (CDCl3, 125 MHz) 22.4 (CH3), 57.2 (CH), 108.0 (CH), 110.8 
(CH), 117.3 (CH), 118.3 (CH), 119.4 (CH), 120.3 (CH), 120.5 (CH), 122.7 (Cq), 123.1 (Cq), 126.0 (CH), 
128.8 (CH), 136.0 (CH), 139.2 (Cq), 140.0 (Cq), 140.2 (Cq); MS (ESI): m/z = 262 [M++H]. 
2-(1-(1H-Imidazol-1-yl)ethyl)-7-fluoro-9H-carbazole, 35. Synthesised according to Method A  using 
35a (0.30 g, 1.30 mmol) and CDI (0.42 g, 2.60 mmol); yield: 0.08 g (23%); Rf = 0.11 (EtOAc); δH (CDCl3, 
500 MHz) 1.93 (d, J = 7.0 Hz, 3H), 5.64 (q, J = 7.0 Hz, 1H), 6.90 (ddd, J = 2.2, 8.5, 9.6 Hz, 1H), 6.99 (t, J = 
1.3 Hz, 1H), 7.07 (ddd, J = 0.6, 1.6, 8.2 Hz, 1H), 7.11 (dd, J = 2.2, 9.6 Hz, 1H), 7.18 (t, J = 1.3 Hz, 1H), 7.28 
(d, J = 1.6 Hz, 1H), 7.80 (s, br, 1H), 7.96–7.99 (m, 2H); δC (CDCl3, 125 MHz) 22.5 (CH3), 58.6 (CH), 98.2 
(d, CH), 107.9 (d, CH), 109.4 (CH), 118.6 (CH), 119.7 (CH), 120.6 (Cq), 121.1 (CH), 122.2 (CH), 123.8 
(Cq), 128.9 (CH), 137.4 (CH), 140.4 (Cq), 142.2 (Cq), 142.8 (Cq), 163.5 (Cq); MS (ESI): m/z = 280 [M++H]. 
Method B: Grignard reaction 
Under exclusion of air and moisture a 1.0 M Grignard reagent (1.2 eq) solution in THF was added 
dropwise to a solution of the aldehyde or ketone (1 eq) in THF (12 mL / mmol). The mixture was stirred at 
room temperature overnight. Subsequently ethyl acetate (10 mL) and water (10 mL) were added and the 
organic phase was separated. The organic phase was extracted with water and brine, dried over Na2SO4, and 
evaporated under reduced pressure. The crude products were purified by flash chromatography on silica gel.  
1-Biphenyl-4-yl-3-methyl-butan-1-ol, 5a. Synthesised according to Method B using Biphenyl-4-
carbaldehyde (1.00 g, 5.48 mmol) and a 1.0 M iso-butylmagnesiumbromide solution in THF (7.13 mL, 7.13 
mmol); yield: 0.96 g (73%); Rf = 0.28 (PE / EtOAc, 5:1); δH (CDCl3, 500 MHz) 0.97 (d, J = 4.9 Hz, 6H, 
CH3),  1.51–1.58 (m, 1H, CH), 1.72 (s, br, 1H, OH), 1.75–1.81 (m, 2H, CH2), 4.79 (t, J = 2.7 Hz, 1H, CH), 
7.33 (t, J = 7.5 Hz, 1H), 7.43 (d, J = 8.4 Hz, 4H), 7.57 (d, J = 8.4 Hz, 4H); MS (ESI): m/z = 241 [M++H]. 
1-[4'-(tert-Butyl-dimethyl-silanyloxy)-biphenyl-4-yl]-propan-1-ol, 22b. Synthesised according to 
method B using 22c (3.30 g, 10.6 mmol) and 1.0 M EtMgBr (12.7 mL). Yield: 1.89 g (52%); Rf = 0.40 (PE / 
EtOAc, 9:1); δH (CDCl3, 500 MHz) 0.23 (s, 6H), 0.95 (t, J = 7.3 Hz, 3H), 1.00 (s, 9H), 1.76–1.89 (m, 2H), 
4.64 (t, J = 6.6 Hz, 1H), 6.90 (d, J = 8.5 Hz, 2H), 7.38 (d, J = 8.5 Hz, 2H), 7.46 (d, J = 8.5 Hz, 2H), 7.54 (d, J 
= 8.5 Hz, 2H); MS (ESI): m/z = 344 [M++H]. 
3-(4'-Fluorobiphenyl-4-yl)pentan-3-ol, 25a. Synthesised according to Method B using 23b (0.58 g, 2.53 
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mmol) and a 1.0 M ethylmagnesiumbromide solution in THF (25.0 mL, 25.0 mmol); yield: 0.58 g (89%); Rf  
= 0.28 (DCM); δH (CDCl3, 500 MHz): 0.82 (s, 6H, CH3), 1.68 (s, br, 1H, OH), 1.82–1.93 (m, 4H, CH2), 
7.10–7.14 (m, 2H), 7.43–7.45 (m, 2H), 7.51–7.58 (m, 4H); MS (ESI): m/z = 259 [M++H]. 
Method C: Suzuki-Coupling 
The corresponding brominated aromatic compound (1 eq) was dissolved in toluene (7 mL / mmol), an 
aqueous 2.0 M Na2CO3 solution (3.2 mL / mmol) and an ethanolic solution (3.2 mL / mmol) of the 
corresponding boronic acid (1.5-2.0 eq) were added. The mixture was deoxygenated under reduced pressure 
and flushed with nitrogen. After repeating this cycle several times Pd(PPh3)4 (4 mol%) was added and the 
resulting suspension was heated under reflux for 8 h. After cooling ethyl acetate (10 mL) and water (10 mL) 
were added and the organic phase was separated. The water phase was extracted with ethyl acetate (2 x 10 
mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered over a short plug of 
celite® and evaporated under reduced pressure. The compounds were purified by flash chromatography on 
silica gel.  
1-((4'-(Trifluoromethyl)biphenyl-4-yl)methyl)-1H-imidazole, 11. Synthesised according to Method C 
using 1-(4-bromobenzyl)-1H-imidazole (0.24 g, 1.00 mmol) and 4-trifluoromethylphenylboronic acid (0.38 
g, 2.00 mmol); yield: 0.24 g (80%); brown oil; Rf = 0.14 (EtOAc); δH (CDCl3, 500 MHz) 5.17 (s, 2H, CH2), 
6.93 (s, br, 1H), 7.11 (s, br, 1H), 7.24 (d, J = 7.9 Hz, 2H), 7.57 (d, J = 7.9 Hz, 2H), 7.59 (s, br, 1H), 7.65 (d, J 
= 8.5 Hz, 2H), 7.68 (d, J = 8.5 Hz, 2H); δC (CDCl3, 125 MHz) 50.4 (CH2), 119.2 (CH), 123.1 (Cq), 125.2 
(Cq), 125.7 (CH), 127.3 (CH), 127.7 (CH), 127.8 (CH), 129.8 (CH), 136.2 (Cq), 137.4 (CH), 139.7 (Cq), 
143.8 (Cq); MS (ESI): m/z = 303 [M++H]. 
1-(4'-Fluorobiphenyl-4-yl)propan-1-one, 23b. Synthesised according to Method C using 4-
bromopropiophenone (1.23 g, 6.65 mmol) and 4-fluorophenylboronic acid (1.38 g, 6.47 mmol); yield: 1.20 g 
(79%); Rf = 0.45 (Hex / EtOAc, 10:1); δH (CDCl3, 500 MHz) 1.24–1.27 (t, J = 7.3 Hz, 3H, CH3), 3.01–3.06 
(m, 2H, CH2), 6.97–7.01 (m, 1H), 7.06–7.11 (m, 1H), 7.58–7.61 (m, 2H), 8.02–8.04 (m, 2H); MS (ESI): m/z 
= 229 [M++H]. 
1-(4'-Fluoro-2'-nitrobiphenyl-4-yl)ethanone, 35c. Synthesised according to Method C using 4-fluoro-1-
iodo-2-nitrobenzene  (1.20 g , 4.50 mmol) and 4-acetylbenzeneboronic acid (1.48 g, 9.00 mmol); yield: 1.01 
g (87%); Rf = 0.19 (petrolether / EtOAc, 10:1); δH (CDCl3, 500 MHz) 2.64 (s, 3H, CH3), 7.38 (d, J = 8.5 Hz, 
2H), 7.39–7.41 (m, 1H), 7.43 (dd, J = 5.5, 8.5 Hz, 1H), 7.67 (dd, J = 2.5, 8.0 Hz, 1H), 8.01 (d, J = 8.5 Hz, 
2H); δC (CDCl3, 125 MHz) 26.6 (CH3), 112.1 (d, CH), 119.9 (d, CH), 128.3 (CH), 128.7 (CH), 131.7 (Cq), 
133.2 (CH), 136.8 (Cq), 141.3 (Cq), 161.6 (d, Cq), 197.4 (Cq ); MS (ESI): m/z = 259 [M+-H]. 
Method D: Reduction with NaBH4 
To an ice-cooled solution of the corresponding aldehyde or ketone (1 eq) in methanol (5 mL / mmol) was 
added NaBH4 (2 eq). Then the resulting mixture was heated to reflux for 30 minutes. After cooling to 
ambient temperature, the solvent was distilled off under reduced pressure. Subsequently water (10 mL) was 
added, and the resulting mixture was extracted with ethyl acetate (3 x 10 mL). The combined organic phases 
were washed with brine, dried over MgSO4 and evaporated under reduced pressure. Then the desired product 
was purified by chromatography on silica gel. 
1-(4'-Fluoro-biphenyl-4-yl)-propan-1-ol, 23a. Synthesised according to Method D using 22b (1.20 g, 
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5.26 mmol) and NaBH4 (0.30 g, 7.89 mmol); yield: 1.15 g (95%); the compound was directly used in the 
next step without further purification and characterization. 
1-(9H-Carbazol-2-yl)ethanol, 34a. Synthesised according to Method D using 1-(9H-carbazol-2-
yl)ethanone (0.50 g, 2.39 mmol) and NaBH4 (0.16 g, 4.30 mmol); yield: 0.42 g (83%); Rf  = 0.12 (petrolether 
/ EtOAc, 5:1); light yellow solid: mp 192–194 °C; δH (CDCl3, 500 MHz) 1.41 (d, J = 6.6 Hz, 3H, CH3), 3.13 
(s, br, 1H), 4.88 (q, J = 6.6 Hz, 1H), 7.03 (ddd, J = 1.2, 7.3, 7.9 Hz, 1H), 7.07 (dd, J = 1.6, 8.2 Hz, 1H), 7.22 
(ddd, J = 1.2, 7.2, 8.2 Hz, 1H), 7.30 (dt, J = 1.0, 8.2 Hz, 1H), 7.37–7.39 (m, 1H), 7.85 (d, J = 8.2 Hz, 1H), 
7.88 (d, J = 7.9 Hz, 1H), 9.62 (s, br, 1H); δC (CDCl3, 125 MHz) 25.5 (CH3), 69.9 (CH2), 107.3 (CH), 110.4 
(CH), 116.4 (CH), 118.4 (CH), 119.5 (CH), 119.6 (CH), 121.8 (Cq), 122.6 (Cq), 124.9 (CH), 139.7 (Cq), 
139.8 (Cq), 144.4 (Cq); MS (ESI): m/z = 210 [M+-H]. 
1-(7-Fluoro-9H-carbazol-2-yl)ethanol, 35a. Synthesised according to Method D using 35b (0.25 g, 1.12 
mmol) and NaBH4 (0.08 g, 2.02 mmol); yield: 0.21 g (82%); Rf = 0.19 (petrolether / EtOAc, 5:1); δH (CDCl3, 
500 MHz) 1.50 (d, J = 6.4 Hz, 3H), 4.94 (q, J = 6.4 Hz, 1H), 6.85 (ddd, J = 2.3, 8.5, 8.8 Hz, 1H), 7.08 (dd, J 
= 2.3, 9.8 Hz, 1H), 7.15 (dd, J = 1.2, 8.2 Hz, 1H), 7.43 (s, br, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.93 (dd, J = 5.5, 
8.5 Hz, 1H); δC (CDCl3, 125 MHz) 26.0 (CH3), 71.5 (CH), 98.0 (d, CH), 107.5 (d, CH), 108.6 (CH), 118.2 
(CH), 120.5 (CH), 120.8 (Cq), 121.8 (d, CH), 123.2 (Cq), 142.2 (Cq), 142.4 (Cq), 145.1 (Cq), 163.2 (d, Cq); 
MS (ESI): m/z = 212 [M+-OH]. 
4'-(1H-Imidazol-1-yl-propyl)-biphenyl-4-ylamine, 21a. To a solution of 20 (0.32 g, 0.85 mmol) in DCM 
(10 mL) was added TFA (0.63 mL, 8.5 mmol) slowly in an ice bath. Subsequently it was stirred at room 
temperature overnight. DCM (10 mL) and water (10 mL) were added and the organic phase was separated. 
The organic phase was extracted with water and brine, dried over Na2SO4, and evaporated under reduced 
pressure. The crude products were purified by flash chromatography on silica gel; yield: 0.22 g (95%); Rf = 
0.35 (PE / EtOAc, 2:1); the compound was directly used in the next step without further purification and 
analysis. 
N-[4'-(1H-Imidazol-1-yl-propyl)-biphenyl-4-yl]-acetamide, 21. To a solution of 21a (0.07 g, 0.25 
mmol) in THF (10 mL) were added DMAP (0.02 g, 0.13 mmol) and triethylamine (0.1 mL). After cooling to 
0 °C in an ice bath, acetyl chloride was dropped into the reaction solution slowly. Then it was stirred in the 
ambient temperture overnight. After neutralized to pH = 7 with sodium bicarbonate in an ice bath, ethyl 
acetate (10 mL) and water (10 mL) were added and the organic phase was separated. The organic phase was 
extracted with water and brine, dried over Na2SO4, and evaporated under reduced pressure. The crude 
products were purified by flash chromatography on silica gel; yield: 0.33 g (23%); white solid: mp 221–223 
°C; Rf = 0.27 (DCM / MeOH, 20:1); δH (CDCl3, 500 MHz) 0.97 (t, J = 7.3 Hz, 3H, CH3), 2.20 (s, 3H, 
CH3CO), 2.26 (q, J = 7.3, 7.6 Hz, 2H, CH2), 5.05 (t, J = 7.6 Hz, 1H, CH), 6.99 (s, 1H), 7.11 (s, 1H), 7.23 (d, 
J = 8.2 Hz, 2H), 7.49–7.58 (m, 6H), 7.72 (s, 1H); δC (CDCl3, 125 MHz) 11.0 (CH3), 24.6 (CH3CO), 28.5 
(CH2), 63.2 (CH), 120.1, 126.9, 127.5, 127.5, 135.9, 137.6, 140.5, 168.4; MS (ESI): m/z = 320 [M++H]. 
4'-(1H-Imidazol-1-yl-propyl)-biphenyl-4-ol, 22. To a solution of 22a (0.85 g, 2.16 mmol) in anhydrous 
THF (20 mL) was added TBAF (2.4 mL, 2.4 mmol) and subsequently the solution was stirred at room 
temperature for 4 h. The reaction was terminated with the addition of methanol and the solvent was removed 
under reduced pressure. Then the desired product was purified by chromatography on silica gel. Yield: 0.22 
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g (37%); Yellow solid; Rf = 0.21 (Hex / EtOAc, 5:1); δH (DMSO-d6, 500 MHz) 0.82 (t, J = 7.3 Hz, 3H), 2.21 
(m, 2H), 5.23 (t, J = 7.3 Hz, 1H), 6.82 (d, J = 8.8 Hz, 2H), 6.90 (s, 1H), 7.37 (d, J = 8.5 Hz, 2H), 7.46 (d, J = 
8.8 Hz, 2H), 7.54 (d, J = 8.5 Hz, 2H),  7.82 (s, 1H), 9.55 (s, 1H); δC (DMSO-d6, 125 MHz) 10.9 (CH3), 27.4 
(CH2), 61.5 (CH), 115.6 (CH), 117.7 (CH), 126.0 (CH), 127.1 (CH), 127.6 (CH), 128.4 (Cq), 130.3 (CH), 
130.7 (Cq), 139.3 (CH), 139.5 (Cq), 157.1 (Cq); MS (ESI): m/z = 279 [M++H]. 
3-(4'-Fluorobiphenyl-4-yl)-3-(1H-imidazol-1-yl)propan-1-ol, 26. 26a (0.241 g, 0.45 mmol) was 
dissolved by slowly adding dropwise to 15 mL THF and 1M TBAF (0.55 mL, 0.55 mmol) in THF.  1 hour 
later, according to TLC (DCM / methanol, 95:5) the deprotection was quantitative.  The batch was diluted 
with a large quantity of ethyl acetate and extracted three times with water and once with brine, then dried 
over MgSO4 and the solvent removed under reduced pressure.  The crude product was subsequently purified 
by column chromatography; yield: 0.09 g (67%); Rf = 0.34 (DCM / MeOH, 9:1); δH (CDCl3, 500 MHz) 
2.43–2.49 (m, 2H, CH2), 3.50–3.54 (m, 1H), 3.68–3.72 (m, 1H), 5.56–5.59 (q, 1H, CH), 6.98–6.99 (m, 1H), 
7.08–7.09 (m, 1H´), 7.13–7.14 (m, 2H), 7.26–7.29 (m, 2H), 7.48–7.51 (m, 4H), 7.56–7.57 (m, 1H); δC 
(CDCl3, 125 MHz) 37.1 (CH2), 50.5 (CH), 57.7 (CH2-OH), 116.3, 127.6, 128.6, 129.8, 136.8, 137.2, 139.9, 
140.0, 161.4; MS (ESI): m/z = 297 [M++H]. 
1-(3-Chloro-1-(4'-fluorobiphenyl-4-yl)propyl)-1H-imidazole, 27. 26 (0.044 g, 0.148 mmol) was 
dissolved in 10 mL dry DCM and mixed with 13 µL thionyl chloride.  The batch was stirred for 2 hours at 
room temperature; according to the TLC control, the reaction was quantitative.  The batch was diluted with a 
large quantity of DCM and water.  The organic phase was separated off and extracted 5 times with water and 
once with brine, then dried over MgSO4 and  the solvent removed under reduced pressure; yield: 0.05 g 
(99%); Rf  = 0.63 (DCM / MeOH, 9:1); δH (CDCl3, 500 MHz) 2.87–2.97 (m, 2H, CH2), 3.50–3.60 (m, 2H, 
CH2Cl), 5.80–5.83 (m, 1H, CH),  7.11–7.16 (m, 2H), 7.16–7.17 (m, 1H), 7.35–7.37 (m, 1H), 7.49–7.53 (m, 
4H), 7.58–7.60 (m, 2H), 9.51–9.53 (m, 1H); δC (CDCl3, 125 MHz) 34.2 (CH2), 41.4 (CH2Cl), 61.8 (CH), 
119.6, 122.9, 116.5, 128.4, 129.4, 135.7, 136.3, 137.6, 136.4, 142.5, 163.5; MS (ESI): m/z = 315 [M++H]. 
1-(7-(tert-Butyldimethylsilyloxy)-9H-fluoren-2-yl)ethanone, 30c. Imidazole (0.17 g, 2.45 mmol) and 1-
(7-hydroxy-9H-fluoren-2-yl)ethanone  (0.50 g , 2.23 mmol) were dissolved in 20 mL DCM. Then tert-
butyldimethylsilylchloride (0.37 g, 2.45 mmol) dissolved in 3 mL DCM were slowly added. The resulting 
mixture was stirred for 18 h at room temperature. Afterwards the mixture was extracted with water and brine. 
The organic phase was separated, dried over Na2SO4 and evaporated; yield: 0.58 g (77%); Rf = 0.40 
(petrolether / EtOAc, 10:1); MS (ESI): m/z = 339 [M++H]. 
7-(1-(1H-imidazol-1-yl)ethyl)-9H-fluoren-2-ol, 30. 30a (0.16 g, 0.40 mmol) was dissolved in 10 mL 
THF and 1M TBAF (0.41 mL, 0.41 mmol) solution in THF was added dropwise.  After 1 hour according to 
TLC (DCM / methanol 95:5) the deprotection was quantitative.  The batch was diluted with a large quantity 
of ethyl acetate and extracted three times with water and once with brine, then dried over MgSO4 and the 
solvent removed under reduced pressure; yield: 0.10 g (90%); Rf  = 0.12 (MeOH / EtOAc, 5:95); orange 
solid: mp 217–218 °C; δH (CDCl3, 500 MHz) 1.81 (d, J = 6.9 Hz, 3H), 3.70 (s, 2H), 5.31 (q, J = 6.9 Hz, 1H), 
6.77 (dd, J = 2.2, 8.2 Hz, 1H), 6.90 (s, 1H), 6.93 (s, 1H), 6.95 (s, 1H), 7.06 (d, J = 7.9 Hz, 1H), 7.18 (s, 1H), 
7.50 (d, J = 8.2 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.55 (s, 1H); δC (CDCl3, 125 MHz) 21.9 (CH3), 36.6 
(CH2), 56.9 (CH), 112.0 (CH), 114.1 (CH), 118.1 (CH), 118.8 (CH), 120.6 (CH), 122.4 (CH), 124.7 (CH), 
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128.2 (CH), 132.8 (Cq), 135.6 (CH), 137.9 (Cq), 142.0 (Cq), 143.2 (Cq), 145.2 (Cq), 156.6 (Cq); MS (ESI): 
m/z = 277 [M++H]. 
1-(7-Fluoro-9H-carbazol-2-yl)ethanone, 35b. 35c was dissolved in 3 mL P(OEt)3 and refluxed for 16 h. 
The resulting mixture was directly purified using column chromatography; yield: 0.28 g (53%); Rf = 0.13 
(petrolether / EtOAc, 5:1); δH (CDCl3, 500 MHz) 2.54 (s, 3H), 6.79 (ddd, J = 2.3, 8.6, 9.5 Hz, 1H), 7.01 (dd, 
J = 2.3, 9.6 Hz, 1H), 7.65 (dd, J = 1.6, 8.2 Hz, 1H), 7.85 (dd, J = 5.4, 8.5 Hz, 1H), 7.87 (d, J = 8.5 Hz, 1H), 
7.93 (dd, J = 0.6, 1.6 Hz, 1H), 10.53 (s, br, 1H); δC (CDCl3, 125 MHz) 26.5 (CH3), 97.4 (d, CH), 107.3 (d, 
CH), 110.9 (CH), 118.4 (Cq), 119.0 (CH), 119.2 (CH), 121.6 (d, CH), 126.2 (Cq), 133.6 (Cq), 139.7 (Cq), 
142.0 (d, Cq), 162.2 (d, Cq), 197.8 (Cq); MS (ESI): m/z = 227 [M++H]. 
Docking studies 
All molecular modelling studies were performed on Intel(R) P4 CPU 3.00GHz running Linux Suse 10.1.  
Ligands. The structures of the inhibitors were built with SYBYL 7.3.2 (Sybyl, Tripos Inc., St. Louis, 
Missouri, USA) and energy-minimized in MMFF94s force-field24a as implemented in Sybyl. The resulting 
geometries for our compounds were then subjected to ab initio calculation employing the B3LYP 
functional24b–c in combination with a 6-31G* basis set using the package Gaussian03 (Gaussian, Inc., 
Pittsburgh, PA, 2003). 
Docking. Various inhibitors were docked into our CYP17 homology model by means of the GOLD v3.0.1 
software.25 Since it is known that non-steroidal inhibitors of CYP enzymes primary interact by complexation 
of the heme iron with their sp2 hybridized nitrogen15c a distance constraint of a minimum of 1.9 and a 
maximum of 2.5 Å between the nitrogen of the imidazole and the iron was set. 
Ligands were docked in 50 independent genetic algorithm (GA) runs using GOLD. Heme iron was chosen 
as active-site origin, while the active site radius was set equal to 19 Å. The automatic active-site detection 
was switched on. A distance constraint of a minimum of 1.9 and a maximum of 2.5 Å between the sp2-
hybridised nitrogen of the imidazole and the iron was set. Furthermore, some of the GOLDSCORE 
parameters were modified to improve the weight of hydrophobic interaction and of the coordination between 
iron and nitrogen. The genetic algorithm default parameters were set as suggested by the GOLD authors. On 
the other hand, the annealing parameters of fitness function were set at 3.5 Å for hydrogen bonding and 6.5 
Å for Van der Waals interactions. 
All 50 poses for each compound were clustered with ACIAP26 and the representative structure of each 
significant cluster was selected. The quality of the docked representative poses was evaluated based on 
visual inspection of the putative binding modes of the ligands, as outcome of docking simulations and cluster 
analysis. Further the different interaction patterns were manually analyzed using Silver 1.1,25b a program 
included for use with GOLD and used to post-process docking results. 
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Paper II 
 
Abstract: It has been illuminated that the growth of most prostate carcinoma depends on androgen 
stimulation. Therefore the inhibition of CYP17 to block androgen biosynthesis is regarded as a promising 
therapy. Based on our previously identified lead compound Ref 1, a series of fluorine substituted biphenyl 
methylene imidazoles were designed, synthesized and evaluated as CYP17 inhibitors, to elucidate the 
influence of fluorine on in vitro and in vivo activity. It has been found that meta- F substitution on the C- 
ring improved the activity, whereas ortho- substitution reduced the potency. Docking studies which were 
performed with our human CYP17 homology model suggest multi-polar interactions between fluorine and 
Arg109, Lys231, His235 and Glu305. As expected, introduction of fluorine also prolonged the plasma half-
life. The SARs obtained confirm the reliability of the protein model and result in compound 9 (IC50 = 131 
nM) as strong CYP17 inhibitor showing potent activity in the rat, a high bioavailability and a long plasma 
half-life (12.8 hours).  
 
Keywords: prostate cancer, CYP17 inhibitors, fluorine, pharmacokinetics, testosterone plasma 
concentrations. 
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Introduction 
As the most common malignancy in male elders, prostate carcinoma also acts as a major cause of death.[1] 
It has been illuminated that the growth of up to 80 % of prostate carcinoma depends on androgen stimulation. 
Therefore, segregation of tumour cells from androgen will effectively prevent cancer cell proliferation. Since 
more than 90 % of testosterone is produced in testes, orchidectomy or treatment with gonadotropin-releasing 
hormone (GnRH) analogues[2] (chemical castration) are applied in clinic. As this therapy has no effect on the 
minor amount of androgen produced in the adrenals, androgen receptor antagonists are employed 
additionally. This is the current standard therapy for prostate carcinoma, the so called “combined androgen 
blockade” (CAB).[3] However, CAB often leads to resistance which can be associated with androgen receptor 
mutations. The mutated androgen receptor recognizes antagonists and glucocorticoids as agonists, finally 
resulting in the collapse of CAB therapy.[4]  
The shortcomings of CAB waken a more promising alternative: total blockage of androgen biosynthesis, 
which means inhibition of cytochrome P450-17 (17α-hydroxylase-17,20-lyase, CYP17). CYP17 is one of six 
CYP enzymes involved in steroid biosynthesis. Like all CYP enzymes, CYP17 consists of a heme and an 
apoprotein moiety. Although all potent inhibitors interfere with the heme, which is common to CYP enzymes, 
by complexing its central iron ion, it is nevertheless possible to selectively inhibit these enzymes as has been 
demonstrated with CYP19 (aromatase, estrogen synthase)[5] and CYP11B2 (aldosterone synthase).[6] While 
aromatase inhibitors are already in clinical use, [5a] the first highly potent and selective CYP11B2 inhibitors 
have been identified just recently, [6] some of which are extremely selective.  
CYP17, located in both testicular and adrenal tissue,[7] is the key enzyme catalyzing the conversion of 
pregnenolone and progesterone to dehydroepiandrosterone (DHEA) and androstenedione, respectively. 
DHEA can be transformed into androstenedione by 3β-HSD, which is subsequently converted into the most 
potent androgen dihydrotestosterone (DHT) in androgen target cells through two enzymatic steps catalyzed 
by 17β-HSD1 or 3 and steroid 5α-reductase (5αR). Thus, inhibition of CYP17 could annihilate the androgen 
production both in testes and in adrenals. Furthermore, targeting genetically stable human tissue instead of 
cancer cells would avoid the resistance caused by mutation. 
Ketoconazole (Figure 1), an antimycotic agent showing non-selective inhibition of CYP17, is the first 
medication which has been used clinically in treatment of prostate carcinoma. Although withdrawn because 
of side-effects, Ketoconazole shows good curative effects,[8] which demonstrates the feasibility of prostate 
carcinoma treatment via CYP17 inhibition. Since then, in mimicry of the physiological substrates, many 
steroidal CYP17 inhibitors were synthesized by others[9] and our group,[10] including Abiraterone (Figure 1), 
which has entered into phase II clinical trial recently. However, the affinity of steroidal compounds toward 
steroid receptors, which often results in side effects no matter acting as agonists or antagonists, prompted us 
to develop non-steroidal CYP17 inhibitors.[11, 12] 
Our group has reported about series of biphenyl methylene imidazoles as potent CYP17 inhibitors.[12] A 
promising lead compound 1-[1-(4'-fluoro-biphenyl-4-yl)-propyl]-1H-imidazole[12g] (Ref 1, Figure 1) was 
identified in the optimization process. In the present investigation this compound was further modified to 
elevate potency, selectivity as well as pharmacokinetic properties. Since fluorine is known to be able to form 
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multi-polar interactions with several amino acids [13e-l] and due to its capability to enhance metabolic stability, 
the biphenyl core was substituted with additional fluorine atoms leading to compounds 1–22. Exchanging the 
1-imidazolyl group by a 5-imidazolyl moiety while maintaining 4-fluoro-phenyl as A-ring, compounds 23–
26 were subsequently obtained. Furthermore, besides determination of inhibitory activities toward human 
CYP17 in vitro, selected compounds were examined for their potency to reduce plasma testosterone 
concentration and for their pharmacokinetic properties in rats. Moreover, computational investigations were 
performed: molecular docking studies using our homology model of human CYP17[12e] to elucidate the 
enzyme-inhibitor interactions and quantum mechanical studies to explore the influence of fluorine 
substitution on potency and pharmacokinetic properties of this type of CYP17 inhibitors. 
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Figure 1. Typical CYP17 inhibitors. 
Drug design 
Fluorine, as the most electronegative atom, has been widely employed to prevent undesired metabolism 
because of the strong C-F bonds. Besides the increase of metabolic stability, fluorine can also improve other 
pharmacokinetic properties by means of influencing pKa, elevating lipophilicity and reducing plasma protein 
binding.[13] Recently, multi-polar interactions between fluorine and some amino acid residues, responsible for 
the enhanced binding potency, have also been reported.[13e-l] Based on these findings, fluorophilicity and 
fluorophobicity in protein active site have been discussed,[13c, d] and systemic fluorine scan was recommended 
in drug discovery and lead optimization. 
We found that fluorine substitution at the para- position of the A-ring could significantly increase the 
inhibitory potency of biphenyl methylene imidazole type CYP17 inhibitors, resulting in compound Ref 1 
(IC50 = 345 nM).[12g] Besides the complexation of the heme iron, recognized as the main anchor point for 
non-steroidal CYP inhibitors (first notified for CYP19 inhibitors[5b-c]), by a heterocyclic nitrogen, polar 
interactions between this fluorine atom and the guanidinium side chain of Arg109 and the amino side chain 
of Lys231 were observed for Ref 1 and considered as important for binding affinity[12g] (Figure 2). The A-
ring is presumably stabilized by a strong T-shaped arene quadrupole interaction with Phe114, a 
conformationally flexible residue responsible for dividing the CYP17 active site into two lobes. Furthermore, 
some more amino acid residues such as Asn, Arg or Gln were identified close to the A- or C-ring, which 
might provide the potential for additional fluorine substituents to form multi-polar interaction with H-X 
(where X = N, O, S)[13h-l] and backbone C=O (in an orthogonal manner),[13e-f] or even with the H-Cα.[13c, 13g] 
Consequently, the following strategies to increase the inhibitory potency and the metabolic stability of Ref 1 
were applied: a) shifting the fluorine to other positions in the A-ring; b) additional introduction of fluorine 
atoms on the A- or C-ring in order to identify new interaction areas. Since these modifications change the 
molecular electrostatic potentials (MEP) of the compounds, the protein pocket surrounding of the C-ring was 
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scrutinized with the aim to identify potential interaction areas influenced by MEP variations, especially the 
backbone π-systems of amino acids such as Gly301-Ala302.  
 
Figure 2. Amino acid residues surrounding Ref 1: Arg109 and Lys231 interact with the para- F on the A-ring. Some more amino 
acid residues around the A-ring or C-ring might form additional multi-polar interactions with further F substituents. 
Results and Discussion 
Chemistry  
The syntheses of compounds 1–26 are shown in Schemes 1–3. For 1-imidazole analogues 1–22, a general 
synthetic strategy was employed: ketone or aldehyde intermediates were obtained by means of Suzuki 
coupling (Method C) from the corresponding bromides and boronic acids.[14] Subsequently they were 
converted to the alcohols by reduction with NaBH4 (Method D) or Grignard reaction (Method B). The 
alcohol intermediates reacted with 1,1-carbonyl diimidazole (CDI) to give the racemic mixtures of the 
desired products, which were not separated into their enantiomers. Using different reaction conditions, such 
as solvent and reaction temperature, different products were obtained in this SNt reaction. After refluxing in 
NMP for 4 hours (Method A),[15] biphenyl methylene imidazoles were obtained; whereas boiling in THF for  
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a Reagents and conditions: Compounds were synthesized from the corresponding a or b intermediates unless annotated otherwise. a) 
Method C: Pd(PPh3)4, Na2CO3, toluene, reflux, 6h. b) Method D: NaBH4, MeOH. c) Method B: EtMgBr, THF. d) Method E: CDI, 
THF, reflux, 4 days. e) Method A: CDI, NMP, reflux, 4h. 
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Scheme 2.a  
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a Reagents and conditions: a) Method C: 4-fluoro boronic acid, Pd(PPh3)4, Na2CO3, toluene, reflux, 6h. b) i. imidazole, n-BuLi, 
TrtCl, THF, 0 °C, 2h; ii. n-BuLi, tert-Bu-diMe-SiCl, THF, 0 °C, 2h; c. n-BuLi, 23b, THF, room temp, 8h. c) pyridinium 
hydrochloride, MeOH, 60 °C, 4h. 
 
Scheme 3.a  
F
HN
N
F
HN
N
HN
N
HO
F
N
N
HO
Br Trt
a) b) c)
24 25 26  
a Reagents and conditions: a) i. Method C: 4-fluoro boronic acid, Pd(PPh3)4, Na2CO3, toluene, reflux, 6h; ii. pyridinium 
hydrochloride, MeOH, 60 °C, 4h. b) HCl / i-PrOH, 80 °C, 2h. c) Pd(OH)2, ethanol, THF, H2, room temp, 3h. 
4 days (Method E) gave imidazole-1-carboxylic acid biphenyl esters as major products. Distinguishing 
between these two products is easy as the chemical shifts of imidazole 2-H in biphenyl methylene imidazoles 
are around 7.6 ppm, whereas they are beyond 8.2 ppm in imidazole-1-carboxylic acid biphenyl esters. [15] 
Moreover, the proton chemical shift of CH is 5.1 ppm in the biphenyl methylene imidazoles, whereas in the 
imidazole-1-carboxylic acid biphenyl esters it is 5.9 ppm. Additionally, the strong carbonyl signal in the IR 
spectra contributes to the identification of the latter class of compounds. For the synthesis of the 5-imidazole 
analogues (23–26) trityl was employed as protecting group for imidazole. The alcohol intermediates, 
commercially available or obtained by reaction of imidazolyl lithium with aldehyde, underwent elimination 
of the H2O group in acidic environment to give the corresponding isopropylidene product, which was 
subsequently saturated by hydrogenation of the double bond.  
In vitro activity 
CYP17 inhibition of all compounds was evaluated using the 50,000 sediment after homogenation of E.coli 
expressing human CYP17 as well as cytochrome P450 reductase.[12d] The assay was run with progesterone as 
substrate and NADPH as cofactor. Separation of substrate and product was accomplished by HPLC using 
UV detection.[16] IC50 values are presented in comparison to Ketoconazole and Abiraterone in Tables 1–2. 
It is striking that in the series of 1-imidazole compounds (1–22) a sharp structure activity relationship is 
observed. The analogues can be divided into 3 classes regarding the fluorine substitution on the C-ring, i.e. 
without F, meta-F and ortho-F (positions relative to the A-ring, Table 1).  
It can be seen that, in the class of compounds without fluorine on the C-ring, additional substitution at the 
A-ring by fluorine, methyl or methoxy (1, 2, 4, 6 and 7), did not enhance the inhibitory activity compared to 
Ref 1 (IC50 = 345 nM). For example, extra fluorine substitution at meta- or ortho-position of the A-ring, 
resulting in 3’,4’-di F (2) and 2’,4’-di F (4) analogues, decreased activity somewhat (IC50 = 803 and 985 nM, 
respectively). Interestingly, 2’,5’-di F substitution (7) exhibited similar inhibitory potency (IC50 = 956 nM) 
as seen with the 2’,4’-di F analogue.  
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Table 1. Inhibition of CYP17 by compounds 1–22. 
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Ref 1, 1-2, 4, 6-7, 9, 11, 13-22 3, 5, 8, 10, 12
 
Compd R1 R2 R3 IC50[a] Compd R1 R2 R3 IC50[a] Compd R1 R2 R3 IC50[a] 
Ref 1 4'-F H Et 345 9 4'-F m-F Et 131 19 4'-F o-F Et 657 
     10 4'-F m-F Et 4643      
     11 4'-F m-F H 2110 20 4'-F o-F H 2800 
     12 4'-F m-F H >5000      
1 4'-F, 2'-Me H Et 951           
2 3',4'-di F H Et 803 13 3',4'-di F m-F Et 305 21 3',4'-di F o-F Et 825 
3 3',4'-di F H Et >5000 14 3',4'-di F m-F H >5000      
4 2',4'-di F H Et 985 15 2',4'-di F m-F Et 381      
5 2',4'-di F H Et >5000 16 2',4'-di F m-F H >5000 22 2',4'-di F o-F H >5000 
6 2',4'-di F, 3'-MeO H Me >10000           
7 2',5'-di F H Et 956 17 2',5'-di F m-F Et 364      
8 2',5'-di F H Et >5000 18 2',5'-di F m-F H 1640      
KTZ[b]    2780      ABT[b]    72 
[a] Concentration of inhibitors required to give 50 % inhibition. The mean values of at least three experiments are given in nM within ±10 % deviation.  
[b] KTZ: Ketoconazole; ABT: Abiraterone.  
3 Results and Discussions 
胡庆忠博士论文 
- 61 -
Importantly, the introduction of fluorine at the meta- position of the C-ring significantly increased the 
inhibitory potency. Compound 9 showed IC50 of 131 nM, being 3 fold more potent than Ref 1. Similar 
improvements can be found for the other compounds in this class (13, 15 and 17, IC50 values around 350 nM) 
being 3 fold more potent than the corresponding compounds without F at the C-ring (2, 4 and 7, respectively, 
IC50 values around 900 nM). Moreover, it can be seen that the analogue with only one para-F at the A-ring 
(9) is more potent than other analogues with multi-F on the A-ring as mentioned above. A similar ranking of 
potency can be observed for multi-F analogues in this class of compounds too: the 3’,4’-di F compound (13, 
IC50 = 305 nM) being more potent than the others, e. g. the 2’,5’-di F compound (15, IC50 = 381 nM) and  the 
2’,4’-di F compound (17, IC50 = 364 nM).  
On the contrary, ortho-F substitution at the C ring decreased activity. Compound 19 (IC50 = 657 nM) was 
less potent than the corresponding analogues with meta-F (9, IC50 = 131 nM) or without F (Ref 1, IC50 = 345 
nM). However, compound 19 exhibited stronger inhibition compared to compound 21 furnished with two 
fluorine substituents in 3’,4’-position as expected. 
Moreover, all imidazole-1-carboxylic acid biphenyl esters (3, 5, 8, 10 and 12), which have been proven to 
be stable in incubation buffer by HPLC, were found to be inactive. This is probably due to the fact that these 
molecules are too large to fit into the binding pocket. Noteworthy is the importance of the ethyl substituent at 
the methylene bridge, as already reported,[12g] i.e. that ethyl substitution results in more potent compounds 
compared to the corresponding non- or methyl substituted analogues. 
Furthermore, 5-imidazole was employed instead of 1-imidazole leading to compounds 23–26 as shown in 
table 2. It is apparent that compounds with a hydroxy group substituted at the methylene bridge are inactive. 
Nonetheless, isopropyl substitution resulted in an active compound (26, IC50 = 502 nM), which was, however, 
less potent compared to Ref 1. Surprisingly, the compound with an isopropylidene substitution (25) turned 
out to be very potent (IC50 = 159 nM). 
Table 2. Inhibition of CYP17 by compounds 23–26. 
F
R5 R6
HN N  
Compd R5 R6 IC50[a]  Compd R5 R6 IC50[a] 
23 OH H >>10000  25 i-Propylidene 159 
24 OH i-Pr >5000  26 H i-Pr 502 
KTZ[b]   2780  ABT[b]   72 
[a] Concentration of inhibitors required to give 50 % inhibition. The mean values of at least three experiments are given in nM within 
±10 % deviation.  
[b] KTZ: Ketoconazole; ABT: Abiraterone. 
Finally, inhibition values of the most active compounds 9, 13, 15, 17 and 25 toward the hepatic enzyme 
CYP3A4 were also determined, because of its important role in drug metabolism and drug-drug interaction. 
It turned out that the compounds tested showed only marginal inhibition (around 50 % at 10 µM), clearly 
lower than that shown by Ketoconazole (98 % at 10 µM).  
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Computational studies  
Docking  
Compounds Ref 1, 9, 11, 13, 15, 17 and 19, both enantiomers if existing, were docked into the homology 
model of human CYP17 [12e] by means of two commercial docking softwares, GOLD_v4.0[17] and FlexX 
3.1.3,[18] in order to elucidate their binding into the active site of the enzyme. The docking with GOLD was 
performed with both the scoring functions GOLDSCORE and CHEMSCORE, while FlexX was used with 
the FlexX-Pharm module, with the iron of the heme chosen as pharmacophoric constraint. A clustering with 
AClAP[19] of all the docking poses of the three procedures resulted in one main, statistical predominant 
binding mode (BM1)[12e] and two minor representative clusters. Interestingly, each of the latter two clusters 
solely consisted of either the S- (BM2)[12e] or the R- (BM-ABT)[12h] enantiomers respectively (Figure 3). This 
finding indicates that, together with the necessary perpendicular interaction angle between imidazole N and 
heme Fe to ensure sufficient coordination, the orientation of the hydrophobic pocket, which is occupied by 
the substituent on the methylene bridge, limits the pose distribution of different enantiomers. This 
geometrical restriction forces the S- enantiomers into BM2 area and the R-enantiomers into BM-ABT. 
However, as the intersection of both areas, BM1 is a better area for both enantiomers to bind.  
 
Figure 3. Presentation of the three main binding modes, exemplified by compounds 9 (magenta, BM1), 15 (red, BM2) and 13 (blue, 
BM-ABT). Heme, interacting residues and ribbon rendered tertiary structure of the active site are shown. Polar interactions are 
marked with red solid lines, whereas π-π stacking and metal complexation with cyan dotted lines. Figure was generated with MOE 
(http:// www.chemcomp.com). 
It can be observed for BM1 that a conjugated scaffold orienting almost parallel to the I-helix is one of the 
key factors for high activity as previously described.[12g] According to our docking studies this extended π-
system obviously interacts not only with the π-system of the amino acid backbone in the I-helix (i.e. Gly301, 
Ala302, Gly303, Val304), but also with Phe114, which is oriented perpendicular toward the A-ring (Figure 3 
BM1) to form a quadrupole-quadrupole interaction. More importantly, fluorine in the molecule showed 
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profound influence on the affinity for the enzyme. This can be explained by the obviously existing 
interactions of the para-F substituent with Arg109, Lys231 and His235 (Figure 3). When the fluorines were 
shifted to other positions in the A-ring resulting in 2’,5’-di F analogues, a decrease of activities can be 
observed. Obviously, the interactions mentioned above can no longer be maintained. These observations 
nicely validate the reliability of our protein model. Furthermore, the elevated activity of C-ring meta-F 
substituted compounds can be explained by a multi-polar interaction between F and the N-H group of 
Glu305 (Figure 3) stabilizing the π-π interaction between the C-ring and the backbone π-system of Gly301-
Ala302. 
Additionally, a further flexible docking run was performed with GOLDv4.0-GOLDSCORE, with the side 
chains of Phe114, Arg109, Lys231, Asn202, Glu305, and Ile371 being set freely rotatable. Very similar 
results were observed as seen for the docking runs with the rigid side chains (data not shown).  
MEP maps  
To obtain an insight which physicochemical parameters might influence biological activity, the charge 
density distribution was considered and the molecular electrostatic potentials (MEPs) of selected compounds 
were determined. The geometry of these compounds (Ref 1, 2, 9, 13, 15, 17 and 25) was optimized in the gas 
phase at the B3LYP/6-311++G** (d,p)[20] level of density functional theory (DFT) by means of Gaussian 
03.[21] MEPs of electron density were plotted for every compound with GaussView 3.09.[22] 
 
Figure 4. (A) Structure, CYP17 inhibitory activity and MEP maps (bottom and top view) of compounds 9 and 13. For compounds 15 
and 17, nearly the same MEP maps (not shown) as for of compound 13 were observed. (B) MEP maps of compound 25, highlighting 
in the side-views of the conjugated π-π system, enhanced by the isopropylidene substituent on the methylene bridge. The electrostatic 
potential surfaces shown in (A) and (B) were plotted with GaussView 3.0 in a range of -6 to +12 kcal/mol. (C) Transparent color-
coded front and back view of the electrostatic potential maps of the imidazoles of both Ref 1 and compound 9, in a range of -15.7 to 
+0 kcal/mol, illustrative for the influence exerted on the electron distribution of the imidazole by fluorine substitutents on the C-ring. 
The introduction of a second fluorine or the shift of fluorine into another position on the A-ring always 
leads to a reduction of the A-ring electron density, which can be clearly seen in the different MEP maps of 
compounds 9, 13, 15, 17 and 25 (Figure 4A). This observation correlates with the different electron-
withdrawing effects of the fluorine in meta- or para-position (σ values of +0.337 and +0.067, respectively). 
This reduction of electron density weakens the T-shaped interaction of the A-ring with Phe114, and 
consequently decreases the inhibitory potency of the compound.  
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The lower inhibitory potency of compounds with ortho-F substitution on the C-ring (19 and 21) might be 
due to the adverse effect that the fluorine exerts on the overall charge density of the biphenyl system by 
deforming the conjugated π-π system and by concentrating the electrons on the fluorine. However, for meta- 
F compounds (9, 13, 15 and 17) it seems that fluorine induces an increase in electron distribution on the 
imidazole ring, as visualized in the MEP maps of compounds Ref 1 and 9 (Figure 4C), which is linked with 
an augmented inhibitory potency of the compounds. An analogous phenomenon was observed for compound 
25, where the isopropylidene strengthened the π-π system and extended the conjugation over the whole 
molecule (Figure 4B). 
In vivo activity 
The in vivo evaluation of the most potent compounds 9, 13, 15 and 17, including the ability of reducing 
plasma testosterone concentration (Figure 5) and the determination of pharmacokinetic properties (Table 3) 
was performed in male Wistar rats after oral application. Abiraterone which was administered as acetate to 
improve its oral absorption and Ref 1 were used as reference compounds. The plasma concentrations of 
testosterone were determined using an ELISA assay and plasma drug concentrations were measured using 
LC-MS. In the case of Abiraterone acetate only the signals of free Abiraterone were monitored, as the acetate 
is inactive as CYP17 inhibitor. As can be seen from Figure 5 all compounds significantly reduced the plasma 
testosterone concentration. It is striking at each time point investigated that all non-steroidal compounds, 
which were less active in vitro, exhibited higher activities in vivo than Abiraterone. After 24 hours, 
Table 3. Pharmacokinetic properties of selected compounds[a] 
Compd t 1/2 z(h)[b] t max (h)[b] C max (nM)[b] C 24h (nM)[b] AUC 0-∞ (nM * h)[b] 
9 12.8 2.0 3473 1528 80448 
13 6.1 8.0 3496 1173 56114 
15 4.2 6.0 2539 556 35091 
17 2.2 1.0 458 187 2055 
Ref 1 10.0 6.0 11729 4732 252297 
Abiraterone  1.6 2.0 1694 253 11488 
[a] Compounds Ref 1, 9, 13, 15 and 17 were applied at a dose of 50 mg / kg body weight; Abiraterone was administrated as 
Abiraterone acetate (56 mg / kg body weight, equivalent to Abiraterone 50 mg / kg body weight). 5 to 6 intact adult male Wistar rats 
were employed for each treatment group; each sample was tested for 3 times.  
[b] t ½ z: terminal half-life; t max: time of maximal concentration; C max: maximal concentration; C 24h: concentration at 24h; AUC 0-∞: 
area under the curve. 
compound 9 and Ref 1 still showed strong inhibitory activity, compounds 13 and 17 showed almost no 
inhibition, whereas compound 15 and Abiraterone exhibited an increase of testosterone levels above control 
at this time point, probably caused by feed-back stimulation. As expected this activity profile correlates to 
the pharmacokinetic properties of the compounds. Abiraterone exhibited a plasma half-life of only 1.6 hours, 
while the half-lifes of other compounds are much longer (10 hours for Ref 1 and 12.8 hours for 9). 
Accordingly, the AUC values of the test compounds, except for compound 17, are higher than for 
Abiraterone, indicating better bioavailability properties. Interestingly, the introduction of an additional 
fluorine into the C- ring of Ref 1 prolongs plasma half-life (9), whereas introduction of further fluorine 
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atoms into the A-ring reduces half-lives strongly (13, 15 and 17, half-lives between 2 to 6 hours). This 
observation is probably due to the electron withdrawing effects by multi F substitution. They significantly 
weaken the adjacent aromatic C-H bonds conferring them vunerable to nucleophilic attacks.[13m] 
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Figure 5. Reduction of the plasma testosterone concentrations in rats by selected compounds. Compounds Ref 1, 9, 13, 15 and 17 
were applied at a dose of 50 mg / kg body weight; Abiraterone was administrated as Abiraterone acetate (56 mg / kg body weight, 
equivalent to Abiraterone 50 mg / kg body weight). 5 to 6 intact adult male Wistar rats were employed for each treatment group; each 
sample was tested for 3 times. The average plasma testosterone concentrations (1.97 ng / mL) at pre-treatment time points (-1, -0.5 
and 0 h) were set to 100 %. The values shown are the relative levels compared to the pre-treatment value. 
Conclusion 
Herein, we reported the design, synthesis and bioactivity evaluation of a series of fluorine substituted 
biphenyl methylene imidazoles as CYP17 inhibitors. Fluorine substitution was found to show profound 
influence on the in vitro and in vivo activities, as well as the pharmacokinetic profiles.  
It has been unveiled that fluorine in the meta-position of the C-ring increased the activity compared to the 
non-substituted analogues, whereas ortho-substitution reduced the potency. Compounds furnished with 
fluorine at the A-ring always followed the same activity ranking: 4’-F > 3’,4’-di F > 2’,5’-di F ≥ 2’,4’-di F. 
Both the R- and S- enantiomers of the docked compounds predominantly adapt BM1 suggesting only a small 
difference in activity between these two enantiomers. The inspection of the docking poses revealed that the 
biphenyl moieties of both enantiomers are placed in the same area, interacting with Arg109 and Lys231, and 
their imidazolylmethylene group is located with only slight difference. The conformational flexibility of the 
latter group allows the ethyl substituents of both enantiomers to orient toward the hydrophobic pocket which 
is opposite to the I-helix and delimited by Ile371 and Ala367. Moreover, the biological data were well 
deciphered by docking studies and MEP mapping of selected compounds. The multi-polar interactions 
between the C-ring fluorine substituents and interacting amino acids residues significantly increased the 
binding affinities compared to the parent compound. The charge distribution difference on both the A- and 
the C-ring indicates π-π stacking (i.e. with both Phe114 and Gly301-Ala302), hydrophobic and Van der 
Waals interactions as determinants for activity. Furthermore, it could be demonstrated once again that 
fluorine substituted in an appropriate position, like in the C-ring, prolongs the plasma half life; in an 
unsuitable position, however, it decreases the t1/2 value of the parent compound. This phenomenon might be 
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due to a decrease in metabolic stability and is interesting for further investigations in the future. 
Finally, after the modification compound 9 is identified as strong CYP17 inhibitor showing potent activity 
in vivo, a high bioavailability and a long plasma half-life. Thus, Compound 9 appears to be an optimal 
candidate which after further structural optimization could be the first non-steroidal CYP17 inhibitor to be 
applied clinically. CYP17 inhibitors should be superior to the presently used GnRH analogues as mentioned 
above due to the fact that they reduce not only testicular but also adrenal androgen formation. Nevertheless, 
PC treatment could be further optimized by combining CYP17 inhibitors with inhibitors of androgen 
activation to DHT, catalyzed by 17β-HSD1[23] and / or 17β-HSD3, as well as 5α-reductase.[24] 
Experimental Section 
CYP17 preparation and assay 
Human CYP17 was expressed in E. coli (coexpressing human CYP17 and cytochrome P450 reductase) 
and the assay was performed as previously described.[12d, 16] 
Inhibition of hepatic CYP enzymes 
The recombinantly expressed enzymes from baculovirus-infected insect microsomes (Supersomes) were 
used and the manufacturer’s instructions (www.gentest.com) were followed. 
In vivo study 
The in vivo tests were performed with intact adult male Wistar rats (Harlan Winkelmann, Germany), 5 to 6 
for each treatment group. These rats were cannulated with silicone tubing via the right jugular vein. 
Compounds 9, 13, 15 and 17 were applied p.o. with doses of 50 mg / kg body weight, while Abiraterone was 
administrated as acetate 56 mg / kg body weight (equivalent to Abiraterone 50 mg / kg body weight). The 
concentrations of testosterone in the rat plasma were determined using the ELISA (EIA - 1559) from DRG 
Instruments according to the manufacturer’s instructions. The plasma drug levels were measured by LC-MS. 
Non-compartmental pharmacokinetic analysis of concentration vs time data was performed for each 
compound on the mean plasma level using a validated computer program (PK solution 2 software; Summit 
Research Services, Montrose, USA). Plasma concentrations below the limit of detection were assigned a 
value of zero. 
Chemistry Section 
General 
Melting points were determined on a Mettler FP1 melting point apparatus and are uncorrected. IR spectra 
were recorded neat on a Bruker Vector 33FT-infrared spectrometer. 1H and 13C NMR spectra were measured 
on a Bruker DRX-500 (500 MHz). Chemical shifts are given in parts per million (ppm), and TMS was used 
as an internal standard for spectra. All coupling constants (J) are given in Hz. ESI (electrospray ionization) 
mass spectra were determined on a TSQ quantum (Thermo Electron Corporation) instrument. High 
resolution mass spectra were measured using LTQ Orbitrap (Thermo Electron Corporation) with positive 
ESI. The purities of the final compounds were controlled by Surveyor®-LC-system. Purities were greater 
than 98 %. Column chromatography was performed using silica-gel 60 (50–200 µm), and reaction progress 
was determined by TLC analysis on Alugram® SIL G/UV254 (Macherey-Nagel). Boronic acids and 
bromoaryls used as starting materials were commercially obtained (CombiBlocks, Chempur, Aldrich, Acros 
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Method A: CDI reaction in NMP 
To a solution of the corresponding alcohol (1 eq) in NMP or acetonitrile (10 mL / mmol) was added CDI 
(5 eq). Then the solution was heated to reflux for 4 to 18 h. After cooling to ambient temperature, it was 
diluted with water (30 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic phases were 
washed with brine, dried over MgSO4 and evaporated under reduced pressure. Then the desired product was 
purified by chromatography on silica gel. 
1-[1-(4'-Fluoro-2'-methyl-biphenyl-4-yl)-propyl]-1H-imidazole (1). Synthesized according to Method 
A using 1a (0.15 g, 0.61 mmol) and CDI (0.20 g, 1.23 mmol); yield: 0.06 g (32 %); colorless oil; Rf = 0.27 
(DCM / MeOH, 95:5); 1H NMR (DMSO, 500 MHz) δ = 0.98 (t, J = 7.3 Hz, 3H, CH3), 2.23 (s, 3H, CH3), 
2.24–2.30 (m, 2H, CH2), 5.07 (t, J = 7.6 Hz, 1H, CH), 6.90–6.93 (m, 1H), 6.95–6.97 (m, 1H), 7.01 (s, 1H), 
7.11 (s, 1H), 7.14 (dd, J = 6.0, 8.4 Hz, 1H), 7.22-7.26 (m, 4H), 7.67 ppm (s, 1H); 13C NMR (DMSO-d6, 125 
MHz) δ = 11.1 (CH3), 20.5 (CH3), 28.6 (CH2), 63.2 (CH), 112.5, 112.6, 116.7, 116.9, 126.3, 129.7, 131.1, 
131.1, 137.0, 137.6, 137.7, 138.9, 140.9, 161.1, 163.0 ppm; HRMS (ESI): calcd for C19H20FN2 [M+H]+: 
295.1611, found: 295.1607; MS (ESI): m/z = 295 [M++H].  
1-[1-(3',4'-Difluoro-biphenyl-4-yl)-propyl]-1H-imidazole (2). Synthesized according to Method A  
using 2a (0.27 g, 1.09 mmol) and CDI (0.34 g, 2.06 mmol); yield: 0.09 g (27 %); colorless oil; Rf = 0.29 
(DCM / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 0.98 (t, J = 7.3 Hz, 3H, CH3), 2.23–2.31 (q, J = 7.3, 
7.6 Hz, 2H, CH2), 5.06 (t, J = 7.6 Hz, 1H, CH), 6.97–7.02 (m, 1H), 7.10–7.14 (m, 1H), 7.18–7.28 (m, 4H), 
7.23–7.37 (m, 1H), 7.49 (m, 2H), 7.62–7.66 ppm (m, 1H, Im-2H); 13C NMR (CDCl3, 125 MHz) δ = 11.3 
(CH3), 29.6 (CH2), 63.0 (CH), 116.3, 117.5, 118.7, 123.2, 127.3, 130.5, 136.5, 137.4, 140.5, 151.3 ppm; 
HRMS (ESI): calcd for C18H17F2N2 [M+H]+: 299.1360, found: 299.1363; MS (ESI): m/z = 299 [M++H]. 
1-[1-(2',4'-Difluorobiphenyl-4-yl)propyl]-1H-imidazole (4). Synthesized according to Method A  using 
4a (0.27 g, 1.09 mmol) and CDI (0.34 g, 2.06 mmol); yield: 0.12 g (36 %); colorless oil; Rf = 0.34 (DCM / 
MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 0.85 (t, J = 7.3 Hz, 3H, CH3), 2.12–2.18 (m, 2H, CH2), 4.96 
(t, J = 7.6 Hz, 1H, CH), 6.77–6.85 (m, 2H), 6.87–6.90 (m, 1H), 6.99–7.02 (m, 1H), 7.13–7.15 (m, 2H), 7.23–
7.28 (m, 1H), 7.35–7.37 (m, 2H), 7.62–7.68 ppm (m, 1H, Im-2H); 13C NMR (CDCl3, 125 MHz) δ = 11.1 
(CH3), 29.3 (CH2), 63.3 (CH), 104.5, 112.7, 117.8, 118.6, 124.6, 126.3, 130.2, 131.4, 135.7, 136.6, 140.3, 
163.5 ppm; HRMS (ESI): calcd for C18H17F2N2 [M+H]+: 299.1360, found: 299.1352; MS (ESI): m/z = 299 
[M++H]. 
1-[1-(2',4'-Difluoro-3'-methoxybiphenyl-4-yl)ethyl]-1H-imidazole (6). Synthesized according to 
Method A using 6a (0.30 g, 1.09 mmol) and CDI (0.34 g, 2.06 mmol); yield: 0.34 g (71 %); yellow oil; Rf = 
0.30 (DCM / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 1.75 (d, J = 7.5 Hz, 3H, CH3), 3.91 (s, 3H, 
OCH3), 5.18–5.31 (q, J = 7.5 Hz, 1H, CH), 6.82–6.83 (m, 1H), 6.84–6.86 (m, 1H), 6.89–6.93 (m, 1H), 6.97–
6.99 (m, 1H), 7.09–7.10 (m, 2H), 7.34–7.36 (m, 2H), 7.50–7.51 ppm (m, 1H, Im-2H); 13C NMR (CDCl3, 125 
MHz) δ = 21.1 (CH3), 56.7 (CH), 62.5 (OCH3), 112.3, 117.7, 123.9, 125.6, 127.8, 128.4, 134.1, 136.1, 141.6 
ppm; HRMS (ESI): calcd for C18H17F2N2O [M+H]+: 315.1309, found: 315.1297; MS (ESI): m/z = 315 
[M++H]. 
1-[1-(2',5'-Difluorobiphenyl-4-yl)propyl]-1H-imidazole (7). Synthesized according to Method A  using 
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7a (0.27 g, 1.09 mmol) and CDI (0.34 g, 2.06 mmol); yield: 0.13 g (41 %); colorless oil; Rf = 0.38 (DCM / 
MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 0.98 (t, J = 7.3 Hz, 3H, CH3), 2.26 (q, J = 7.3, 7.6 Hz, 2H, 
CH2), 5.05 (t, J = 7.6 Hz, 1H, CH), 6.97–7.01 (m, 2H), 7.08–7.12 (m, 3H,), 7.25–7.27 (m, 2H), 7.49–7.51 
(m, 2H), 7.62–7.65 ppm (m, 1H, Im-2H); 13C NMR (CDCl3, 125 MHz) δ = 11.3 (CH3), 29.6 (CH2), 63.1 
(CH), 116.8, 118.4, 126.5, 130.5, 135.4, 136.9, 140.0, 158.8, 160.7 ppm; HRMS (ESI): calcd for C18H17F2N2 
[M+H]+: 299.1360, found: 299.1351; MS (ESI): m/z = 299 [M++H]. 
1-[1-(3,4'-difluorobiphenyl-4-yl)propyl]-1H-imidazole (9). Synthesized according to Method A  using 
9a (0.38 g, 1.53 mmol) and CDI (0.47 g, 2.88 mmol); yield: 0.08 g (17 %); yellow oil; Rf = 0.38 (DCM / 
MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 0.99 (t, J = 7.3 Hz, 3H, CH3), 2.21–2.31 (m, 2H, CH2), 5.38 
(t, J = 7.5 Hz, 1H, CH), 7.01 (s, 1H), 7.08 (s, 1H), 7.10–7.14 (m, 2H), 7.19–7.25 (m, 2H), 7.27–7.29 (m, 1H), 
7.40–7.51 (m, 2H), 7.64 ppm (s, 1H, Im-2H); 13C NMR (CDCl3, 125 MHz) δ = 11.3 (CH3), 28.6 (CH2), 56.4 
(CH), 114.5, 116.3, 118.0, 123.7, 126.6, 127.3, 128.9, 129.5, 130.9, 135.0, 136.5, 161.7, 163.4 ppm; 19F 
NMR (CDCl3, 400 MHz) δ = -114.19 (s, 1F), -117.98 ppm (s, 1F); HRMS (ESI): calcd for C18H17F2N2 
[M+H]+: 299.1360, found: 299.1352; MS (ESI): m/z = 299 [M++H]. 
1-[(3,4'-Difluorobiphenyl-4-yl)methyl]-1H-imidazole (11). Synthesized according to Method A using 
11a (0.28 g, 1.27 mmol) and CDI (0.41 g, 2.54 mmol); yield: 0.11 g (31 %); colorless oil; Rf = 0.53 (EtOAc / 
MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 5.20 (s, 2H, CH2), 6.98 (s, br, 1H), 7.10 (s, br, 1H), 7.11–
7.16 (m, 3H), 7.26–7.31 (m, 2H), 7.50 (dd, J = 5.4, 8.8 Hz, 2H), 7.64 ppm (s, br, 1H, Im-2H); 13C NMR 
(CDCl3, 125 MHz) δ = 44.4 (CH2), 114.2, 115.9, 119.2, 122.2, 123.1, 128.6, 129.6, 129.9, 135.3, 137.3, 
142.9, 160.6, 162.9 ppm; HRMS (ESI): calcd for C16H13F2N2 [M+H]+: 271.1047, found: 271.1039; MS 
(ESI): m/z = 271 [M++H]. 
1-[1-(3,3',4'-Trifluorobiphenyl-4-yl)propyl]-1H-imidazole (13). Synthesized according to Method A  
using 13a (0.40 g, 1.70 mmol) and CDI (0.53 g, 3.20 mmol); yield: 0.11 g (20 %); colorless oil; Rf = 0.35 
(DCM / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 0.99 (t, J = 7.3 Hz, 3H, CH3), 2.22–2.33 (m, 2H, 
CH2), 5.39 (t, J = 7.6 Hz, 1H, CH), 7.01 (s, 1H), 7.09 (s, 1H), 7.20–7.29 ( m, 5H), 7.31-7.35 (m, 1H), 7.64 
ppm (s, 1H, Im-2H); 13C NMR (CDCl3, 125 MHz) δ = 11.3 (CH3), 28.6 (CH2), 56.3 (CH), 114.5, 116.2, 
118.4, 123.9, 127.5, 128.3, 130.5, 136.7, 149.4, 161.7 ppm; 19F NMR (CDCl3, 400 MHz) δ = -117.56 (s, 1F), 
-136.80 (d, 3JFF = -20.7, 1F), -138.64 ppm (d, 3JFF = -20.7, 1F); HRMS (ESI): calcd for C18H16F3N2 [M+H]+: 
317.1266, found: 317.1257; MS (ESI): m/z = 317 [M++H]. 
1-[(3,3',4'-trifluorobiphenyl-4-yl)methyl]-1H-imidazole (14). Synthesized according to Method A  using 
14a (0.35 g, 1.67 mmol) and CDI (0.53 g, 3.20 mmol); yield: 0.10 g (23 %); white powder: mp 60–61 °C; Rf 
= 0.26 (DCM / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 5.19 (s, 2H, CH2), 6.97 (s, 1H), 7.10 (s, 1H), 
7.11–7.14 (m, 2H), 7.20–7.28 (m, 3H), 7.31–7.35 (m, 1H), 7.59 ppm (s, 1H,  Im-2H); 13C NMR (CDCl3, 125 
MHz) 44.3 (CH2), 114.9, 116.4, 118.6, 119.3, 123.9, 129.5, 136.8, 137.3, 141.4, 149.3, 151.7, 161.4 ppm; 
HRMS (ESI): calcd for C16H12F3N2 [M+H]+: 289.0953, found: 289.0944; MS (ESI): m/z = 289 [M++H]. 
1-[1-(2',3,4'-Trifluorobiphenyl-4-yl)propyl]-1H-imidazole (15). Synthesized according to Method A  
using 15a (0.27 g, 1.14 mmol) and CDI (0.35 g, 2.10 mmol); yield: 0.09 g (24 %); colorless oil;  Rf = 0.37 
(DCM / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 0.99 (t, J = 7.3 Hz, 3H, CH3), 2.23–2.32 (m, 2H, 
CH2), 5.40 (t, J = 7.6 Hz, 1H, CH), 6.89–6.97 (m, 2H), 7.02 (s, 1H), 7.08 (s, 1H), 7.19–7.27 (m, 3H), 7.34–
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7.38 (m, 1H), 7.64 ppm (s, 1H, Im-2H); 13C NMR (CDCl3, 125 MHz) δ = 11.3 (CH3), 27.7 (CH2), 56.2 (CH), 
104.5, 112.7, 116.9, 117.7, 125.4, 127.0, 130.8, 136.5, 137.9, 160.3, 161.2 ppm; 19F NMR (CDCl3, 400 
MHz) δ = -109.86 (d, 4JFF = 8.0, 1F), -113.15 (d, 4JFF = 8.0, 1F), -118.03 ppm (s, 1F); HRMS (ESI): calcd for 
C18H16F3N2 [M+H]+: 317.1266, found: 317.1257; MS (ESI): m/z = 317 [M++H]. 
1-[(2',3,4'-Trifluorobiphenyl-4-yl)methyl]-1H-imidazole (16). Synthesized according to Method A 
using 16a (0.18 g, 0.76 mmol) and CDI (0.24 g, 1.51 mmol); yield: 0.09 g (42 %); orange oil; Rf = 0.52 
(EtOAc / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 5.20 (s, 2H, CH2), 6.89–6.97 (m, 2H), 6.98 (s, br, 
1H), 7.10 (s, br, 1H), 7.12 (dd, J = 7.9, 8.2 Hz, 1H), 7.24–7.27 (m, 2H), 7.36 (ddd, J = 6.4, 8.5, 8.8 Hz, 1H), 
7.61 ppm (s, br, 1H, Im-2H); 13C NMR (CDCl3, 125 MHz) δ = 44.3 (CH2), 104.6, 111.8, 116.2, 119.2, 122.8, 
123.3, 125.1, 129.4, 129.8, 131.1, 137.4, 159.2, 159.6, 161.2, 162.7 ppm; HRMS (ESI): calcd for C16H12F3N2 
[M+H]+: 289.0953, found: 289.0952; MS (ESI): m/z = 289 [M++H]. 
1-[1-(2',3,5'-Trifluorobiphenyl-4-yl)propyl]-1H-imidazole (17). Synthesized according to Method A 
using 17a (0.40 g, 1.70 mmol) and CDI (0.53 g, 3.20 mmol); yield: 0.14 g (26 %); colorless oil; Rf = 0.38 
(DCM / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 0.99 (t, J = 7.3 Hz, 3H, CH3), 2.23–2.32 (m, 2H, 
CH2), 5.40 (t, J = 7.6 Hz, 1H, CH), 7.00–7.04 (m, 2H), 7.08–7.14 (m, 2H), 7.20–7.24 (m, 1H), 7.26–7.30 (m, 
2H), 7.64 ppm (s, 1H, Im-2H); 13C NMR (CDCl3, 125 MHz) δ = 11.3 (CH3), 27.6 (CH2), 56.3 (CH), 116.7, 
117.9, 125.5, 127.0, 130.3, 136.7, 158.5, 159.7, 161.4 ppm; 19F NMR (CDCl3, 400 MHz) δ = -117.81 (s, 1F), 
-118.39 (d, 5JFF = 17.7, 1F), -123.67 ppm (d, 5JFF = 17.7, 1F); HRMS (ESI): calcd for C18H16F3N2 [M+H]+: 
317.1266, found: 317.1257; MS (ESI): m/z = 317 [M++H]. 
1-[(2',3,5'-Trifluorobiphenyl-4-yl)methyl]-1H-imidazole (18). Synthesized according to Method A  
using 18a (0.17 g, 0.71 mmol) and CDI (0.23 g, 1.43 mmol); yield: 0.09 g (45 %); light yellow solid: mp 
125–126 °C; Rf = 0.48 (EtOAc / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 5.21 (s, 2H, CH2), 6.98 (s, 
br, 1H), 7.00–7.05 (m, 1H), 7.08–7.16 (m, 4H), 7.28–7.31 (m, 2H), 7.64 ppm (s, br, 1H, Im-2H); 13C NMR 
(CDCl3, 125 MHz) δ = 44.4 (CH2), 116.0, 116.4, 116.6, 117.4, 119.3, 125.1, 123.4, 129.5, 129.8, 137.1, 
137.4, 156.5, 154.6, 158.7, 160.2 ppm; HRMS (ESI): calcd for C16H12F3N2 [M+H]+: 289.0953, found: 
289.0955; MS (ESI): m/z = 289 [M++H]. 
1-[1-(2,4'-Difluorobiphenyl-4-yl)propyl]-1H-imidazole (19). Synthesized according to Method A  using 
19a (0.31 g, 1.22 mmol) and CDI (0.40 g, 2.46 mmol); yield: 0.11 g (31 %); colorless oil; Rf = 0.56 (EtOAc / 
MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 0.97 (t, J = 7.3 Hz, 3H), 2.21–2.27 (m, 2H), 5.04 (t, J = 7.7 
Hz, 1H), 6.96–6.99 (m, 2H), 7.02 (dd, J = 1.9, 7.9 Hz, 1H), 7.11 (s, br, 1H), 7.12 (t, J = 8.6 Hz, 2H), 7.37 (t, 
J = 7.9 Hz, 1H), 7.47 (ddd, J = 1.3, 5.4, 8.8 Hz, 1H), 7.64 ppm (s, br, 1H, Im-2H); 13C NMR (CDCl3, 125 
MHz) δ = 11.0 (CH3), 28.4 (CH2), 62.5 (CH), 114.3, 115.4, 117.5, 122.4, 127.8, 129.6, 130.5, 131.0, 136.3, 
141.8, 141.9, 159.6, 162.5 ppm; HRMS (ESI): calcd for C18H17F2N2 [M+H]+: 299.1360, found: 299.1351; 
MS (ESI): m/z = 299 [M++H]. 
1-(2,4'-Difluoro-biphenyl-4-ylmethyl)-1H-imidazole (20). Synthesized according to Method A  using 
20a (0.10 g, 0.44 mmol) and CDI (0.40 g, 2.46 mmol); yield: 0.05 g (42 %); white solid: mp 93–94 °C; Rf = 
0.52 (EtOAc / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 5.15 (s, 2H, CH2), 6.90–6.98 (m, 3H), 7.11–
7.13 (m, 2H), 7.25–7.27 (m, 3H), 7.36–7.39 (m, 1H), 7.60 ppm (s, 1H, Im-2H); 13C NMR (CDCl3, 125 MHz) 
50.0 (CH2), 114.9, 115.1, 115.5, 119.3, 123.0, 129.9, 130.6, 130.7, 130.9, 131.2, 137.6, 158.8, 160.8, 161.6, 
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163.6 ppm; HRMS (ESI): calcd for C16H13F2N2 [M+H]+: 271.1047, found: 271.1045; MS (ESI): m/z = 271 
[M++H]. 
1-[1-(2,3',4'-Trifluorobiphenyl-4-yl)propyl]-1H-imidazole (21). Synthesized according to Method A 
using 21a (0.28 g, 1.03 mmol) and CDI (0.34 g, 2.06 mmol); yield: 0.09 g (29 %); light brown oil; Rf = 0.53 
(EtOAc / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 0.97 (t, J = 7.4 Hz, 3H), 2.20–2.28 (m, 2H), 5.04 (t, 
J = 7.6 Hz, 1H), 6.96–6.99 (m, 2H), 7.03 (dd, J = 1.9, 7.9 Hz, 1H), 7.11 (s, br, 1H), 7.18-7.23 (m, 2H), 7.31–
7.34 (m, 1H), 7.35 (t, J = 8.0 Hz, 1H), 7.64 ppm (s, br, 1H, Im-2H); 13C NMR (CDCl3, 125 MHz)  δ = 10.0 
(CH3), 27.5 (CH2), 61.5 (CH), 113.5, 116.4, 116.5, 117.0, 121.6, 124.0, 125.8, 128.7, 129.9, 130.8, 135.3, 
141.5, 149.0, 149.2, 158.6 ppm; HRMS (ESI): calcd for C18H16F3N2 [M+H]+: 317.1266, found: 317.1257; 
MS (ESI): m/z = 317 [M++H]. 
1-(2,2',4'-Trifluoro-biphenyl-4-ylmethyl)-1H-imidazole (22). Synthesized according to Method A  using 
22a (0.10 g, 0.39 mmol) and CDI (0.40 g, 2.46 mmol); yield: 0.06 g (54 %); white solid: mp 112–113 °C; Rf 
= 0.47 (EtOAc / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 5.21 (s, 2H, CH2), 6.90–6.98 (m, 4H), 7.02 
(d, J = 7.8 Hz, 1H), 7.16 (s, 1H), 7.33–7.35 (m, 2H), 7.85 ppm (s, 1H, Im-2H); 13C NMR (CDCl3, 125 MHz) 
δ = 52.2 (CH2), 104.3, 111.5, 114.8, 119.4, 122.8, 129.1, 132.2, 132.2, 137.3, 138.3, 158.9, 161.0, 161.9, 
162.0, 164.1 ppm; HRMS (ESI): calcd for C16H12F3N2 [M+H]+: 289.0953, found: 289.0957; MS (ESI): m/z = 
289 [M++H]. 
Method B: Grignard reaction 
Under exclusion of air and moisture a 1.0 M EtMgBr (1.2 eq) solution in THF was added dropwise to a 
solution of the aldehyde or ketone (1 eq) in THF (12 mL / mmol). The mixture was stirred over night at room 
temperature. Then ethyl acetate (10 mL) and water (10 mL) were added and the organic phase was separated. 
The organic phase was extracted with water and brine, dried over Na2SO4, and evaporated under reduced 
pressure. The crude products were purified by flash chromatography on silica gel.  
Method C: Suzuki-Coupling 
The corresponding brominated aromatic compound (1 eq) was dissolved in toluene (7 mL / mmol), an 
aqueous 2.0 M Na2CO3 solution (3.2 mL / mmol) and an ethanolic solution (3.2 mL / mmol) of the 
corresponding boronic acid (1.5-2.0 eq) were added. The mixture was deoxygenated under reduced pressure 
and flushed with nitrogen. After repeating this cycle several times Pd(PPh3)4 (4 mol%) was added and the 
resulting suspension was heated to reflux for 8 h. After cooling down, ethyl acetate (10 mL) and water (10 
mL) were added and the organic phase was separated. The water phase was extracted with ethyl acetate (2 x 
10 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered over a short plug 
of celite® and evaporated under reduced pressure. The compounds were purified by flash chromatography 
on silica gel.  
1-(4'-Fluorobiphenyl-4-yl)-1-(1H-imidazol-5-yl)-2-methylpropan-1-ol (24). Synthesized according to 
Method C using 1-(4-Bromophenyl)-2-methyl-1-(1-trityl-1H-imidazol-5-yl)propan-1-ol (0.50 g, 0.93 mmol) 
and 4-fluorophenyl boronic acid (0.23 mg, 1.63 mmol). After workup, the crude was stirred with pyridinium 
hydrochloride (0.17 g, 1.5 mmol) in MeOH (40 mL) at 60° C for 4 hours. Then the reaction was quenched by 
adding saturated NaHCO3 aq (10 mL). After 20 mL EtOAC were added, the phases separated. The water 
phase was extracted 2 times with EtOAc (20 mL), the combined organic extracts were dried over Na2SO4 
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and concentrated under reduced pressure. The crude product was purified by flash chromatography; yield: 
0.21 g (73 %); colorless oil; Rf = 0.17 (EtOAc / MeOH, 95:5);  1H NMR (CDCl3, 500 MHz) δ = 0.82 (d, J = 
6.8 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H), 2.63–2.65 (m, 1H),  7.01 (s, 1H), 7.10 (dd, J = 8.7, 8.8 Hz, 2H), 7.49 
(d, J = 8.5 Hz, 2H), 7.53 (dd, J = 5.4, 8.7 Hz, 2H), 7.58 (s, 1H), 7.62 ppm (d, J = 8.3 Hz, 2H); 13C NMR 
(CDCl3, 125 MHz) δ = 17.3, 60.4, 77.7, 115.5, 115.6, 126.2, 126.4, 128.4, 128.5, 133.9, 136.9, 136.9, 138.3, 
144.8, 161.4, 163.3 ppm; HRMS (ESI): calcd for C19H20FN2O [M+H]+: 311.1560, found: 311.1559; MS 
(ESI): m/z = 311 [M++H]. 
Method D: Reduction with NaBH4 
To an ice-cooled solution of the corresponding aldehyde or ketone (1 eq) in methanol (5 mL / mmol) was 
added NaBH4 (2 eq). Then the resulting mixture was heated to reflux for 30 minutes. After cooling to 
ambient temperature, the solvent was distilled off under reduced pressure. Then water (10 mL) was added, 
and the resulting mixture was extracted with ethyl acetate (3 x 10 mL). The combined organic phases were 
washed with brine, dried over MgSO4 and evaporated under reduced pressure. Then the desired product was 
purified by chromatography on silica gel. 
Method E: CDI reaction in THF 
To a solution of the corresponding alcohol (1 eq) in THF (10 mL / mmol) was added CDI (2 eq). Then the 
solution was heated to reflux at 70 ℃ for 4 days. After cooling to ambient temperature, the mixture was 
poured into water and extracted with CH2Cl2 (3 x 25 mL). The combined organic phases were washed with 
brine, dried over MgSO4 and evaporated under reduced pressure. Then the desired product was purified by 
chromatography on silica gel. 
Imidazole-1-carboxylic acid 1-(3',4'-difluoro-biphenyl-4-yl)-propyl ester (3). Synthesized according to 
Method E  using 2a (0.10 g, 0.42 mmol) and CDI (0.14 g, 0.83 mmol); yield: 0.09 g (37 %); white solid: mp 
49–50 °C; Rf = 0.29 (DCM / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 1.01 (t, J = 14.8 Hz, 3H, CH3), 
2.01–2.21 (q, J = 14.8, 15.5 Hz, 2H, CH2), 5.88 (t, J = 15.5 Hz, 1H, CH), 7.15 (s, 1H), 7.22–7.29 (m, 2H), 
7.32–7.34 (m, 1H), 7.36–7.38 (m, 1H), 7.46 (d, J = 8.2 Hz, 2H), 7.54 (d, J = 8.2 Hz, 2H), 8.35 ppm (s, 1H, 
Im-2H); 13C NMR (CDCl3, 125 MHz) δ = 9.9 (CH3), 28.9 (CH2), 82.6 (CH), 115.9, 116.1, 117.5, 117.7, 
122.4, 122.9, 123.0, 127.3, 127.4, 129.5, 137.8, 140.2, 149.0, 149.1, 151.2 ppm; HRMS (ESI): calcd for 
C19H17F2N2O2 [M+H]+: 343.1258, found: 343.1250; MS (ESI): m/z = 343 [M++H]. 
Imidazole-1-carboxylic acid 1-(2',4'-difluoro-biphenyl-4-yl)-propyl ester (5). Synthesized according to 
Method E  using 4a (0.21 g, 0.85 mmol) and CDI (0.28 g, 1.69 mmol); yield: 0.11 g (43 %); white solid: mp 
76–77 °C; Rf = 0.29 (DCM / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 1.01 (t, J = 14.8 Hz, 3H, CH3), 
2.03–2.19 (q, J = 14.8, 15.5 Hz, 2H, CH2), 5.87 (t, J = 15.5 Hz, 1H, CH), 6.89–7.06 (m, 2H), 7.09–7.11 (m, 
1H),  7.36–7.40 (m, 1H), 7.45–7.48 (m, 3H), 7.52 (dd, J = 1.6, 1.9 Hz, 2H), 8.24 ppm (s, 1H, Im-2H); 13C 
NMR (CDCl3, 125 MHz) δ = 9.9 (CH3), 28.9 (CH2), 82.2 (CH), 104.4, 111.7, 117.2, 124.5, 126.8, 129.3, 
130.7, 135.5, 136.9, 137.9, 148.0, 158.5, 1160.7, 161.4, 163.4, 171.2 ppm; HRMS (ESI): calcd for 
C19H17F2N2O2 [M+H]+: 343.1258, found: 343.1247; MS (ESI): m/z = 343 [M++H]. 
Imidazole-1-carboxylic acid 1-(2',5'-difluoro-biphenyl-4-yl)-propyl ester (8). Synthesized according to 
Method E  using 7a (0.12 g, 0.46 mmol) and CDI (0.15 g, 0.93 mmol); yield: 0.10 g (69 %); white solid: mp 
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77–78 °C; Rf = 0.29 (DCM / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 1.01 (t, J = 14.8 Hz, 3H, CH3), 
2.02–2.20 (q, J = 14.8, 15.5 Hz, 2H, CH2), 5.88 (t, J = 15.5 Hz, 1H, CH), 6.93–7.02 (m, 1H), 7.09–7.15 (m, 
3H),  7.46–7.48 (m, 3H), 7.52–7.55 (m, 2H), 8.23 ppm (s, 1H, Im-2H); 13C NMR (CDCl3, 125 MHz) δ = 9.9 
(CH3), 28.9 (CH2), 82.2 (CH), 115.5, 116.7, 117.6, 126.9, 127.4, 129.4, 130.2, 135.3, 136.9, 138.4, 148.0, 
154.7, 156.7, 157.8, 159.4 ppm; HRMS (ESI): calcd for C19H17F2N2O2 [M+H]+: 343.1258, found: 343.1250; 
MS (ESI): m/z = 343 [M++H]. 
Imidazole-1-carboxylic acid 1-(3,4'-difluoro-biphenyl-4-yl)-propyl ester (10). Synthesized according to 
Method E  using 7a (0.19 g, 0.75 mmol) and CDI (0.24 g, 1.50 mmol); yield: 0.10 g (69 %); colorless oil; Rf 
= 0.29 (DCM / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 1.01 (t, J = 14.8 Hz, 3H, CH3), 2.02–2.20 (q, 
J = 14.8, 15.5 Hz, 2H, CH2), 5.88 (t, J = 15.5 Hz, 1H, CH), 6.14 (s, 1H), 7.26–7.28 (m, 2H),  7.19–7.25 (m, 
1H),  7.34–7.35 (m, 1H), 7.42–7.48 (m, 2H), 7.50–7.53 (m, 2H), 8.22 ppm (s, 1H, Im-2H); 13C NMR (CDCl3, 
125 MHz) δ = 9.7 (CH3), 28.1 (CH2), 82.2 (CH), 114.3, 114.4, 115.8, 116.0, 117.2, 122.9, 128.1, 128.7, 
135.3, 137.0, 159.3, 161.3, 161.9, 163.9, 171.1 ppm; HRMS (ESI): calcd for C19H17F2N2O2 [M+H]+: 
343.1258, found: 343.1250; MS (ESI): m/z = 343 [M++H]. 
Imidazole-1-carboxylic acid 3,4'-difluoro-biphenyl-4-ylmethyl ester (12). Synthesized according to 
Method E  using 11a (0.26 g, 1.20 mmol) and CDI (0.39 g, 2.40 mmol); yield: 0.09 g (28 %); white solid: 
mp 220–221°C; Rf = 0.29 (DCM / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) δ = 5.33 (s, 2H, CH2), 7.07 (s, 
1H), 7.12–7.15 (t, J = 17.4 Hz, 2H), 7.20 (s, 1H), 7.29 (d, J = 11.0 Hz, 1H), 7.33–7.35 (m, 2H), 7.49–7.52 (m, 
2H), 8.32 ppm(s, 1H, Im-2H); 13C NMR (CDCl3, 125 MHz) δ = 45.3 (CH2), 114.3, 115.9, 116.0, 121.1, 
123.3, 126.7, 128.6, 128.7, 130.6, 130.7, 143.5, 143.6, 161.8, 162.0, 164.0 ppm; HRMS (ESI): calcd for 
C17H13F2N2O2 [M+H]+: 315.0945, found: 315.0943; MS (ESI): m/z = 315 [M++H]. 
(4'-Fluorobiphenyl-4-yl)(1H-imidazol-5-yl)methanol (23). A solution of 23a (0.10 g, 0.20 mmol) in 
MeOH (5 mL) was stirred with pyridinium hydrochloride (35 mg, 0.30 mmol) at 60° C for 4 hours. Then the 
reaction was quenched by adding saturated NaHCO3 aq (10 mL), 20 mL EtOAC were added and the phases 
separated. The water phase was extracted 3 times with EtOAc (20 mL), the combined organic extracts were 
dried over Na2SO4, and concentrated under reduced pressure. The crude product was purified by flash 
chromatography; yield: 0.05 g (91 %); colorless oil; Rf = 0.19 (EtOAc / MeOH, 95:5); 1H NMR (CDCl3 + d6-
DMSO, 500 MHz) δ = 2.99 (s, 1H), 5.84 (s, 1H), 6.87 (s, 2H), 7.02–7.06 (m, 2H), 7.41–7.47 ppm (m, 6H); 
13C NMR (CDCl3 + DMSO-d6, 125 MHz) δ = 71.2 (COH), 115.8, 116.0, 116.4, 127.2, 127.9, 129.1, 129.4, 
137.1, 138.6, 140.7, 142.3, 150.9, 162.1, 164.1 ppm; HRMS (ESI): calcd for C16H14FN2O [M+H]+: 269.1090, 
found: 269.1088; MS (ESI):m/z = 269 [M++H]. 
5-(1-(4'-Fluorobiphenyl-4-yl)-2-methylprop-1-enyl)-1H-imidazole (25). Compound 24 (0.10 mg, 0.32 
mol) was refluxed in an i-PrOH solution of HCl (10 mL, 3N) for 2 hours. Afterwards, the resulting solution 
was concentrated under reduced pressure and washed 3 times with Et2O. No further purification was 
necessary; yield: 0.07 g (77 %); colorless oil; Rf = 0.29 (EtOAc / MeOH, 95:5); 1H NMR (CDCl3, 500 MHz) 
δ = 1.80 (s, 3H), 2.05 (s, 3H), 6.98 (s, 1H), 7.12 (dd, J = 8.7, 8.8 Hz, 2H), 7.19 (d, J = 8.3 Hz, 2H), 7.50 (d, J 
= 8.3 Hz, 2H), 7.54 (dd, J = 5.3, 8.7 Hz, 2H), 7.63 ppm (s, 1H); 13C NMR (CDCl3, 125 MHz) δ = 22.7 (CH3), 
23.1 (CH3), 115.6, 115.8, 123.4, 125.2, 126.9, 128.5, 128.5, 129.8, 130.3, 132.6, 133.6, 133.7, 134.9, 136.6, 
136.7, 136.7, 137.1, 138.8, 139.8, 160.9, 161.5 ppm; 19F NMR (CDCl3, 400 MHz) δ = -115.56 ppm (s, 1F); 
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HRMS (ESI): calcd for C19H18FN2 [M+H]+: 293.1454, found: 293.1455; MS (ESI):m/z = 293 [M++H]. 
5-(1-(4'-Fluorobiphenyl-4-yl)-2-methylpropyl)-1H-imidazole (26). Pearlman's catalyst (5 mg, 7.12 
µmol) and 25 (50 mg, 0.17 mmol) were prepared in EtOH and THF (2:1, 5mL) under H2 atmosphere. The 
mixture was left stirring for 3 hours, then the catalyst was filtered off 3 times and the solution concentrated 
under reduced pressure. The obtained solid was washed 3 times with Et2O. No further purification was 
necessary; yield: 50 mg (100%); yield: 0.07 g (77 %); colorless oil; Rf = 0.29 (EtOAc / MeOH, 95:5);1H 
NMR (CDCl3, 500 MHz) δ = 0.86 (d, J = 6.6 Hz, 3H, CH3), 0.99 (d, J = 6.6 Hz, 3H, CH3), 3.60 (d, J = 9.4 
Hz, 1H, CH), 6.90 (s, 1H), 7.09 (dd, J = 8.7, 8.8 Hz, 2H), 7.36 (d, J = 8.2 Hz, 2H), 7.45 (d, J = 8.2 Hz, 2H), 
7.51 (dd, J = 5.4, 8.7 Hz, 2H), 7.55 ppm (s, 1H); 13C NMR (CDCl3, 125 MHz) δ = 21.2, 21.8, 32.5, 51.9, 
115.4, 115.6, 123.1, 126.9, 128.4, 128.5, 128.9, 134.4, 137.1, 138.1, 142.4 ppm; HRMS (ESI): calcd for 
C19H20FN2 [M+H]+: 295.1611, found: 295.1605; MS (ESI):m/z = 295 [M++H]. 
Docking studies 
Ligands: All molecular modeling studies were performed on Intel(R) P4 CPU 3.00GHz running Linux 
CentOS5.2. The structures of the inhibitors were built with SYBYL 8 (Sybyl, Tripos Inc., St. Louis, 
Missouri, USA) and energy-minimized in MMFF94s force-field[25] as implemented in Sybyl.  
Docking: Molecular docking calculations were performed for various inhibitors of Table 1. Since the 
GOLD docking program allows flexible docking of the compounds, no conformational search was employed 
to the ligand structures. GOLD gave the best poses by a genetic algorithm (GA) search strategy. Ligands 
were docked in 50 independent genetic algorithm runs for each of the three GOLD-docking runs. Heme iron 
was chosen as active-site origin, while the radius was set equal to 19 Å. The automatic active-site detection 
was switched on. A distance constraint of a minimum of 1.9 and a maximum of 2.5 Å between the sp2-
hybridised nitrogen of the imidazole and the iron was set. Additionally, the goldscore.p450_pdb parameters 
were used and some of the GOLDSCORE parameters were modified to improve the weight of hydrophobic 
interaction and of the coordination between iron and nitrogen. The genetic algorithm default parameters were 
set as suggested by the GOLD authors. On the other hand, the annealing parameters of fitness function were 
set at 3.5 Å for hydrogen bonding and 6.5 Å for Van der Waals interactions.  
Analogously as for GOLD, no conformational search was performed prior docking with FlexX, since the 
ligands are docked according to an incremental fragment docking strategy. Standard parameter settings were 
used except for “base placement”, which was set on single interaction scan, and “chemical parameters”, in 
which the maximum overlap volume of the subroutine “clash handling” was set at a range of 3.6 Å. 
Additionally the “FlexX-Pharm” module was employed, setting the heme iron as an octahedrical 
coordinating metal pharmacophore point. The very same iron atom was chosen as active site center and 
amino acid residues within 16 Å were considered as part of the active site. 
All the poses resulting from three docking runs (GOLD-chemscore, GOLD-GOLDSCORE and FlexX) for 
each compound were clustered with ACIAP [19] and the representative structure of each significant cluster 
was selected. After the docking simulations and cluster analysis were performed, the quality of the docked 
representative poses was evaluated based on visual inspection of the putative binding modes of the ligands. 
The latter were further evaluated by means of MOE (www.chemcmpd.com) with its LigX module and 
evaluated by means of the various scoring functions (GOLDSCORE, CHEMSCORE and the empirical 
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FlexX Score). 
MEP 
For each docked compound geometry optimization was performed employing the B3LYP hybrid 
functional [20] in combination with a 6-311++G (d,p) basis set using the package Gaussian03 (Gaussian, Inc., 
Pittsburgh, PA, 2003). The molecular electrostatic potential (MEP) maps were plotted using GaussView, 
version 3.0, the 3D molecular graphics package of Gaussian. These electrostatic potential surfaces were 
generated by mapping 6-311++G** electrostatic potentials onto surfaces of molecular electron density 
(isovalue = 0.004 electron/Å) and the ESP values on the surface color-coded ranging from -6 (red) to +12 
(blue) kcal/mol.  
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Paper III 
 
Abstract: Androgens are well known to stimulate prostate cancer (PC) growth. Thus, blockade of androgen 
production in testes and adrenals by CYP17 inhibition is a promising strategy for the treatment of PC. 
Moreover, many PC patients suffer from glucocorticoid overproduction and importantly mutated androgen 
receptors can be stimulated by glucocorticoids. In this study, the first dual inhibitor of CYP17 and CYP11B1 
– the enzyme responsible for the last step in glucocorticoid biosynthesis – is described. A series of biphenyl 
methylene pyridines has been designed, synthesized and tested as CYP17 and CYP11B1 inhibitors. The most 
active compounds were also tested for selectivity against CYP11B2 (aldosterone synthase), CYP19 
(aromatase) and hepatic CYP3A4. In detail, compound 6 was identified as a dual inhibitor of CYP17 / 
CYP11B1 (IC50 values of 226 and 287 nM) showing little inhibition of the other enzymes as well as 
compound 9 as a selective, highly potent CYP17 inhibitors (IC50 = 52 nM) exceeding Abiraterone in terms of 
activity and selectivity. 
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Introduction 
As the growth of up to 80% of prostate carcinoma is androgen dependent,1 blockage of androgen 
production or action will effectively prevent cancer cells from proliferation. Currently, the standard therapy 
for prostate tumor is the so called “combined androgen blockade” (CAB), which means orchidectomy or 
treatment with gonadotropin-releasing hormone (GnRH) analogues (chemical castration)2 combined with 
androgen receptor antagonists.3 In CAB therapy, orchidectomy or GnRH treatment are employed to 
annihilate testicular androgen production, and consequently to reduce plasma androgen concentration. 
However, although about 90% of androgens are no longer produced, the minor amount of androgens from 
the adrenals is still sufficient to prompt cancer growth. To solve this problem, androgen receptor antagonists 
are additionally applied to prevent androgen stimulation. Nonetheless, mutations in androgen receptor are the 
reason for the emerging resistance to this therapy.  The mutated receptor can be activated by recognizing 
antiandrogens4 and glucocorticoids5 as agonists.  
A promising alternative to CAB is the total blockage of androgen biosynthesis in both testes and adrenals. 
An elegant way to achieve this is to inhibit 17α-hydroxylase-17,20-lyase (CYP17). CYP17 is the crucial 
enzyme catalyzing the conversion of pregnenolone and progesterone to dehydroepiandrosterone (DHEA) and 
androstenedione in gonadal and adrenal glands6 (Chart 1). Subsequently, these two weak androgens are 
converted to testosterone. In the prostate cells, the latter steroid is transformed into the most potent androgen 
dihydrotestosterone (DHT) by 5α-reductase (5α-R). As inhibitors of 5α-R7 reduce the intracellular prostatic 
DHT stimulation, they are exploited in the treatment of benign prostatic hyperplasia. For PC treatment, 
however, total blockade of androgen production is necessary. 
Chart 1. Androgen biosynthesis. 
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However, a major portion of patients becomes “castration resistant” which might be caused by androgen 
receptor mutations, as mentioned above. Androgen receptor activation by glucocorticoids, especially cortisol, 
stimulates cancer cell proliferation.5 Moreover, small cell anaplastic prostate carcinoma, which originates 
from neuro-endocrine cells, is found to be capable of ectopic ACTH production.8a The elevated ACTH levels 
promote adrenals to synthesize and release high concentrations of cortisol leading to Cushing’s syndrome,8b-d 
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diabetes mellitus, osteoporosis, hypertension and obesity. High cortisol levels have also been considered as a 
sign of PC cell growth.8b Importantly, some patients die of severe infections largely due to the immuno-
suppression caused by the glucocorticoid.8c-d Hence, for these patients the control of cortisol concentration is 
urgently needed. As the key step in the biosynthesis of this hormon is catalyzed by CYP11B1 (Chart 1), 
additional inhibition of this enzyme could be a substantial way to improve curative effects, relieve symptoms 
and increase survival of prostate cancer patients.  
Two decades ago, the first attempt to cure prostate cancer via CYP17 inhibition was described: the 
antimycotic Ketoconazole (Chart 2) was exploited as CYP17 inhibitor for the treatment of prostate cancer 
clinically.9a Although curative response was observed,9b Ketoconazole was withdrawn because of side effects 
associated with its poor selectivity against other steroidogenic and hepatic CYP enzymes. Later on, several 
steroidal inhibitors were designed based on endogenous substrates.10 Recently, Abiraterone11a (Chart 2) 
entered into phase II and III clinical trials. Castration resistant patients showed good response to 
Abiraterone,11b which confirms the superiority of prostate carcinoma treatment via CYP17 inhibition. 
However, the potential side effects might not be neglected which are caused by the affinity of steroidal 
scaffolds toward steroid receptors. Therefore, non-steroidal CYP17 inhibitors, such as heterocycle 
substituted tetrahydronaphthalenes,12a adamantine-carboxylates12b and biphenyls,13 attract more and more 
attention. 
Our group has reported about several series of biphenyl methylene imidazoles13 as potent CYP17 inhibitors. 
All these compounds were designed based on the mechanism that the sp2 hybrid nitrogen can coordinate with 
the heme iron, which was first14a identified for aromatase (CYP19, estrogen synthase) inhibitors,14 and later 
was also proven to be valid for aldosterone synthase (CYP11B2)15 and CYP17 inhibitors.10, 12-13  
Although potent inhibitors, like 1K13e (Chart 2, IC50 = 131 nM, for comparison: Abiraterone IC50 = 72 nM), 
were obtained after systematic modification on the biphenyl core and methylene bridge, activity and 
selectivity could possibly be further improved. Furthermore, compounds with additional CYP11B1 inhibition 
seemed feasible. After Abiraterone, 1K and Metyrapone (Chart 2) were superimposed using their 
heterocyclic N as a common atom, it is apparent that all of three compounds compose of three structural 
features: the hydrophobic core, an alkyl linker in between and a heterocycle containing N. Since Metyrapone 
is a CYP11B1 inhibitor, which has been applied in clinic to treat Cushing’s syndrome for nearly half a 
century,16 and 1K also exhibits weak CYP11B1 inhibition, this common structural pattern might be the basis 
of dual inhibition, while the inhibitory potency toward each enzyme depends on the choice of the structural 
features. It is obvious that the steroidal scaffold of Abiraterone and the biphenyl core of 1K mate sterically. 
Nevertheless, the steroidal scaffold was avoided when choosing the hydrophobic core due to the potential 
affinities of steroidal structures for various steroidal receptors. As for Metyrapone, the nicotinoyl moiety 
occupies the same space as the steroidal C-ring. Since pyridyl as C-ring leads to a total loss of CYP17 
inhibition,13d the nicotinoyl moiety was replaced by a biphenyl moiety furnished with polar substituents. 
Moreover, a substituted methylene bridge, observed for these three inhibitors, was sustained, as we regard it 
to be crucial for inhibition of the two enzymes. Furthermore, inspired by the facts that pyridyl has already 
been successfully employed in other types of CYP17 inhibitors12a-b leading to compounds being more potent  
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Chart 2. Inhibitor design conception. 
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than the corresponding imidazoles,12a and, importantly, that the pyridyl group is a common feature of CYP17 
and CYP11B1 inhibitors, we replaced imidazole by pyridine. Accordingly, using this segmentation and 
hybridization procedure, biphenyl methylene pyridines were designed. Depending on the substituents at the 
core, these new compounds could be dual inhibitors of CYP17 and CYP11B1 or selective CYP17 inhibitors. 
This is because maximization of CYP17 inhibition was pursued as the first priority during the segment 
selection by choosing biphenyl instead of nicotinoyl, high inhibitory potency toward this enzyme should be 
the result, whereas inhibition toward CYP11B1 will largely depend on the substituents at the core.  
As the first step, the effects of this design strategy on CYP17 inhibition were substantiated by comparing 
the imidazole, 3- and 4-pyridine analogues, i.e. Ref. 1–2 and compounds 1–4 (Table 1). Encouraged by the 
positive results, more modifications on the A-ring were performed by introducing groups with different 
electrostatic potential, H-bond forming properties and various steric demand to improve both inhibition 
toward CYP17 and CYP11B1 (5–25, Tables 2–3). After determination of CYP17 inhibition, the most potent 
compounds were further tested for CYP11B1 inhibition and for selectivity against CYP11B2, CYP19 and 
hepatic CYP3A4. 
Results  
Chemistry. The synthesis of compounds 1–25 is shown in Schemes 1 and 2. A general strategy was 
employed starting from the corresponding (4-bromophenyl)-pyridyl-methanones, which are commercially 
available, but were easily prepared from bromobenzene and the corresponding nicotinic or isonicotinic acid 
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via Friedel-Crafts acylation. The starting material and the corresponding boronic acids were first reacted via 
Suzuki coupling to form the biaryl moieties, and then the ketone group was transferred by Wolff-Kishner 
reduction to afford the final methylene products. Subsequently, a more efficient strategy was used by first 
synthesizing the 4-bromobenzyl pyridine 5a as a common building block, followed by introduction of the 
aryl ring via Suzuki coupling. For compounds 1 and 2 substituted with an ethyl rest on the methylene bridge, 
the ketone intermediates were reacted with ethylmagnesium bromide to give the corresponding alcohols 1b 
and 2b. After H2O elimination in formic acid using Pd(OAc)2 as catalyst,  hydrogenation was performed to 
yield the final compounds. Moreover, the OH analogues 8–10 and 25 were obtained by ether cleavage of the 
corresponding methoxy compounds 8a, 9a, 16 and 24, respectively, using boron tribromide. 
Scheme 1.a  
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a Reagents and conditions: (i) Method A: Pd(OAc)2, 4-methoxyphenylboronic acid, Na2CO3, TBAB, toluene, H2O, ethanol, reflux, 
6h. (ii) Method C: EtMgCl, THF; (iii) Method E: Pd(OAc)2, HCOOH, reflux, 16h. (iv) Method F: Pd/C, H2. (v) Method B: N2H4, 
KOH, ethylene glycol, reflux, 4h. (vi) Method D: BBr3, DCM. 
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a Reagents and conditions: (i) Method A: Pd(OAc)2, corresponding boronic acid, Na2CO3, TBAB, toluene, H2O, ethanol, reflux, 
6h. (ii) Method B: N2H4, KOH, ethylene glycol, reflux, 4h. 
CYP17 inhibition. Inhibitory activities of the synthesized compounds for CYP17 were determined using 
the 50,000g sediment after homogenation of E.coli expressing human CYP17 as well as cytochrome P450 
reductase.17a The assay was run with progesterone as substrate at high concentrations of 25 μM and NADPH 
as cofactor.13c Separation of substrate and product was accomplished by HPLC using UV detection. IC50  
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Table 1. Inhibition of CYP17 by compounds 1–4. 
R2
Het
Ref. 1 - 2, 1 - 4
R1
A
C
 
Compd R1 R2 Heterocycles IC50 [nM]b  Compd R1 R2 Heterocycles IC50 [nM]b 
Ref. 1 Et OMe 1-Im >5000  Ref. 2c H OH 1-Im >5000 
1 Et OMe 3-Py >5000  3 H OH 3-Py 4040 
2 Et OMe 4-Py 1610  4 H OH 4-Py 248 
MYPa    >10000  KTZa    2780 
ABTa    72       
a MYP: Metyrapone; KTZ: Ketoconazole; ABT: Abiraterone. 
b Concentration of inhibitors required to give 50 % inhibition. The given values are mean values of at least three experiments. The 
deviations were within ±10 %. The assay was run with human CYP17 expressed in E.coli using progesterone as substrate (25 μM).  
c Ref. 1 was taken from reference 13a, where the inhibitory potency was test with human testicular microsome as 0.31 μM. 
values are presented in comparison to Ketoconazole and Abiraterone in Tables 1–3. 
To validate the possible benefits achieved after replacement of imidazolyl by pyridyl, the inhibitory 
potencies of imidazole, 3-pyridine and 4-pyridine analogues were compared. The SARs obtained from our 
previous work on biphenyl methylene imidazoles confirm that a) an ethyl group substituted on the methylene 
bridge elevates the inhibitory potency and b) H-bond forming groups such as hydroxy at 4-position of the A-
ring increase the activity.13d-g Taking these SARs into consideration, reference compounds Ref. 113f and Ref. 
213a were chosen, each possessing one advantageous structural feature, ethyl or hydroxy, but showing low 
activity. Accordingly, the 3- and 4-pyridyl analogues were synthesized (Table 1). It becomes apparent that 
no matter which substituent furnished, the 3-pyridine analogues 1 and 3 showed similar inhibitory potencies 
compared to the reference compounds (IC50 ≥ 5000 nM). However, the 4-pyridine analogue with an ethyl 
substituent on the methylene bridge exhibited IC50 of 1610 nM, thus, being more potent than the 
corresponding imidazole analogue Ref. 1 (IC50 > 5000nM). The most active compound was the 4-pyridine 
analogue 4 furnished with hydroxy at the 4-position of the A-ring, showing IC50 of 248 nM. 
Encouraged by these results more compounds were designed based on the biphenyl methylene 4-pyridine 
scaffold (Table 2). It can be seen that the substituents at the A-ring showed a significant influence on the 
inhibitory potencies. The 4-amino substituted compound 5 showed IC50 of 408 nM, whereas its 3-amino 
analogue 6 was even more potent (IC50 = 226 nM). Interestingly, the 3, 4-diamino compound 7 exhibited 
potent activity with IC50 in between (337 nM). Moreover, the hydroxy analogues were more potent than the 
amino derivatives. The 3-OH compound 8 was three fold more potent (IC50 = 97 nM) compared to its 
corresponding NH2 analogue, and to the 4-OH compound 4 (IC50 = 248 nM). The 3,4-di OH compound 9 
turned out to be the most potent one in this series with IC50 of 52 nM, being even more potent than 
Abiraterone (IC50 = 72 nM). The introduction of fluorine in 3-position of compound 4 resulting in compound 
10 increased activity to 186 nM. The phenomenon that 3-substituted analogues are more potent than the 
corresponding 4-substituted compounds was also observed with the 4-acetamido compound 11 and its 3-
analogue 12 (IC50 = 876 nM). The retro-amide 13 (IC50 = 1790 nM) showed a slightly increased potency  
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Table 2. Inhibition of CYP17 by compounds 5–20. 
R1
N
5 - 20
R2
A
C
 
Compd R1 R2 IC 50 [nM]b  Compd R1 R2 IC 50 [nM]b 
5 NH2 H 408  13 NH2CO H 1790 
6 H NH2 226  14 F H 386 
7 NH2 NH2 337  15 F F 598 
4 OH H 248  16 OMe F 3340 
8 H OH 97  17 BocNH H 1370 
9 OH OH 52  18 BocNH F >10000 
10 OH F 186  19 BocNH BocNH >10000 
11 AcNH H >5000  20 OMe BocNH >10000 
12 H AcNH 876  KTZa   2780 
MYPa   >10000  ABTa   72 
a MYP: Metyrapone; KTZ: Ketoconazole; ABT: Abiraterone. 
b Concentration of inhibitors required to give 50 % inhibition. The given values are mean values of at least three experiments. The 
deviations were within ±10 %. The assay was run with human CYP17 expressed in E.coli using progesterone as substrate (25 μM). 
compared to compound 11. As for fluorine derivatives introduction of additional F resulted in loss of 
inhibitory potency (15), which is in accordance with our previous findings, 13g while the compound with 
single fluorine in the 4-position of the A-ring (14) exhibited strong inhibition (IC50 = 386 nM). Another 
interesting observation was the little activity of compounds 17 to 20 indicating that the Boc-amido group is 
not appropriate for highly active compounds, no matter introduced at the 3- or 4-position. 
Table 3. Inhibition of CYP17 by compounds 21–25 
N
Het
N
R
21 - 23 24 - 25  
Compd Het R IC 50 [nM]b  Compd Het R IC 50 [nM]b 
21 2-Thiophene  577  24  OMe 2000 
22 3-Thiophene  647  25  OH 438 
23 5-Indole  760  KTZa   2780 
MYPa   >10000  ABTa   72 
a MYP: Metyrapone; KTZ: Ketoconazole; ABT: Abiraterone. 
b Concentration of inhibitors required to give 50 % inhibition. The given values are mean values of at least three experiments. The 
deviations were within ±10 %. The assay was run with human CYP17 expressed in E.coli using progesterone as substrate (25 μM). 
Finally, the A-ring phenyl group was exchanged by heterocycles and substituted naphthalenes (Table 3). 
The thiophene (21 and 22) and indole (23) compounds showed modest activity with IC50 values around 600 
nM. For the naphthalene analogues, the great influence of the substituent on the A-ring was again observed. 
The hydroxy derivative 25 showed rather potent inhibition (IC50 = 438 nM), while the corresponding 
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methoxy derivative 24 was less active. 
CYP11B1 inhibition. After it has been shown that the replacement of imidazolyl by pyridyl significantly 
increased the CYP17 inhibition, selected compounds (4–10, 12, 14, 15, 21–23 and 25) were examined for 
their CYP11B1 inhibition (Table 4). The inhibitory activities were determined in V79 MZh cells expressing 
human CYP11B1.17b-c The V79 MZh cells were incubated with [14C]-deoxycorticosterone as substrate and 
the inhibitor in different concentrations. Product formation was monitored by HPTLC using a 
phosphoimager. It becomes apparent that the substituents on the A-ring also show profound influence on the 
inhibition of this enzyme. Compounds 4 and 6 exhibited rather strong effects with IC50 values around 250 
nM. Compounds 9 and 15 showed only weak or no inhibition (IC50 values of 1400 and 4742 nM, 
respectively), thus, being rather selective inhibitors of CYP17, whereas all of the rest compounds 5, 7, 8, 10, 
12, 14, 15, 21–23 and 25 showed modest inhibition values between 300 and 930 nM.  
Selectivity. The inhibition of CYP11B2 by selected potent compounds was determined as well using V79 
MZh cells expressing human CYP11B2 (Table 4). CYP11B2 is the crucial enzyme responsible for the final 
steps in aldosterone biosynthesis (Chart 1). Inhibition of CYP11B2 could cause hyponatremia, hyperkalemia 
and a series of recessive disorders, such as adrenal hyperplasia and hypovolemic shock.18a Selectivity over 
CYP11B2 is difficult to reach especially for the compounds inhibiting CYP11B1 because of the very high 
homology between these two enzymes of 93%. It can be seen that although compounds 8, 10 and 15  
exhibited strong inhibition toward CYP11B2 (IC50 values around 250 nM), some compounds (4, 5, 7, 12, 14 
and 21–23) showed modest inhibition with IC50 values ranging from 300 to 800 nM, whereas other 
compounds (6, 9 and 25) were very selective with IC50 values around 1000 nM. Important is that compound 
6 as a dual inhibitor of CYP17 and CYP11B1 exhibiting a selectivity factor of 3.2 between CYP11B1 and 
CYP11B2.  
Table 4. Inhibition of CYP11B1, CYP11B2, CYP19 and CYP3A4 by selected compounds. 
IC50 (nM)b  IC50 (nM)b 
Comp 
CYP11B1c CYP11B2c CYP19d CYP3A4e 
Comp 
CYP11B1c CYP11B2c CYP19d CYP3A4e 
4 251 341 3070 3210  12 307 567 n.d.a n.d.a 
5 522 406 24500 2450  14 928 515 n.d.a 668 
6 287 921 2830 1520  15 4742 273 n.d.a n.d.a 
7 902 367 >25000 n.d.a  21 422 331 n.d.a n.d.a 
8 342 261 663 538  22 415 796 n.d.a n.d.a 
9 1400 948 2440 7580  23 469 231 n.d.a n.d.a 
10 850 210 2693 896  25 627 1130 n.d.a 1140 
MYPa 15 72 >5000 n.d.a       
KTZa 127 67 >5000 57  ABTa 1610 1750 >5000 2700 
a MYP: Metyrapone; KTZ: Ketoconazole; ABT: Abiraterone; n.d.: not determined. 
b Standard deviations were within < ±5 %;  All the data are the mean values of at least 3 tests. 
c Hamster fibroblasts expressing human CYP11B1 or CYP11B2 are used with deoxycorticosterone as the substrate at a concentration 
of 100 nM. 
d Human placental CYP19 is used with androstenedione as the substrate at a concentration of 500 nM. 
e Recombinantly expressed enzyme from baculovirus-infected insect microsome is used with 7-benzyloxy-trifluoromethyl coumarin 
as the substrate at a concentration of 50 μM.  
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Furthermore, the selectivity of these potent compounds toward CYP19 and hepatic CYP3A4 has also been 
tested as a criterion for safety (Table 4). CYP19 is the unique enzyme catalyzing the peripheral conversion of 
androgens to estrogens by hydroxylation and subsequent elimination of the C19 methyl group resulting in 
steroid A-ring aromatization. Estrogen deficiency causes osteoporosis, increased fracture risk17b and memory 
loss.18c Under CYP17 inhibition, there is a reduction of the estrogen plasma concentrations because the 
androgens, as substrates for estrogen formation, are decreased. A further reduction of estrogen levels by 
CYP19 inhibition would be detrimental.  As can be seen, all the tested compounds except 8 showed no 
inhibition of CYP19 (IC50 values above 2000 nM).  
Besides, the important role of CYP3A4 in drug metabolism and drug-drug interaction has been addressed 
and the compounds have been tested for inhibition of this enzyme as well. Most of them showed weak or no 
inhibition of CYP3A4 (IC50 > 1000 nM). Compounds 4 and 9 exhibited a better selectivity than Abiraterone 
(IC50 values of 3210 nM and 7580 nM vs 2700 nM). 
Discussion and Conclusion 
The design concept applied in the present paper using the steroidal CYP17 inhibitor Abiraterone, the 
CYP11B1 inhibitor Metyrapone and our experience in non-steroidal biphenyl methylene based CYP17 
inhibitors (including 1K) was successful. Exchange of the imidazolyl moiety by a 4-pyridyl rest led – 
depending on the substitution pattern at the A-ring – on the one hand to compound 9, exceeding Abiraterone 
in activity and selectivity, and on the other hand to compound 6, a dual inhibitor of CYP17 and CYP11B1.  
The elevated inhibition of CYP17 caused by the novel pyridines compared to the corresponding 
imidazoles might be due to the prolonged distance between the sp2 hybrid N and the methylene C. This 
elongation of the molecule places the H-bond forming groups at the A-ring closer to the amino acid residues, 
facilitating better H-bond formation. Moreover, it has been found that substituents on the A-ring showed 
profound influence on the inhibitory potency of both CYP17 and CYP11B1. Hydrogen bond forming groups, 
like OH and NH2, significantly elevated CYP17 inhibition, probably due to the interaction with Arg109, 
Lys231, His235 and Asp298, similar as we described recently.13f This finding indicates that  imidazoles and 
pyridines may adopt the same binding mode in the enzyme pocket. Among them, OH analogues were found 
to be more potent than the corresponding NH2 analogues (e.g. compounds 4 and 5 (IC50 values of 248 nM 
and 408 nM), compounds 8 and 6 (IC50 values of 97 nM and 226 nM) and compounds 9 and 7 (IC50 values of 
52 nM and 337 nM)), probably because the hydrogen bonds formed by O are stronger than the ones formed 
by N.19 Interestingly, meta-substituted analogues are more potent than the corresponding para-analogues. 
After methylation of OH (compounds 16 and 20) or acylation of NH2 (11, 12, 17–20), the inhibitory potency 
dropped along with the augment of bulk, which is probably due to the steric hindrance with His235, Arg109 
and the proximal I-helix residues as described previously.13f  
Regarding the additional CYP11B1 inhibition we were aiming at in this study, the exchange of the 
nicotinoyl moiety from Metyrapone –– because it leads to a loss of CYP17 inhibition –– by a biphenyl 
moiety with small polar substituents was successful and resulted in compounds with dual, CYP17 and 
CYP11B1, inhibition. It was found that compounds 4–6, 8 and 12 with one single H-bond donor showed 
potent to modest inhibition (IC50 values ranged 250 to 350 nM, with compound 5 as an exception showing 
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IC50 value of 522 nM), whereas H-bond acceptors or two donors resulted in rather weak inhibitors of 
CYP11B1 (compounds 7, 9 and 10; IC50 values more than 800 nM). Since these compounds with differing 
CYP11B1 inhibition are potent CYP17 inhibitors, they are accordingly either dual inhibitors of CYP17 / 
11B1 or selective CYP17 inhibitors.  
The A-ring substituents also diversified the inhibitory potency toward the non-target enzyme CYP11B2. It 
was found that compounds with strong CYP11B1 inhibition were also associated with CYP11B2 inhibition. 
This is not surprising since homology between these two enzymes is more than 93%. As inhibition of 
CYP11B2 has to be avoided, the most interesting dual inhibitor in this study is compound 6 showing a 
selectivity factor of 3.2 regarding CYP11B1 and CYP11B2. For the application as a dual CYP17 / CYP11B1 
inhibitor, this selectivity toward CYP11B2 is certainly not sufficient. However, compound 6 should be an 
interesting lead for further optimization. Since highly active and selective CYP11B2 inhibitors with in vivo 
activity15a reaching selectivity factors of 100015b have been identified by our group for the treatment of 
congestive heart failure and myocardial fibrosis, we are confident that the selectivity of compound 6 can be 
further improved. Structure modifications are presently being performed. 
The use of selective multi-target-directed ligands has already been proposed for the treatment of other 
diseases to enhance efficacy and to improve safety, for example agents inhibiting angiotensin converting 
enzyme (ACE) and neutral endopeptidase (NEP) in the treatment of hypertension, multi-kinase inhibitors 
(MKI) with combined inhibition of vascular endothelial growth factor (VEGF) and platelet-derived growth 
factor (PDGF) for cancer therapy and dual binding site acetylcholinesterase inhibitors (AChEI) for 
Alzheimer’s disease.20 Comparing to the traditional combinational application of two or more drugs, multi-
target-directed agents can reduce the risk of drug-drug interactions and achieve better compliance. The 
conception of selective dual inhibition of CYP17 and CYP11B1 is a novel treatment for PC. There is indeed 
a high medical need in prostate cancer patients to combat elevated glucocorticoid levels and to prevent 
stimulation of mutated androgen receptors by glucocorticoids. CYP11B1 catalyzing the last step in cortisol 
biosynthesis is an ideal target to decrease corticosterone and cortisol production. However, there are no 
highly selective inhibitors of this enzyme described so far which could be used in a combination therapy with 
CYP17 inhibitors. Metyrapone is a compound not selective enough that inhibits other steroidogenic CYP 
enzymes and therefore shows severe side effects. Accordingly it is not an appropriate candidate for this 
purpose, although it has been used in the treatment of Cushing’s syndrome for a long time. Another 
unselective compound, the antimycotic Ketoconazole has already been employed to treat prostate cancer 
patients with ectopic adrenocorticotropic hormone syndrome8d because it inhibits both androgen and 
corticosteroid –– not only glucocorticoid but also mineralocorticoid –– biosynthesis. However, the response 
was not satisfactory due to the weak potency of Ketoconazole (CYP17 IC50 = 2780 nM). Compound 6 should 
be a much better candidate than Ketoconazole showing a good dual inhibition of CYP17 and CYP11B1 with 
IC50 values around 200 nM for both enzymes, a three fold selectivity of CYP11B1 over CYP11B2 and nearly 
no inhibition of CYP19 and CYP3A4. As selectivity for CYP11B2 should be further enhanced, compound 6 
could be an ideal candidate for this optimization process.  
 Importantly, compound 9 showed an excellent selectivity with almost no inhibition of all other enzymes 
tested. It is highly active showing an IC50 value of 52 nM. As in our experimental set-up with high substrate 
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concentrations, this value has to be ranked higher than similar IC50 values obtained by other groups using 
much lower substrate concentrations. The fact that compound 9 not only shows strong inhibition of androgen 
formation (CYP17), but also does not block androgen conversion to estrogens (CYP19) provides maximally 
low androgen levels –– a prerequisite for the therapeutic success. After validation in vivo, this compound 
could be a promising drug candidate for further development. 
Based on the results of the present study we would like to propose a novel strategy for the treatment of 
prostate cancer: CYP17 inhibitors with different selectivity profiles according to the status of the patients 
should be applied. For normal patients, selective CYP17 inhibitors that do not interfere with other 
steroidogentic CYPs should be used to avoid side effects, whereas for patients with mutated androgen 
receptors or ectopic adrenocorticotropic hormone syndrome, dual inhibitors of CYP17 and CYP11B1 are the 
best choice in the view of a personalized medicine. 
Experimental Section 
CYP17 preparation and assay 
Human CYP17 was expressed in E. coli17a (coexpressing human CYP17 and NADPH-P450 reductase) and 
the assay was performed as previously described.13c  
Inhibition of hepatic CYP3A4 
The recombinantly expressed enzyme from baculovirus-infected insect microsomes (Supersomes) was 
used and the manufacturer’s instructions (www.gentest.com) were followed. 
Inhibition of CYP11B1 and CYP11B2 
V79MZh cells expressing human CYP11B1 or CYP11B2 were incubated with [14C]-11-
deoxycorticosterone as substrate. The assay was performed as previously described.17b-c 
Inhibition of CYP19 
The inhibition of CYP19 was determined in vitro using human placental microsomes with [1β-
3H]androstenedione as substrate.17d 
Chemistry Section 
General 
Melting points were determined on a Mettler FP1 melting point apparatus and are uncorrected. IR spectra 
were recorded neat on a Bruker Vector 33FT-infrared spectrometer. 1H-NMR spectra were measured on a 
Bruker DRX-500 (500 MHz). Chemical shifts are given in parts per million (ppm), and TMS was used as an 
internal standard for spectra. All coupling constants (J) are given in Hz. ESI (electrospray ionization) mass 
spectra were determined on a TSQ quantum (Thermo Electron Corporation) instrument. The purities of the 
final compounds were controlled by Surveyor®-LC-system. Purities were greater than 95%. Column 
chromatography was performed using silica-gel 60 (50–200 µm), and reaction progress was determined by 
TLC analysis on Alugram® SIL G/UV254 (Macherey-Nagel). Boronic acids and bromoaryls used as starting 
materials were commercially obtained (CombiBlocks, Chempur, Aldrich, Acros). 
Method A: Suzuki-Coupling 
The corresponding brominated aromatic compound (1 eq) was dissolved in toluene (7 mL / mmol), and an 
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aqueous 2.0 M Na2CO3 solution (3.2 mL / mmol), an ethanolic solution (3.2 mL / mmol) of the 
corresponding boronic acid (1.5–2.0 eq) and tetrabutylammonium bromide (1 eq) were added. The mixture 
was deoxygenated under reduced pressure and flushed with nitrogen. After having repeated this cycle several 
times Pd(OAc)2 (5 mol%) was added and the resulting suspension was heated under reflux for 2–6 h. After 
cooling, ethyl acetate (10 mL) and water (10 mL) were added and the organic phase was separated. The 
water phase was extracted with ethyl acetate (2 x 10 mL). The combined organic phases were washed with 
brine, dried over Na2SO4, filtered over a short plug of celite® and evaporated under reduced pressure. The 
compounds were purified by flash chromatography on silica gel.  
4'-(Pyridin-4-ylmethyl)biphenyl-4-amine (5). Synthesised according to Method A using 5a (0.35 g, 1.41 
mmol) and 4-aminophenyl boronic acid (0.29 g, 2.12 mmol); yield: 0.32 g (87%); white solid: mp 217–218 
°C;  Rf = 0.19 (DCM/MeOH, 20:1); δH (CD3OD, 500 MHz) 4.04 (s, 2H), 6.77 (d, J = 8.5 Hz, 2H), 7.23 (d, J 
= 8.1 Hz, 2H), 7.29 (d, J = 5.9 Hz, 2H, Py 2,6-H), 7.36 (d, J = 8.5 Hz, 2H), 7.48 (d, J = 8.2 Hz, 2H), 8.40 (d, 
J = 6.1 Hz, 2H, Py 3,5-H); MS (ESI): m/z = 261 [M++H]. 
4'-(Pyridin-4-ylmethyl)biphenyl-3-amine (6). Synthesised according to Method A using 5a (0.30 g, 1.21 
mmol) and 3-aminophenyl boronic acid (0.25 g, 1.81 mmol); yield: 0.26 g (83%); white solid: mp 79–80 °C; 
Rf = 0.45 (DCM/MeOH, 95:5); δH (CDCl3, 500 MHz)  4.00 (s, 2H), 5.13 (s, 2H), 6.54 (dd, J = 2.2, 7.9 Hz, 
1H), 6.74 (dd, J = 1.6, 7.6 Hz, 1H), 6.81 (t, J = 1.9 Hz, 1H), 7.07 (t, J = 7.9 Hz, 1H), 7.27 (d, J = 5.9 Hz, 
2H), 7.30 (d, J = 8.2 Hz, 2H), 7.49 (d, J = 7.9 Hz, 2H), 8.46 (d, J = 5.9 Hz, 2H); MS (ESI): m/z = 261 
[M++H]. 
4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diamine (7). Synthesised according to Method A using 5a (0.35 g, 
1.41 mmol) and 3,4-diaminophenyl boronic acid (0.32 g, 2.11 mmol); yield: 0.32 g (83%); white solid: mp 
180–181 °C;  Rf = 0.15 (DCM/MeOH, 20:1); δH (CDCl3, 500 MHz) 3.48 (s, br, 4H, NH2), 3.98 (s, 2H, CH2), 
6.76 (d, J = 8.2 Hz, 1H,), 6.92–6.96 (m, 2H), 7.13 (d, J = 6.0 Hz, 2H), 7.18 (d, J = 8.2 Hz, 2H), 7.47 (d, J = 
8.2 Hz, 2H),  8.50 (dd, J = 1.6, 6.0 Hz, 2H); MS (ESI): m/z = 276 [M++H]. 
4-[(3',4'-Dimethoxybiphenyl-4-yl)methyl]pyridine (9a). Synthesised according to Method A using 5a 
(0.31 g, 1.25 mmol) and 3,4-dimethoxyphenylboronic acid (0.34 g, 1.88 mmol); yield: 0.34 g, (90%). This 
compound was used directly in the next step without further purification and characterization. 
4'-(Pyridin-4-ylmethyl)biphenyl-4-carboxamide (13). Synthesised according to Method A using 5a 
(0.25 g, 1.01 mmol) and 4-carbamoylphenyl boronic acid (0.25 g, 1.51 mmol); yield: 0.26 g (89%); white 
solid: mp 241–242 °C;  Rf = 0.21 (DCM/MeOH, 50:1); δH (CD3OD, 500 MHz) 4.09 (s, 2H,CH2), 7.09–7.11 
(m, 4H), 7.64 (d, J = 7.9 Hz, 2H), 7.71 (d, J = 7.8 Hz, 2H), 7.94 (d, J = 8.1 Hz, 2H), 8.42 (d, J = 4.7 Hz, 2H, 
Py 3,5-H); MS (ESI): m/z = 289 [M++H]. 
4-[(4'-Fluoro-biphenyl-4-yl)methyl]-pyridine (14). Synthesised according to Method A using 5a (301 
mg, 1.21 mmol) and 4-fluorophenyl boronic acid (254 mg, 1.82 mmol); yield: 168 mg (53%); white solid: 
mp 114–115 °C; Rf = 0.49 (DCM / MeOH, 95:5) δH (CDCl3, 500 MHz) 3.96 (s, 2H), 7.03–7.07 (m, 2H), 7.12 
(d, J = 5.4 Hz, 2H), 7.17 (d, J = 8.5 Hz, 2H), 7.43 (d, J = 8.2 Hz, 2H), 7.44–7.47 (m, 2H), 8.45 (d, J = 5.3 Hz, 
2H); MS (ESI): m/z = 264 [M++H] 
4-[(3',4'-Difluorobiphenyl-4-yl)methyl]pyridine (15). Synthesised according to Method A using 5a 
(0.125 g, 0.5 mmol) and 3,4-difluorophenyl boronic acid (0.21 g, 0.75 mmol); yield: 0.12 g (87%); 
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colourless oil; Rf = 0.27 (hexane/EtOAc, 1:1); δH (CDCl3, 500 MHz) 3.93 (s, 2H), 7.05 (d, J = 6.1 Hz, 2H), 
7.10–7.22 (m, 4H), 7.26–7.31 (m, 1H), 7.39 (d, J = 8.2 Hz, 2H), 8.44 (d, J = 6.1 Hz, 2H); MS (ESI): m/z = 
282 [M++H]. 
tert-Butyl 4'-(pyridin-4-ylmethyl)biphenyl-4-yl carbamate (17). Synthesised according to Method A 
using 5a (0.30 g, 1.21 mmol) and 4-(tert-butoxycarbonylamino)phenyl boronic acid (0.43 g, 1.81 mmol); 
yield: 0.38 g (87%); white solid: mp 198–199 °C;  Rf = 0.26 (DCM/MeOH, 50:1); δH (CD3OD, 500 MHz) 
1.53 (s, 9H, Boc), 4.05 (s, 2H, CH2), 7.28–7.29 (m, 4H), 7.51–7.53 (m, 6H), 8.40 (d, J = 4.9 Hz, 2H); MS 
(ESI): m/z = 361 [M++H]. 
4-[4-(Thiophen-2-yl)benzyl]pyridine (21). Synthesised according to Method A using 5a (0.35 g, 1.41 
mmol) and thiophen-2-yl boronic acid (0.27 g, 2.12 mmol); yield: 0.32 g (91%); white solid: mp 82–83 °C;  
Rf = 0.26 (DCM/MeOH, 50:1); δH (CD3OD, 500 MHz) 4.00 (s, 2H, CH2), 7.05 (dd, J =  4.0, 4.6 Hz, 1H), 
7.22 (d, J = 7.2 Hz, 2H), 7.26 (d, J = 4.6 Hz, 2H), 7.33 (d, J = 4.7 Hz, 2H), 7.56 (d, J = 7.9 Hz, 2H), 8.40 (d, 
J = 3.9 Hz, 2H); MS (ESI): m/z = 252 [M++H]. 
4-[4-(Thiophen-3-yl)benzyl]pyridine (22). Synthesised according to Method A using 5a (0.35 g, 1.41 
mmol) and thiophen-3-yl boronic acid (0.27 g, 2.12 mmol); yield: 0.31 g (90%); white solid: mp 97–98 °C;  
Rf = 0.26 (DCM/MeOH, 50:1); δH (CD3OD, 500 MHz) 4.03 (s, 1H, CH2), 7.24 (d, J = 8.2 Hz, 2H), 7.28 (d, J 
= 6.0 Hz, 2H), 7.43–7.45 (m, 2H), 7.60–7.63 (m, 3H), 8.40 (d, J = 6.45 Hz, 2H); MS (ESI): m/z = 252 
[M++H]. 
5-[4-(Pyridin-4-ylmethyl)phenyl]-1H-indole (23). Synthesised according to Method A using 5a (0.30 g, 
1.21 mmol) and 1H-indol-5-yl boronic acid (0.27 g, 2.12 mmol); yield: 0.30 g (87%); white solid: mp 170–
171 °C;  Rf = 0.23 (DCM/MeOH, 20:1); δH (CD3OD, 500 MHz) 4.04 (s, 2H, CH2), 6.48 (d, J = 3.7 Hz, 1H), 
7.25–7.27 (m, 3H), 7.30 (d, J = 5.9 Hz, 2H), 7.35–7.37 (m, 1H), 7.42 (d, J = 8.5 Hz, 2H), 7.58 (d, J = 8.2 Hz, 
2H), 7.76–7.78 (m, 1H), 8.40 (d, J = 5.9 Hz, 2H);  MS (ESI): m/z = 285 [M++H]. 
Method B: Wolff-Kishner-Reduction 
To an ice-cooled solution of the appropriate ketone (10 mmol) in ethylene glycol (100 mL) was added 
hydrazine hydrate (70 mmol) and potassium hydroxide (10 mmol). Then the resulting mixture was heated to 
150 °C for 1 hour. After cooling down, a further batch of potassium hydroxide (50 mmol) was added, and the 
mixture was heated to 210 °C for 2 hours. After cooling to ambient temperature, it was diluted with water 
(300 mL), and the resulting mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic 
phases were washed with brine, dried over MgSO4 and evaporated under reduced pressure. Then the desired 
product was purified by chromatography on silica gel. 
4-(4-Bromobenzyl)pyridine (5a). Synthesised according to Method B using (4-bromophenyl)-pyridin-4-
yl-methanone (0.39 g, 1.5 mmol); yield: 0.21 g (52%); amber oil; Rf = 0.35 (PE / EtOAc, 10:1); δH (CDCl3, 
500 MHz) 3.89 (s, 2H, CH2), 7.02 (d, J = 8.3 Hz, 2H), 7.05 (d, J = 5.9 Hz, 2H), 7.41 (d, J = 8.3 Hz, 2H), 
8.48 (d, J = 5.9 Hz, 2H); δC (CDCl3, 125 MHz) 40.5 (CH2), 120.5, 124.0, 130.6, 131.7, 137.7, 149.8; MS 
(ESI): m/z = 249 [M++H]. 
N-(4'-Isonicotinoylbiphenyl-3-yl)acetamide (12). Synthesised according to Method B using 12a (0.32 g, 
1.0 mmol); yield: 0.19 g (62%); yellowish solid: mp 123–124 °C; Rf = 0.27 (DCM/MeOH, 95:5); δH 
(DMSO-d6, 500 MHz)  2.06 (s, 3H, CH3), 4.00 (s, 2H, CH2), 7.27 (d, J = 5.9 Hz, 2H), 7.29 (t, J = 1.9 Hz, 
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1H), 7.32–7.38 (m, 3H), 7.52–7.57 (m, 3H), 7.88 (t, J = 1.9 Hz, 1H), 8.47 (d, J = 5.9 Hz, 2H), 10.01 (s, 1H); 
MS (ESI): m/z = 303 [M++H]. 
4-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)methyl]pyridine (16). Synthesised according to Method B using 
16a (0.43 g, 1.38 mmol); yield: 0.37 g (91%); white solid: mp 98–99 °C; Rf = 0.46 (hexane/EtOAc, 1:1); δH 
(CDCl3, 500 MHz) 3.84 (s, 3H), 3.91 (s, 2H), 6.93 (t, J = 8.5 Hz, 1H), 7.05 (d, J = 6.3 Hz, 2H), 7.14 (d, J = 
7.9 Hz, 2H), 7.18–7.26 (m, 1H), 7.21 (s, 1H), 7.39 (d, J = 7.9 Hz, 2H), 8.43 (d, J = 6.3 Hz, 2H); MS (ESI): 
m/z = 294 [M++H]. 
4-[4-(6-Methoxynaphthalen-2-yl)benzyl]pyridine (24). Synthesised according to Method B using 24a 
(0.40 g, 1.18 mmol); yield: 0.34 g (89%); white solid; Rf = 0.49 (DCM/MeOH, 95:5); δH (CDCl3, 500 MHz) 
3.89 (s, 3H), 4.02 (s, 2H), 7.18 (dd, J = 2.5, 8.8 Hz, 1H), 7.29 (d, J = 6.0 Hz, 2H), 7.34 (d, J = 2.5 Hz, 1H), 
7.37 (d, J = 8.5 Hz, 2H), 7.73 (d, J = 8.2 Hz, 2H), 7.77 (dd, J = 1.9, 8.5 Hz, 1H), 7.88 (d, J = 8.8 Hz, 2H), 
8.11 (d, J = 1.6 Hz, 1H), 8.47 (d, J = 6.0 Hz, 2H); MS (ESI): m/z = 326 [M++H]. 
Method C: Grignard reaction 
Under exclusion of air and moisture a 1.0 M RMgBr (1.2 eq) solution in THF was added dropwise to a 
solution of the aldehyde or ketone (1 eq) in THF (12 mL / mmol). The mixture was stirred over night at rt. 
Then ethyl acetate (10 mL) and saturated ammonium chloride solution (10 mL) were added and the organic 
phase was separated. The organic phase was extracted with water and brine, dried over Na2SO4, and 
evaporated under reduced pressure. The crude products were purified by flash chromatography on silica gel.  
Method D: Ether cleavage with BBr3 
To a solution of the corresponding ether (1 eq) in DCM (5 mL / mmol) at -78 °C was added 1 M 
borontribromide in DCM (5 eq). The resulting mixture was stirred at rt for 16 hours. Then water (25 mL) 
was added and the emulsion was stirred for further 30 minutes. The resulting mixture was extracted with 
ethyl acetate (3 x 25 mL). The combined organic phases were washed with brine, dried over Na2SO4 and 
evaporated under reduced pressure. Then the desired product was purified by chromatography on silica gel. 
4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine (4). Synthesised according to Method D using 4a (0.38 g, 
1.37 mmol) and 1 M BBr3 solution in DCM (6.85 mL, 6.85 mmol); yield: 0.39 g (10%); white solid: mp 
224–225 °C; Rf = 0.24 (DCM/MeOH, 95:5); δH (DMSO-d6, 500 MHz) 3.97 (s, 2H), 6.83 (d, J = 8.5 Hz, 2H), 
7.25–7.30 (m, 4H), 7.45 (d, J = 8.5 Hz, 2H), 7.50 (d, J = 8.2 Hz, 2H), 8.46 (d, J = 5.9 Hz, 2H), 9.52 (s, 1H); 
MS (ESI): m/z = 262 [M++H]. 
4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine (8). Synthesised according to Method D using 8a (0.17 g, 
0.62 mmol) and 1 M BBr3 solution in DCM (3.10 mL, 3.10 mmol); yield: 0.10 g (62%); white solid: mp 
153–154 °C; Rf = 0.41 (EtOAc/hexane, 4:1); δH (DMSO-d6, 500 MHz) 3.99 (s, 2H), 6.74 (dd, J = 2.5, 8.2 
Hz, 1H), 6.99 (t, J = 2.1 Hz, 1H), 7.04 (d, J = 7.9 Hz, 1H), 7.23 (t, J = 7.9 Hz 1H), 7.28 (d, J = 5.7 Hz, 2H), 
7.31 (d, J = 8.2 Hz, 2H), 7.53 (d, J = 8.2 Hz, 2H), 8.47 (d, J = 5.7 Hz, 2H), 9.50 (s, 1H); MS (ESI): m/z = 
262 [M++H]. 
4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol (9). Synthesised according to Method D using 9a (0.26 g, 0.85 
mmol) and 1 M BBr3 solution in DCM (4.20 mL, 4.20 mmol); yield: 0.22 g (93%); white solid; Rf = 0.55 
(DCM/MeOH, 10:1); δH (DMSO-d6, 500 MHz) 3.97 (s, 2H), 6.79 (d, J = 8.2 Hz, 1H), 6.90 (dd, J = 2.2, 8.2 
Hz, 1H), 7.00 (d, J = 2.2 Hz, 1H), 7.22–7.29 (m, 4H), 7.45 (d, J = 8.2 Hz, 2H), 8.46 (d, J = 6.0 Hz, 2H), 8.98 
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(s, 1H), 9.02 (s, 1H); MS (ESI): m/z = 278 [M++H]. 
3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol (10). Synthesised according to Method D using 16 (0.18 
g, 0.64 mmol) and 1 M BBr3 solution in DCM (3.20 mL, 3.20 mmol); yield: 0.12 g (67%); white solid: mp 
229–230 °C; Rf = 0.16 (DCM/MeOH, 19:1); δH (DMSO-d6, 500 MHz) 3.98 (s, 2H), 7.00 (t, J = 8.8 Hz, 1H), 
7.25–7.31 (m, 5H), 7.44 (dd, J = 2.2 Hz, 2JHF = 12.9 Hz, 1H), 7.55 (d, J = 8.5 Hz, 2H), 8.46 (d, J = 5.9 Hz, 
2H), 9.95 (s, 1H); MS (ESI): m/z = 280 [M++H]. 
6-[4-(Pyridin-4-ylmethyl)phenyl]naphthalen-2-ol (25). Synthesised according to Method D using 24 
(0.33 g, 1.00 mmol) and 1 M BBr3 solution in DCM (3.00 mL, 3.00 mmol); yield: 0.25 g (80%); white solid; 
Rf = 0.49 (DCM/MeOH, 10:1); δH (DMSO-d6, 500 MHz) 4.00 (s, 2H, CH2), 7.11 (dd,  J = 2.2, 8.8 Hz, 1H), 
7.14 (d, J = 2.2 Hz, 1H), 7.27 (d, J = 6.0 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 7.68–7.70 (m, 3H), 7.74 (d, J = 
8.8 Hz, 1H), 7.82 (d, J = 8.8 Hz, 1H), 8.04 (s, 1H), 8.46 (d, J = 6.0 Hz, 2H), 9.80 (s, 1H); MS (ESI): m/z = 
312 [M++H]. 
Method E: Dehydroxylation with HCOOH 
Under exclusion of air and moisture the appropriate alcohol (1 mmol) was dissolved in formic acid (10 mL 
per mmol), Pd(OAc)2 (1 mol%) was added and the mixture was heated to reflux for 16 h. After cooling the 
reaction mixture, formic acid was distilled off and the mixture was neutralised using saturated sodium 
bicarbonate solution. Then the mixture was extracted with ethyl acetate (3 x 10 mL), the combined organic 
phases were washed with brine, dried over Na2SO4, evaporated to dryness and purified using column 
chromatography. 
Method F: Hydrogenation 
A solution the corresponding alkene (1 mmol) in dry THF (15 mL / mmol) was treated with 10% Pd on 
charcoal (15 mg). The reaction vessel was repeatedly evacuated and flushed with hydrogen gas and left to 
stir at room temperature for 3 h, pressurized with 1 bar of H2. The resulting reaction mixture was filtered 
through a short plug of Celite, which was washed with THF (40 mL). The filtrates were concentrated on an 
oil pump und purified using column chromatography. 
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Paper IV 
 
Abstract: CYP17 inhibition is a promising therapy for prostate cancer (PC) because proliferation of 80 % of 
PC depends on androgen stimulation. Introduction of i-propylidene substituents onto the linker of biphenyl 
methylene 4-pyridines resulted in several strong CYP17 inhibitors, which were more potent and selective, 
regarding CYP 11B1, 11B2, 19 and 3A4, than the drug candidate Abiraterone.  
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Introduction 
Prostate cancer (PC) is the carcinoma with the highest incidence in male, and it accounts for a quarter of 
cancer related deaths each year. Few patients in early stages can be cured by local therapy, like 
prostatectomy or radiotherapy, the majority, especially the ones with metastases, are treated with hormone 
therapy. Due to severe side effects, chemotherapy is usually reserved as the last choice. Hormone therapy is 
based on the finding that up to 80% of PCs depend on androgen stimulation for proliferation. Early attempts 
to suppress androgen production by estrogen application were soon replaced by orchidectomy and later by 
administration of gonadotropin-releasing hormone (GnRH) analogues.1 GnRH analogues unfold their 
activity via the hypothalamic, pituitary and gonadal axis resulting in an annihilation of testicular androgen 
production. However, adrenal androgen formation is not affected. Although approximately 90% of 
androgens are no longer produced and the plasma testosterone concentration is reduced below 50 ng/dL, 
androgen levels (testosterone and subsequently dihydrotestosterone, DHT) in the prostate are higher and 
maintain cancer cell growth.2-3 This accumulation is due to the presence of androgen receptor (AR) and 
steroidogenic enzymes which convert adrenal steroids into testosterone and DHT.3-4 Hence, AR antagonists 
(anti-androgens) are employed in combination with GnRH analogues to prevent adrenal androgens from 
unfolding activity.5 This is the current standard therapy, the so called “combined androgen blockade” (CAB). 
However, long term application of antagonists induce mutations of AR which renders the receptor to be 
activated by the anti-androgenic drug6 or by endogenous glucocorticoids7 resulting in resistance to CAB.  
To avoid the stimulation, the inhibition of 17α-hydroxylase-17,20-lyase (CYP17) was proposed as a 
superior alternative to CAB. CYP17 catalyzes not only the testicular but also the adrenal conversion of 
pregnenolone and progesterone to the weak androgens DHEA and androstenedione, respectively. Moreover, 
recent observations suggest that there is also CYP17 activity in prostate cancer cells.6 Testosterone 
subsequently formed from these two weak androgens is in the prostate converted to DHT, which is the most 
potent androgen. This final step of androgen activation can be inhibited by 5α-reductase (5αR) inhibitors.8 
However, CYP17 inhibition should be a better strategy than 5αR inhibition as it totally blocks not only 
androgen biosynthesis in testes and adrenals, but also intracellular androgen formation in the cancer cell. 
The benefit of PC treatment via CYP17 inhibition was shown by the off-label administration of the 
antimycotic Ketoconazole.9 However, Ketoconazole had to be withdrawn because of severe hepatic toxicity 
resulting from its non-selective inhibition of other CYP enzymes. Nevertheless, as it has been demonstrated 
by the success of aromatase (CYP19)10 and more recently aldosterone synthase (CYP11B2) inhibitors,11 high 
selectivity can be achieved. As for CYP17, Abiraterone12 is an outstanding example of a potent and selective 
inhibitor among the steroidal compounds synthesized.13 This compound exhibited significant anti-tumour 
effects in patients diagnosed as “castration resistant” in phase II and III clinical trials.12b However, the 
potential affinity of steroidal scaffolds for steroid receptors, which often results in side effects no matter 
acting as agonists or antagonists, prompted the development of non-steroidal CYP17 inhibitors.14 
Our group has designed and synthesized several series of biphenyl methylene heterocycles15 as CYP17 
inhibitors, in which some imidazoles were found to be very potent.15a-f During further optimization, it has 
been revealed that the replacement of imidazolyl by 4-pyridyl significantly improved potency and selectivity, 
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whereas 3-pyridyl analogues exhibited similar activity as imidazoles.15g For the imidazoles, we had observed 
that small alkyl groups, especially ethyl, significantly increase inhibitory potency, while bulkier substituents 
reduce activity.15c This observation inspired us to perform a thorough study on the influence of the linker 
between the biphenyl and pyridyl moieties, which is described in this article. Besides freely rotable alkyl 
groups, ethylidene and i-propylidene, which rigidify the conformation of the whole molecule, were also 
inserted onto the methylene bridge (compounds 10–22, Chart 1). Because different interaction angles 
between sp2 hybrid N and heme Fe might account for the disparity in potency between 3- and 4-pyridines, 
further modifications, such as prolonging the bridge and inserting various substitutions onto the bridge, were 
performed on the 3-pyridyl scaffold (compounds 1–9, Chart 1). Furthermore, optimizations of the A-ring by 
exchanging phenyl to naphthyl or thiophenyl were also casted resulting in, for example, compound 23. In the 
following, we also describe the selectivity of selected compounds against CYP11B1, CYP11B2, CYP19 and 
hepatic CYP enzyme 3A4 to evaluate safety.  
Chart 1. Design of synthesized compounds 1–23. 
1 - 9
G = 3-thiophenyl, 4-F phenyl;
R1, R2, R3, R4 = H, OH, i-Pr, O=
R
X = H, OH, F, NH2, BocNH;
R = Et, Pr, i-propylidene, ethylidene
10 - 22
N
HO
23
Ref. 1 - 5
X
N
N
X
N
R1 R2
R3 R4
G
 
Results and Discussion 
Chemistry. The synthetic routes for the preparation of compounds 1–23 are shown in Scheme 1–4. For 
the syntheses of the compounds with the two-membered linker between the biphenyl and pyridine moieties, 
the corresponding 4-bromophenyl-pyridin-3-yl ethanones 2a and 5a were prepared as building blocks. These 
bromo compounds were coupled with the corresponding boronic acids via Suzuki coupling to yield the 
ketones 2, 5 and 7, which were then converted to the alcohols 3, 4, 6, 8 and 9 via Grignard reaction or 
reduced by Wolff-Kishner reduction to give compound 1 (Scheme 1 and 2).  
Similarly, the syntheses of the biphenyl methylene pyridines started from (4-bromophenyl)-pyridyl-
methanones, which were subjected to Suzuki coupling and Grignard reaction to form the corresponding 
alcohol intermediates. After elimination of a H2O molecule under acidic conditions, the alcohols were 
converted to the enyl pyridines 10, 13, 15 and 16. The hydrogenation of the double bond led to saturated 
analogues 11, 12 and 14 (Scheme 3). Subsequently, a more efficient strategy was employed by synthesizing 
4-(1-(4-bromophenyl)-2-methylprop-1-enyl)pyridine 17a as a common building block, followed by 
introduction of the aryl ring via Suzuki reaction. Via this route, the final compounds 17–23 were 
conveniently obtained (Scheme 4). 
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a Reagents and conditions: (i) 3-picoline, LDA, HMPA, THF, methyl 4-bromobenzoate, rt, 2h. (ii) Method A: Pd(OAc)2, 4-
fluorophenyl boronic acid, TBAB, Na2CO3, EtOH, toluene, 110 °C, 4 h. (iii) NaOH, N2H4.H2O, diethyleneglycol, 200 °C, 3h. (iv) 
Method B: i-PrMgCl, THF, room temp, 8h. 
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2: G = 4-F-phenyl;
3: G = 4-F-phenyl, R = H;
N
4: G = 4-F-phenyl, R = i-Pr;
7: G = 3-thiophenyl;
8: G = 3-thiophenyl; R = H;
9: G = 3-thiophenyl; R = i -Pr;  
a Reagents and conditions: (i) Na, EtOH; (ii) HBr, reflux 16h. (iii) Method A: Pd(PPh3)4, Na2CO3, toluene, reflux 6h. (iv) Method 
B, for 4, 9: i-PrMgBr, THF.(v) Method C, for 3, 8: NaBH4, MeOH. 
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16 m, p-di OMe Me m, p-di OH 4
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a Reagents and conditions: Compounds were synthesized from the corresponding a, b, c or d intermediates unless annotated 
otherwise. (i) Method A:  Pd(OAc)2, corresponding boronic acid, TBAB, EtOH, Na2CO3 aq, toluene, 110 °C, 4 h. (ii) Method B: i-
PrMgCl or EtMgCl, THF, rt, 8h. (iii) Method D: HCOOH, Pd(OAc)2, reflux, 16h; (iv) Method E: H2, Pd/C, THF, rt, 3h. (v) Method 
F: BBr3, DCM. (vi) Method G: HBr, reflux, 4h. 
 
 
Scheme 4.a  
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17: R = m-BocNH;
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20: R = m,p-di BocNH;
21: R = m-NH2;
22: R = m,p-di NH2.
 
a Reagents and conditions: (i) Method B: i-PrMgCl, THF, room temp, 8h. (ii) Method G: HBr, reflux, 4h. (iii) Method A:  
Pd(OAc)2, corresponding boronic acid, TBAB, EtOH, Na2CO3 aq, toluene, 110 °C, 4 h. (iv) Method F: BBr3, DCM. 
CYP17 inhibitory activity. Inhibition of CYP17 by the synthesized compounds was determined using the 
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50,000 sediment after homogenation of E.coli co-expressing human CYP17 and cytochrome P450 
reductase.16a The assay was run with progesterone (25 μM) as substrate and NADPH as cofactor.15a 
Separation of substrate and product was accomplished by HPLC using UV detection. IC50 values are 
presented in comparison to Ketoconazole, Abiraterone and reference compounds 24–2815g in Table 1. All 3-
pyridyl compounds (detailed structures can be found in Scheme 1 and 2) were only weakly active (IC50 > 
5000 nM), no matter furnished with a two membered linker (1–9) or ethylidene substituted methylene (10). 
Table 1. Inhibition of CYP17 by compounds 11 – 23 and reference compounds 24 – 28. 
N
11 - 22, 24 - 28
R
N
HO
23
X
o
m
p
 
Compd X R IC 50 [nM]b 
24c m-OH H 97 
11 m-OH Et 189 
12 m-OH i-Pr 783 
13 m-OH i-Propylidene 56 
25c m-F, p-OH H 186 
14 m-F, p-OH Et 343 
15 m-F, p-OH i-Propylidene 75 
26c m, p-di OH H 52 
16 m, p-di OH i-Propylidene 37 
17 m-BocNH i-Propylidene 1458 
18 p-BocNH i-Propylidene 493 
19 m-F, p-BocNH i-Propylidene 852 
20 m, p-di BocNH i-Propylidene >10000 
27c m-NH2 H 226 
21 m-NH2 i-Propylidene 38 
28c m, p-di NH2 H 337 
22 m, p-di NH2 i-Propylidene 75 
23   62 
KTZa   2780 
ABTa   72 
a KTZ: Ketoconazole; ABT: Abiraterone. 
b Concentration of inhibitors required to give 50 % inhibition. The given values are mean values of at least three experiments. The 
deviations were within ±10 %. The assay was run with human CYP17 expressed in E.coli using progesterone as substrate (25 μM).  
c Reference compounds 24 – 28 were taken from reference 15g. 
On the contrary, the 4-pyridyl compounds were potent CYP17 inhibitors and the substituents on the 
methylene bridge showed profound influence on the inhibitory potency. It is apparent that for the A-ring m-
OH analogues, the introduction of an ethyl (11) and a propyl (12) group decreased activities to 189 and 783 
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nM, respectively, compared to the corresponding non-substituted reference compound 24 (IC50 = 97 nM). 
However, the i-propylidene substitution increased activity to 56 nM. A similar observation can be made for 
the A-ring m-F, p-OH series: the ethyl compound 14 is less potent than the non-substituted reference 
compound 25 (IC50 values of 343 nM vs 186 nM), whereas the i-propylidene compound 15 once again was 
the most active one exhibiting IC50 of 75 nM. More examples for the enhancement of inhibitory potency 
rendered by i-propylidene were observed with the remaining couples: the di-OH analogues (reference 
compound 26 and 16: IC50 values of 52 nM vs 37 nM ), the amines (reference compound 27 and 21: IC50 
values of 226 nM vs 38 nM ) and the di-amino compounds (reference compound 28 and 22: IC50 values of 
337 nM vs 75 nM ). The change in geometry from sp3 to sp2 leading to a planar compound with less 
conformational flexibility is a plausible explanation for the observed increase in activity. Moreover, the 
conjugation of the biphenyl moiety and the pyridyl ring facilitated by i-propylidene increases the electron 
density in the hetero-aromat, which might additionally contribute to the enhanced affinity to the enzyme. In 
our previous studies on biphenyl methylene imidazoles, introduction of an ethyl group into the methylene 
bridge was found to significantly increase activity.15c The opposite impact of ethyl exhibited with the 
pyridines presented in this paper compared to those imidazoles is probably due to the longer distance 
between the sp2 hybrid N and the methylene group in the pyridines, which might prevent the ethyl group 
from binding into the hydrophobic pocket.15c Furthermore, Boc-amido was again15g proven to be not 
tolerated: the corresponding analogues 17–20 showed modest to no inhibition of CYP17 (IC50 values ranging 
from 493 nM to more than 10,000 nM). Besides the introduction of i-propylidene, the exchange of the A-ring 
from phenyl to 6-OH naphthyl also led to a highly potent CYP17 inhibitor, compound 23 (IC50 = 62 nM).  
Selectivity. As a criterion to evaluate safety, the inhibition values of the most potent CYP17 inhibitors – 
all of them i-propylidene compounds – toward CYP11B1, CYP11B2 and CYP19 were determined (Table 2). 
CYP11B1 and CYP11B2 catalyze the crucial final steps in cortisol and aldosterone biosynthesis, 
respectively. Inhibition of these enzymes could lead to hyponatremia, hyperkalemia, adrenal hyperplasia and 
hypovolemic shock.17a CYP19 catalyzes the formation of estrogens, which have been proven to be capable of 
reducing the incidence of heart disease.17b Furthermore, estrogen deficiency resulting from CYP19 inhibition 
causes osteoporosis, increased fracture risk and memory loss.17c It can be seen that all the i-propylidene 
analogues tested are much more selective compared to the corresponding non-substituted compounds. For 
CYP11B1, only weak inhibition (IC50 values around 2000 to 3000 nM for compounds 13 and 15) or no 
inhibition (IC50 values more than 5000 nM for compounds 16, 21–23) was observed, which makes these 
compounds superior to Abiraterone (IC50 = 1610 nM). A similar selectivity pattern was achieved for 
CYP11B2: most of the tested compounds did not interfere with this enzyme with IC50 values more than 3000 
nM (13, 21 and 23). The only exception was compound 15 exhibiting weak inhibition with IC50 of 1870 nM, 
which is comparable to Abiraterone (IC50 = 1750 nM). Compounds 16 and 22 were less selective with IC50 
values around 1000 nM. Regarding CYP19, all of the tested compounds 13, 15, 16 and 21–23 showed no 
inhibition with IC50 values more than 5000 nM. Furthermore, the inhibition of the hepatic CYP enzyme 3A4 
was also determined, because it accounts for most of the drug metabolism and is therefore to a high extent 
involved in drug-drug interactions. Although compounds 13 and 16 were less selective showing IC50 values 
around 500 to 700 nM, compounds 21 and 22 exhibited only weak inhibition with IC50 values around 1500 
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nM. The most selective compound 15 exhibited almost no inhibition of CYP3A4 with IC50 of more than 
17600 nM, which is much better than the drug candidate Abiraterone (IC50 = 2700 nM). 
Table 2. Selectivity profiles of selected compounds toward CYP11B1, CYP11B2, CYP19 and CYP3A4. 
IC50 (nM)b 
Compd 
CYP11B1c CYP11B2c CYP19d  CYP3A4e 
24f 342 261 663 538 
13 3100 3450 12000 730 
25f 351 110 1670 896 
15 2000 1870 5750 17650 
26f 1400 948 2440 7580 
16 37470 974 9500 464 
27f 287 921 2830 1520 
21 7300 3830 5060 1330 
28f 502 368 24560 n.d.a 
22 7180 1130 49500 1770 
23 5060 49500 48700 n.d.a 
KTZa 127 67 >50000 57 
ABTa 1610 1750 >50000 2700 
a KTZ: Ketoconazole; ABT: Abiraterone; n.d.: not determined. 
b Standard deviations were within < ±5 %;  All the data are mean values of at least three tests. 
c Hamster fibroblasts expressing human CYP11B1 or CYP11B2 are used with deoxycorticosterone as the substrate at a concentration 
of 100 nM. 
d Human placental CYP19 is used with androstenedione as the substrate at a concentration of 500 nM. 
e Microsomal fraction of recombinantly expressed enzyme from baculovirus-infected insect is used with 7-benzoyloxy-trifluoro 
methyl coumarin as the substrate at a concentration of 50 μM. 
f Reference compounds 24 – 28 were taken from reference 15g. 
Conclusion 
CYP17 inhibition is a promising therapy for prostate cancer because it blocks not only the androgen 
biosyntheses in testes and adrenals, but also intracellular androgen formation in the cancer cell.3-4 Biphenyl 
methylene heterocycles, especially pyridines, have been proven to be potent CYP17 inhibitors.15 In the 
present study, modifications of the linker between biphenyl and pyridine moieties were described. Variations 
on the 3-pyridyl scaffold, such as prolongation of the linker and introduction of different substituents onto 
the bridge, resulted in only weak inhibitors. On the contrary, modifications of 4-pyridyl analogues led to 
potent and selective CYP17 inhibitors. The differing substituents on the methylene bridge had a profound 
influence on the inhibitory potency: flexible alkyl groups reduced activity, whereas conformation rigidifying 
i-propylidene groups significantly improved activity and selectivity. Among the nine i-propylidene 
substituted biphenyl methylene 4-pyridines synthesized, six compounds (13, 15, 16, 21, 22 and 23, IC50 
values between 37 and 75 nM) were more potent than or comparable to the drug candidate Abiraterone (IC50 
= 72 nM). Most of these potent compounds also exhibited better selectivity profiles toward CYP11B1, 
CYP11B2, CYP19 and hepatic CYP3A4 than the parent compounds and Abiraterone. Thus, this study 
presents an example that a single substituent can be the key for selectivity among several CYP enzymes. 
3 Results and Discussions 
胡庆忠博士论文 
- 100 - 
Several compounds of this investigation can be considered as promising drug candidates after further 
validation in vivo. 
Experimental Section 
General 
Melting points were determined on a Mettler FP1 melting point apparatus and are uncorrected. IR spectra 
were recorded neat on a Bruker Vector 33FT-infrared spectrometer. 1H-NMR spectra were measured on a 
Bruker DRX-500 (500 MHz). Chemical shifts are given in parts per million (ppm), and TMS was used as an 
internal standard. All coupling constants (J) are given in Hz. ESI (electrospray ionization) mass spectra were 
determined on a TSQ quantum (Thermo Electron Corporation) instrument. The purities of the final 
compounds were controlled by Surveyor®-LC-system. Purities were greater than 95 %. Column 
chromatography was performed using silica-gel 60 (50-200 µm), and reaction progress was determined by 
TLC analysis on Alugram® SIL G/UV254 (Macherey-Nagel).  
Method A: Suzuki-Coupling (see Supporting Information for details)  
4'-[2-Methyl-1-(pyridin-4-yl)prop-1-enyl]biphenyl-3-amine (21). Synthesized according to Method A 
using 17a (0.50 g, 1.74 mmol) and 3-aminophenylboronic acid (0.36 g, 2.60 mmol); yield: 0.39 g (75 %); 
white solid: mp 131–132 °C; Rf = 0.21 (DCM / MeOH, 20:1); δH (CDCl3, 500 MHz) 1.85 (s, 3H, CH3), 1.86 
(s, 3H, CH3), 3.73 (s, br, 2H, NH2), 6.66 (dd, J = 2.1, 7.8 Hz, 1H), 6.90 (t, J = 2.0 Hz, 1H), 6.98 (dt, J = 1.4, 
7.9 Hz, 1H), 7.09 (dd, J = 1.6, 6.1 Hz, 2H), 7.14 (d, J = 8.3 Hz, 2H), 7.21 (t, J = 7.8 Hz, 1H), 7.49 (d, J = 8.3 
Hz, 2H), 8.51 (dd, J = 1.6, 6.0 Hz, 2H); MS (ESI): m/z = 301 [M++H]. 
Method B: Grignard reaction (see Supporting Information for details) 
1-(4-Bromophenyl)-2-methyl-1-(pyridin-4-yl)propan-1-ol (17b). Synthesized according to Method B 
using (4-bromophenyl)(pyridin-4-yl)methanone (2.00 g, 7.63 mmol) and 2.0 M i-propylmagnesium chloride 
solution in THF (4.20 mL, 8.39 mmol); yield: 1.35 g (58 %); amble oil; δH (CDCl3, 500 MHz) 0.84 (d, J = 
6.7 Hz, 3H, CH3), 0.88 (d, J = 6.7 Hz, 3H, CH3), 2.79 (q, J = 6.7 Hz, 1H, CH), 3.25 (s, br, 1H, OH), 7.36–
7.42 (m, 6H), 8.41 (d, J = 6.1 Hz, 2H); MS (ESI): m/z = 307 [M++H]. 
Method C: Reduction with NaBH4 (see Supporting Information for details) 
Method D: Dehydroxylation with HCOOH (see Supporting Information for details)  
Method E: Hydrogenation (see Supporting Information for details) 
Method F: Ether cleavage with BBr3 (see Supporting Information for details)  
6-[4-(2-Methyl-1-pyridin-4-yl-propenyl)-phenyl]-naphthalen-2-ol (23). Synthesized according to 
Method F using 23a (0.25 g, 0.68 mmol) and 1M BBr3 in DCM (2.05 mL, 2.05 mmol); yield: 0.18 g (73 %); 
yellow oil; Rf = 0.52 (DCM / MeOH, 19:1); δH (DMSO-d6, 500 MHz) 1.98 (s, 3H, CH3), 2.02 (s, 3H, CH3), 
7.19 (d, J = 8.2 Hz, 2H), 7.31 (d, J = 8.5 Hz, 1H), 7.65 (d, J = 6.4 Hz, 2H), 7.72 (d, J = 8.2 Hz, 2H), 7.72 (d, 
J = 8.5 Hz, 2H), 7.83 (dd, J = 1.8, 8.5 Hz, 1H), 8.00 (d, J = 1.8 Hz, 1H), 8.14 (d, J = 8.5 Hz, 1H), 8.60 (d, J = 
6.4 Hz, 2H); MS (ESI): m/z = 352 [M++H]. 
Method G: Dehydroxyltion and ether cleavage with HBr (see Supporting Information for details) 
4-[1-(4-Bromophenyl)-2-methylprop-1-enyl]pyridine (17a). Synthesized according to Method G  using 
17b (1.00 g, 3.27 mmol); yield: 0.89 g (95 %); white solid; Rf = 0.21 (DCM / MeOH, 10:1); δH (CDCl3, 500 
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MHz) 1.85 (s, 3H, CH3), 1.86 (s, 3H, CH3), 7.09 (dd, J = 1.6, 6.1 Hz, 2H), 7.14 (d, J = 8.3 Hz, 2H), 7.49 (d, J 
= 8.3 Hz, 2H), 8.51 (dd, J = 1.6, 6.0 Hz, 2H); MS (ESI): m/z = 289 [M++H]. 
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Abstract: It is well known that postmenopausal women are in high risk of cardiovascular diseases because 
of the estrogen deficiency. As for the postmenopausal breast cancer patients, this risk is much higher due to 
inhibition of estrogen biosyntheses in peripheral tissue by aromatase inhibitors applied. Since deficiency of 
estrogen results in significantly elevated aldosterone level, which is a major cause of cardiovascular diseases, 
dual inhibition of CYP19 and CYP11B2 is a promising treatment for breast cancer and the coinstantaneous 
cardiovascular diseases. By combination of important structural features of CYP19 and CYP11B2 inhibitors, 
selective dual inhibitors were successfully obtained as compounds 9 and 11 with IC50 values around 50 and 
20 nM toward CYP19 and CYP11B2, respectively. These compounds also showed good selectivity against 
CYP11B1 with selectivity factors around 50 and no interference with CYP17. Moreover, due to the different 
influence on SAR toward different enzymes by the optimization, selective CYP11B2 inhibitors (1–6 and 16) 
were achieved as well, with IC50 values less than 10 nM, selectivity factors (IC50 CYP11B1 / IC50 CYP11B2) 
arranged from 50 to 170 over CYP11B1 and no inhibition of CYP19 and CYP17. Another compound 13 
turned out to be a selective CYP19 inhibitor with IC50 value of 22 nM and selectivity factors more than 35 
for the other enzymes.  
 
 
 
 
3 Results and Discussions 
胡庆忠博士论文 
- 104 - 
Introduction 
Breast cancer (BC) is the carcinoma with the highest morbidity in female in western countries. Although 
BC is still the second leading cause of death, the mortality is significantly reduced because of the cancer 
screening to identify cases in early stages1 and, more importantly,  the employment of adjuvant endocrine 
therapy. Endocrine therapy is based on the fact that estrogen stimulates the growth of “hormone sensitive” 
breast cancer, in which estrogen receptor (ER) and / or progesterone receptor (PgR) are expressed.2 
Therefore, deprivation of estrogen is a feasible treatment for the hormone sensitive BC, which accounts for 
more than 60 % of all cases. Several decades age, selective estrogen receptor modulators (SERM),3 such as 
Tamoxifen and Raloxifen (Chart 1), were introduced into the clinic. These SERMs competitively bind to ER 
antagonizing transcription and subsequently mitogenic effects. However, the poor risk / benefit profiles 
prevented Tamoxifen from continuous application of more than five years and severe toxicities such as 
endometrial cancer and thrombosis were observed.4 On the contrary, the third generation aromatase 
inhibitors (AI), for example: Anastrozole, Letrozole and Exemestane (Chart 1), exhibited better efficacy and 
tolerability compared to Tamoxifen, which rendered AIs to become the first choice as first-line and adjuvant 
therapy for postmenopausal women –– the majority of breast cancer patients. Aromatase (CYP19) is the 
crucial enzyme catalyzing the final aromatization of steroidal A-ring in the biosynthesis of estrogen from 
corresponding androgen precursors: testosterone and androstenedione. Inhibition of CYP19 can totally block 
estrogen production and consequently prevent BC cells from proliferation. After the administration of the 
third generation AIs, the plasma estrogen concentration can even be reduced to undetectable level.5 Several 
clinic trials demonstrated AIs as adjuvant therapy significantly improved disease-free survival and relapse-
free survival with the overall survival increased accordingly.6  
Chart 1. Structures of selective estrogen receptor modulators: Tamoxifen and Raloxifen; and aromatase 
inhibitors: Anastrozole, Letrozole, Fadrozole and Exemestane. 
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However, it has been unveiled that only around 40% of the BC patients’ deaths are eventually caused by 
BC.7 A lot of people survived BC but died of other diseases, especially cardiovascular diseases (CVD).7 
Therefore it is necessary and urgent to manage CVD to prolong longevity of BC patients and to improve the 
overall survival.  
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Recently, estrogen has been proven to exhibit some protective effects on heart8 and kidney.9 The 
administration of estrogen prevents the development of heart failure post-myocardial infarction8e and 
attenuates ventricular hypertrophy and remodelling.8f-g Moreover, the incidences of CVD in post-menopause 
women triple those of premenopausal women at the same age,10 which indicates the deficiency of estrogen is 
closely correlated with CVD. Regarding post-menopause BC patients under endocrine therapy, AIs further 
decrease the estrogen production leading to even higher risk of CVD. The ischemic side effects observed in 
AIs clinic trials were considered as results of lipid metabolism dysfunction caused by estrogen deficiency.11 
This disturbance of lipid metabolism by AIs has been noticed and can be managed with antihyperlipidemic 
agents.11e-f However, the up-regulation of renin–angiotensin–aldosterone system (RAAS), especially 
aldosterone, was still neglected. It has been established that the depletion of estrogen not only directly 
increases circulating aldosterone level, but also augments the concentrations of other RAAS components 
(Chart 2). Elevated levels of renin, angiotensin II (Ang II), angiotensin converting enzyme (ACE) and 
angiotensin type 1 receptor (AT1R) further stimulate aldosterone biosynthesis.13 Moreover, estrogen 
deficiency also increases the potassium plasma concentration resulting in the promotion of aldosterone 
secretion.14 
The resulted high aldosterone levels exhibit deleterious effects on kidney, vessels, brain and the severest 
on heart (Chart 2).15a After excessive aldosterone binds to mineralocorticoid receptor (MR) in renal 
collecting ducts, sodium and water are retained leading to the increase of blood volume and subsequently 
chronic hypertension.15b-c This pathological process is accompanied with hypokalemia due to the over-
excretion of potassium, which sometimes leads to arrhythmia.15d Moreover, aldosterone increases 
intracellular calcium concentration of vascular smooth muscle cells15e-f and up-regulates the expression of 
adrenomedullin and regulator of G protein signaling-2 (RGS2)15g leading to vasoconstriction. The persisting 
tension of vascular together with the excitatory sympathetic tone irritated by excessive aldosterone15h 
exacerbates chronic hypertension.  Another deleterious effect that aldosterone exhibits on vessels is the 
induction of vascular fibrosis and vascular endothelium stiffening,15i which is mediated by reactive oxygen 
species (ROS)15j and inflammation.15k-n The resulted atherosclerosis15o is a high risk factor for stroke and 
ischemia related myocardial infarction (MI) that lead to disability and death. The subsequent reperfusion 
after ischemia can further stimulate inflammation, and together with renal vascular fibrosis lead to 
glomerular injury, tubular damage and interstitial fibrosis.15p-q  Furthermore, excessive aldosterone causes 
cardiac myocyte necrosis, collagen synthesis and fibroblast proliferation resulting in cardiac fibrosis and 
increase of myocardial stiffness.15r-t During these pathological processes, some genes closely related to 
cardiac fibrosis, such as tenascin-X (TNX), urokinase plasminogen activator receptor (UPAR) and a 
disintegrin and metalloprotease with thrombospondin motifs (ADAMTS1), are also over-expressed within 
the induction of aldosterone.15g Subsequently, cardiac hypertrophy and ventricular remodelling happen as 
further structural deterioration with functional degradation.15u Some more factors as consequences of high 
aldosterone levels are also involved in ventricular remodelling, such as ROS, inflammation, chronic 
hypertension, reperfusion injury and MI.15v-x The ventricular remodeling causes diastolic dysfunction, 
diminishes contractile capability, reduces stroke volume and ultimately results in heart failure, which often 
leads to sudden death.  
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Therefore, reducing the high plasma aldosterone concentration rendered by estrogen deficiency is an 
effective treatment for the cardiovascular diseases in BC patients. Because aldosterone synthase (CYP11B2) 
catalyzing the conversion of 11-deoxycorticosterone to aldosterone is the key enzyme in aldosteron 
biosynthesis, the inhibition of CYP11B2 is a superior means to reduce aldosterone level. Since AIs as 
adjuvant therapy have to be applied for at least 5 years and there are no selective CYP11B2 inhibitors in 
clinic use, it is necessary to design selective dual inhibitors of CYP19 and CYP 11B2. This kind of multi-
target-directed agents16,17 can not only improve the patient compliance, but also avoid possible drug-drug 
interaction. In this study, after integration of CYP19 inhibitors’ important structural features into CYP11B2 
inhibitors, a series of pyridyl dihydroquinolinone derivatives were designed and synthesized leading to 
compounds 1–19. The inhibition of these compounds toward CYP11B2 and CYP19 are presented with 
Fadrozole (Chart 1) as a reference, which is a potent CYP19 inhibitor showing unselective inhibition toward 
11β-hydroxylase (CYP11B1) and CYP11B2. Furthermore, the selectivity of these compounds against 
CYP11B1 and 17α-hydroxylase-17,20-lyase (CYP17), which are the crucial enzymes in the biosynthesis of 
glucocorticoid and androgen respectively, are also determined as safety criteria. 
Chart 2. Deleterious effects of high aldosterone level resulted from estrogen deficiency. 
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Dual inhibitors design conception 
Besides Anastrozole and Letrozole –– the CYP19 inhibitors in clinic use, a lot of potent non-steroidal 
CYP19 inhibitors have been designed and synthesized.18 Almost all these inhibitors are based on the 
mechanism that the sp2 hybrid nitrogen coordinates with the heme iron resulting in the inhibition of this 
enzyme in a reversible manner.18a Since all CYP enzymes contain heme iron as catalysis centre, inhibitors 
toward other steroidogenic enzymes, such as CYP1719 and CYP11B2,20 have also been designed according 
to this mechanism. 
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Two potent CYP19 inhibitors have been employed in the design of dual inhibitors:  Ref. 1 (Chart 3, 
CYP19 IC50 = 71 nM)18b with the imidazolyl furnishing on flavone scaffold, and Ref. 2 (Chart 3, CYP19 IC50 
= 12 nM)18c with a phenyl core substituted by phenoxyl group next to the imidazolyl-methyl moiety. Three 
important structural features can be noticed in these two potent CYP19 inhibitors: heterocycle providing sp2 
hybrid N (imidazolyl), aromatic hydrophobic core (chromenone or benzene) and aryl substituent nearby. 
Besides, a suitable linker between aryl substituent and the core as well as the groups furnished on the core 
are also considered to significantly influence the potency. This was demonstrated by Ref. 3 (Chart 3),20b 
which is one of a series of potent CYP11B2 inhibitors. All the compounds in that series contain these three 
structural features described above, but only Ref. 3 exhibited potent CYP19 inhibition (CYP19 IC50 = 38 nM) 
because of the methoxyl substitution at the 6 position of the naphthalene core.20b Therefore, to design the 
dual inhibitors of CYP19 and CYP11B2, we selected 6-(pyridin-3-yl)-3,4-dihydroquinolin-2(1H)-one (Ref. 4, 
Chart 3),20a which is a highly potent and selective CYP11B2 inhibitor (CYP11B2 IC50 = 28 nM)  showing no 
interference with CYP19, as the template for CYP11B2 inhibition and tried to introduce important structural 
features of CYP19 inhibitors into this template. Ref. 4 is already composed of two structural features 
important for CYP19 inhibition: a) 3-pyridyl as N containing heterocycle and b) dihydroquinolinone as 
aromatic core. The presence of ketone mimicking 6-methoxyl of Ref. 3 as hydrogen bond acceptor fulfilled 
another precondition of potent CYP19 inhibition. Therefore, hydrophobic groups were further introduced to 
the 7- or 8-position of the core including aryl, halogen and alkyl in various sizes. When substituted at 7-
position, an oxygen was exploited as the linker, similar to Ref. 2, because of the SAR observed previously 
that bulky groups furnishing next to pyridyl significantly reduce the CYP11B2 inhibition.20a Furthermore, 
bioisostere exchange of ketone O to S, methylation of amide and replacement of pyridyl by isoquinolinyl 
were performed as well aiming to improve the inhibitory potency toward both enzymes. 
Chart 3. Design of heterocyclic dihydroquinolinones as dual CYP19 / CYP11B2 inhibitors. 
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Results and Discussion 
Chemistry. The synthesis of compounds 1–19 is shown in Schemes 1–3. Firstly, the substituted 3,4-
dihydroquinolin-2(1H)-one cores 1b, 2b, 7b and 16c were built from the corresponding anilines after 
amidation with 3-chloropropanoyl chloride and then cyclization via Friedel-Craft alkylation. For 8- 
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substituted analogues, Friedel-Craft reactions were performed without solvent; whereas N,N-dimethyl 
acetamide (DMA) was employed for 7-substituted derivatives to suppress the side reactions. During 
Scheme 1.a  
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a Reagents and conditions: (i) Method A: 3-chloropropanoyl chloride, pyridine, THF, room temp. (ii) Method B for 7-F: AlCl3, 
DMA, 140 °C, 4h. (iii) Method C for 8-F: AlCl3, 140 °C, 4h. (iv) Method D: NBS, DMF, 0 °C, 9h. (v) Method E: Pd(OAc)2, 
corresponding boronic acid, Na2CO3, TBAB, toluene, H2O, ethanol, reflux, 6h. (vi) Method F: Lawesson’s reagent, toluene, reflux, 
2h. 
 
Scheme 2.a  
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a Reagents and conditions: (i) Method A: 3-chloropropanoyl chloride, pyridine, THF, room temp. (ii) Method B: AlCl3, DMA, 140 
°C, 4h. (iii) Method D: NBS, DMF, 0 °C, 9h. (iv) Method E: Pd(OAc)2, corresponding boronic acid, Na2CO3, TBAB, toluene, H2O, 
ethanol, reflux, 6h. (v) Method G: corresponding halide, K2CO3, KI, EtOH, 70 °C, overnight. (vi) Method H: MeI, KOt-Bu, DMF, 50 
°C, overnight. 
the Friedel-Craft alkylation, methoxyl group was cleaved simultaneously to afford hydroxyl intermediate 7b. 
Secondly, 6-position specified bromination was achieved with N-bromosuccinimide (NBS) in an ice bath, 
which was followed by Suzuki coupling with respective pyridyl or isoquinolinyl boronic acids leading to 
compounds 1–4 and 7. Further derivatives 5, 6 and 8–15 were obtained after sulphuration of ketone with 
Lawesson’s reagent and alkylation of phenol or amide, which were applied either after or before Suzuki 
coupling respectively. As for 8-substituted analogues, 6-(pyridin-3-yl)-3,4-dihydroquinolin-2(1H)-one was 
prepared similarly as described above as a common intermediate, which after 8-position specified 
bromination gave compound 16. Further aryl groups were then introduced via another Suzuki coupling 
reaction resulting in desired compounds 17–19. 
Inhibition of CYP19, CYP11B2 and CYP11B1. Inhibitory activity of the synthesized compounds toward 
CYP19 was determined using human placental microsomes with [1β-3H]androstenedione as substrate,21d 
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whereas V79MZh cells expressing human CYP11B2 were employed for CYP11B2 tests with [14C]-11-
deoxycorticosterone as substrate.21b-c Since CYP11B1 and CYP11B2 exhibit more than 93% of homology 
and inhibition of CYP11B1 results in cortisol deficiency, the selectivity toward CYP11B1 was also 
examined for safety in a similar procedure described for CYP11B2, except for V79MZh cells expressing 
human CYP11B1 as the source of enzyme.21b-c The IC50 values of the synthesized compounds toward these 
three enzymes are presented in Table 1 in comparison with Fadrozole. 
Scheme 3.a  
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a Reagents and conditions: (i) Method I: NBS, DMF, 65 °C, 6h. (ii) Method E: Pd(OAc)2, corresponding boronic acid, Na2CO3, 
TBAB, toluene, H2O, ethanol, reflux, 6h.  
It can be seen that regardless of the substituting position, the introduction of small, strong electron-
withdrawn group fluorine increased CYP11B2 inhibition compared to the non-substituted analogue Ref. 4 
from 28 nM to around 10 nM. However, the resulted compounds 1 and 2 showed no improvement of the 
CYP19 inhibition. Although the selectivity against CYP11B1 was reduced compared to Ref. 4, these 
compounds are still quit selective with the selectivity factors (SF, IC50 CYP11B1 / IC50 CYP11B2) around 150. 
Moreover, the replacement of pyridyl by isoquinolinyl led to compounds 3 and 4 with further elevated 
CYP11B2 inhibitory potency of below 1 nM and good selectivity over CYP11B1 (SF of 91 and 50, 
respectively). Nevertheless, this fusing of extra phenyl to pyridyl paid the cost of total loss of CYP19 
inhibition indicating no more spar space near the heme of this enzyme. Similar phenomenon was observed 
for the bioisostere exchange of ketone O to S (compounds 5 and 6), the enhanced CYP11B2 inhibition was 
accompanied by the deterioration of selectivity against CYP11B1 (SF of 61 and 87) and the total loss of 
CYP19 inhibition. 
On the contrary, the hydroxy substitution at the 7-position (compound 7) slightly improved CYP19 
inhibition, but decreased CYP11B2 inhibitory potency to about 300 nM and selectivity to 38. After 
alkylation of this hydroxy with groups in different sizes, great influence was shown. It can be observed that 
as the bulk of substituents swelling, the inhibition of the corresponding compounds toward CYP19 increased 
from 450–500 nM (compounds 8 and 10 with methoxyl and ethoxyl, respectively) to 162 nM (compound 12 
with cyclopentyloxyl), and finally to 35 nM (compound 14 with benzyloxyl). Simultaneously, the inhibitory 
activity of these compounds toward CYP11B2 largely dropped. Compound 8 (methoxyl) exhibited IC50 of 
268 nM, whereas 673 nM for compound 10 (ethoxyl) and 1700 nM for compound 12 (cyclopentyloxyl). 
Surprisingly, benzyloxyl analogue 14 turned out to be a potent CYP11B2 inhibitor with IC50 of 22 nM 
probably due to a different binding mode. The inhibition toward CYP11B1 followed the same trend. 
However, it seemed that CYP11B1 are less sensitive to the bulky augments compared to CYP11B2, 
therefore significant reduction of selectivity was observed with SF less than 10 for these compounds. 
Nevertheless, further methylation of amide N dramatically improved the inhibition toward CYP19 and 
CYP11B2 as well as the selectivity against CYP11B1. It is apparent that after amide methylation the 
methoxyl (9) and ethoxyl (11) analogues exhibited 10 fold more potent inhibition toward CYP19 than their 
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Table 1. Inhibition of CYP11B1, CYP11B2 and CYP19 by compounds 1–19. 
N R1O
R2R3
N
N
H
R1O
R2
N
N
H
R1S
R2
N
3 - 4 5 - 61 - 2, 7 - 19, Ref. 1  
 R1 R2 R3 
CYP19  
IC50 nMb,d 
CYP11B2  
IC50 nMb,c 
CYP11B1  
IC50 nMb,c 
SFe 
Ref. 4 H H H >5000 28.0 6747.0 241 
1 F H H 4819.4 10.7 1306.0 122 
2 H F H 5750.0 8.6 1454.0 168 
3 F H H >10000 0.59 53.6 91 
4 H F H >10000 0.24 12.1 50 
5 F H H >10000 7.8 471.9 61 
6 H F H >10000 2.7 236.9 87 
7 OH H H 3073.4 312 11940 38 
8 OMe H H 447.4 267.6 2867.0 9 
9 OMe H Me 49.2 18.5 1098.5 59 
10 OEt H H 488.0 673.7 3737.3 5.5 
11 OEt H Me 47.5 19.1 789.8 41 
12 O-c-Pent H H 161.8 1702.6 1077.3 0.6 
13 O-c-Pent H Me 22.2 759.4 1166.7 1.5 
14 OBz H H 35.1 21.5 43.8 2 
15 OBz H Me 11.4 177.5 139.4 0.8 
16 H Br H 2901.3 11.8 1421.8 120 
17 H Ph H 394.2 1166.7 16170 13.9 
18 H 3-Py H 953.5 1097.4 4087.2 3.7 
19 H 3-Thio H 275.0 208.1 4588.9 22 
FDZa    52.0 0.8 6.3 8.3 
a FDZ: Fadrozole. 
b Concentration of inhibitors required to give 50 % inhibition. Standard deviations were within < ±5 %; All the data are the mean 
values of at least 3 tests. 
c Hamster fibroblasts expressing human CYP11B1 or CYP11B2 are used with deoxycorticosterone as the substrate at a concentration 
of 100 nM. 
d Human placental CYP19 is used with androstenedione as the substrate at a concentration of 500 nM.  
e SF: selective factor = IC50 CYP11B1 / IC50 CYP11B2. 
precursors (8 and 10, respectively) with IC50 values about 50 nM. The inhibitory activity of CYP11B2 was 
also significantly increased to less than 20 nM. Important is their selectivity over CYP11B1 was promoted to 
59 and 41 respectively at the same time. Therefore, via optimizing combination of introducing small alkoxyl 
groups at the 7-postion and amide methylation, the desired dual inhibitors of CYP19 / 11B2 were 
successfully obtained with good selectivity over CYP11B1. When the alkoxyl substituent was more bulky 
(13, cyclopentyloxyl), regarding the CYP11B2 inhibition, the promotion of activity rendered by amide 
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methyaltion could hardly neutralize the deterioration from the augment of bulk. As the inhibition toward 
CYP19 was increased to 22 nM, this compound turned out to be a selective CYP19 inhibition with 
selectivity of 35 and 53 (IC50 CYP19 / IC50 CYP11B2 or CYP11B1) over CYP11B2 and CYP11B1, respectively. As for 
the benzyloxyl analogues (14 and 15), which were believed to bind in a different mode to CYP11B, the 
methylation of amide significantly decreased the inhibition of CYP11B to around 150 nM. Since compound 
15 showed potent inhibition toward CYP19 (IC50 = 11 nM), this compound was considered as selective 
CYP19 inhibitor with around 15 fold of selectivity against CYP11B2 and CYP11B1. 
Furthermore, the influence of substituents at the 8-position was also investigated. The bromo analogue 16 
turned out to be a potent selective CYP11B2 inhibitor exhibiting IC50 of 11 nM and SF of 120 over 
CYP11B1. However, this compound showed only weak inhibition of CYP19 (IC50 = 2900 nM). The 
introduction of aryl groups (17 with phenyl and 18 with 3-pyridyl) increased CYP19 inhibition with the 
potency toward CYP11B2 reduced accordingly. It is notable that unlike its bioisostere phenyl, 3-thiophenyl 
group in smaller bulk rendered compound 19 as a modest dual inhibitor of CYP19 / 11B2 (IC50 values of 275 
nM and 208 nM, respectively) with modest SF of 22 over CYP11B1. 
Selectivity. The inhibition of CYP17 by synthesized compounds was also determined as a criterion to 
evaluate safety because this enzyme is crucial in the biosynthesis of androgen. It turned out all compounds 
exhibited IC50 values more than 10000 nM (data not shown) indicating no interference with CYP17. 
Conclusions 
Although AIs as BC treatment are successful, they together with menopausal significantly reduced 
estrogen concentration to prevent BC cells proliferation, the estrogen deficiency also results in elevation of 
aldosterone levels, sometimes not in plasma but inside the heart and other target organs. The abnormally 
high aldosterone level exerts deleterious effects on kidney, vessels, brain and the severest on heart. These 
damages, such as asymptomatic left ventricular dysfunction, may exist long before the clinical syndrome 
appears and sudden death happens. Therefore it is urgent to find a convenient way to cope with breast cancer 
and the coinstantaneous cardiovascular diseases. Since AIs as adjuvant therapy have to be administered for 
long time, the compliance of the patients is another advantage of dual inhibition of CYP19 and CYP11B2, 
besides reduced risk of drug-drug interactions. 
The approach of combining important structural features of CYP19 and CYP11B2 inhibitors to design 
dual inhibitors is demonstrated to be successful. Modifications exhibits various influence on SARs toward 
different enzymes. It has been found that introduction of halogen, bioisostere exchange of ketone O to S and 
replacement of pyridyl by isoquinolinyl significantly increased CYP11B2 inhibitory potency. Nevertheless, 
the resulted compounds (1–6 and 16) showed weak to no inhibition of CYP19, CYP11B1 and CYP17, which 
rendered them as selective CYP11B2 inhibitors (IC50 < 10 nM). Moreover, the bulky augment of alkoxyl 
groups at the 7-position largely elevated CYP19 inhibition, however, reduced CYP11B2 inhibition and 
selectivity over CYP11B1. On the contrary, methylation of amide led to increase of inhibitory toward all of 
these three enzymes. After balancing the different influence on SARs, selective dual inhibitors were 
successfully obtained as compounds 9 and 11 with IC50 values around 50 and 20 nM toward CYP19 and 
CYP11B2, respectively. These compounds also showed good selectivity against CYP11B1 with selectivity 
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factors around 50 and no interference with CYP17. In the same procedure, compound 13 was identified as a 
selective CYP19 inhibitor with IC50 value of 22 nM and selectivity factors more than 35 for the other 
enzymes. The dual inhibitors 9 and 11 are promising treatment for BC patients with risk of CVD after further 
evaluation in vivo. 
Experimental Section 
Inhibition of CYP11B1 and CYP11B2 
V79MZh cells expressing human CYP11B1 or CYP11B2 were incubated with [14C]-11-
deoxycorticosterone as substrate. The assay was performed as previously described.21b-c 
Inhibition of CYP19 
The inhibition of CYP19 was determined in vitro using human placental microsomes with [1β-
3H]androstenedione as substrate.21d 
Inhibition of CYP17 
Human CYP17 was expressed in E. coli19a (coexpressing human CYP17 and NADPH-P450 reductase) and 
the assay was performed with progesterone as substrate at high concentrations of 25 μM as previously 
described.21d  
Chemistry Section 
General 
Melting points were determined on a Mettler FP1 melting point apparatus and are uncorrected. IR spectra 
were recorded neat on a Bruker Vector 33FT-infrared spectrometer. 1H-NMR spectra were measured on a 
Bruker DRX-500 (500 MHz). Chemical shifts are given in parts per million (ppm), and TMS was used as an 
internal standard for spectra obtained. All coupling constants (J) are given in Hz. ESI (electrospray 
ionization) mass spectra were determined on a TSQ quantum (Thermo Electron Corporation) instrument. 
The purities of the final compounds were controlled by Surveyor®-LC-system. Purities were greater than 95 
%. Column chromatography was performed using silica-gel 60 (50-200 µm), and reaction progress was 
determined by TLC analysis on Alugram® SIL G/UV254 (Macherey-Nagel).  
Method A: Amidation 
To the corresponding aniline (1.0 eq.) solution in dry THF (10 mL / mmmol) was added pyridine (1.5 eq.) 
before the mixture was cooled to 0 °C in an ice bath. Then, 3-chloropropanoyl chloride (1.1 eq.) was dropped 
in carefully. After the addition, the reaction mixture was warmed to ambient temperature and stirred 
overnight. THF was then removed by reduced pressure, and the residues were taken up with ethyl acetate (10 
mL) and water (10 mL). After extraction of the water phase for 3 times with ethyl acetate (10 mL), the 
organic phases were combined, washed with brine, dried over Na2SO4, and evaporated under reduced 
pressure to give the crude product. The compounds were then purified by flash chromatography on silica gel. 
Method B: Friedel-Craft alkylation in DMA 
To the cold mixture of corresponding 3-chloro-N-phenylpropanamides (1.0 eq.) and AlCl3 (5.0 eq.) was 
dropped in DMA (1.0 eq.). Then the reaction mixture was heated to 140 °C for 4 hours. After cooling down 
to ambient temperature, the black mixture was worked up with ethyl acetate (20 mL) and ice water (20 mL). 
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After extraction of the water phase for 3 times with ethyl acetate (10 mL), the organic phases were combined, 
washed with brine, dried over Na2SO4, and evaporated under reduced pressure to give the crude product. The 
compounds were then purified by flash chromatography on silica gel. 
7-Fluoro-3,4-dihydro-1H-quinolin-2-one (1b). Synthesized according to Method b using 1c (0.35 g, 1.74 
mmol); yield: 0.15 g (53%); white solid;  Rf = 0.29 (DCM/MeOH, 100:1); δH (CDCl3, 500 MHz) 2.64 (t, J = 
7.8 Hz, 2H, CH2), 2.94 (t, J = 7.8 Hz, 2H, CH2), 6.90–6.99 (m, 3H), 7.83 (s, br, 1H, NH); MS (ESI): m/z = 
166 [M++H]. 
Method C: Friedel-Craft alkylation neat 
The mixture of corresponding 3-chloro-N-phenylpropanamides (1.0 eq.) and AlCl3 (5.0 eq.) was heated to 
140 °C for 4 hours. After cooling down to ambient temperature, the black mixture was worked up with ethyl 
acetate (20 mL) and ice water (20 mL). After extraction of the water phase for 3 times with ethyl acetate (10 
mL), the organic phases were combined, washed with brine, dried over Na2SO4, and evaporated under 
reduced pressure to give the crude product. The compounds were then purified by flash chromatography on 
silica gel. 
8-Fluoro-3,4-dihydro-1H-quinolin-2-one (2b). Synthesized according to Method C using 2C (0.35 g, 
1.41 mmol); yield: 0.24 g (82%); white solid;  Rf = 0.28 (DCM/MeOH, 100:1); δH (CDCl3, 500 MHz) 2.66 (t, 
J = 7.8 Hz, 2H, CH2), 3.01 (t, J = 7.8 Hz, 2H, CH2), 6.57 (dd, J = 2.5 Hz, 3JHF = 9.3 Hz, 1H), 6.67 (ddd, J = 
2.5, 8.4 Hz, 3JHF = 8.5 Hz, 1H), 7.09 (dd, J = 8.2 Hz, 4JHF = 6.0 Hz, 1H), 7.83 (s, br, 1H, NH); MS (ESI): m/z 
= 166 [M++H]. 
Method D: Selective bromination at 6-position 
To the solution of corresponding dihydroquinolinone (1.0 eq.) in DMF (5 mL / mmol) cooling in an ice 
bath was dropped in NBS (1.1 eq.) solution in DMF (2 mL / mmol). The addition lasted for 3 hours, and then 
the reaction mixture was hold at 0 °C for another 6 hours before extraction with ethyl acetate (20 mL) and 
water (20 mL). After extraction of the water phase for 3 times with ethyl acetate (10 mL), the organic phases 
were combined, washed with brine, dried over Na2SO4, and evaporated under reduced pressure to give the 
crude product. The compounds were then purified by flash chromatography on silica gel. 
6-Bromo-8-fluoro-3,4-dihydro-1H-quinolin-2-one (2a). Synthesized according to Method D using 2b 
(0.50 g, 3.02 mmol) and NBS (0.54 g, 3.02 mmol); yield: 0.63 g (85%); white solid;  Rf = 0.29 
(DCM/MeOH, 100:1); δH (CDCl3, 500 MHz) 2.65 (t, J = 7.5 Hz, 2H, CH2), 2.99 (t, J = 7.7 Hz, 2H, CH2), 
7.12 (s, 1H), 7.16 (dd, J = 1.9 Hz, 3JHF = 9.6 Hz, 1H),7.88 (s, br, 1H, NH); MS (ESI): m/z = 244 [M++H]. 
6-Bromo-7-hydroxy-3,4-dihydro-1H-quinolin-2-one (7a). Synthesized according to Method D using 7b 
(0.47 g, 2.88 mmol) and NBS (0.51 g, 2.88 mmol); yield: 0.61 g (87%); white solid;  Rf = 0.25 
(DCM/MeOH, 20:1); δH (CDCl3, 500 MHz) 2.38 (t, J = 7.5 Hz, 2H, CH2), 2.75 (t, J = 7.7 Hz, 2H, CH2), 6.53 
(s, 1H), 7.24 (s, 1H), 10.05 (s, br, 1H, NH); MS (ESI): m/z = 242 [M++H]. 
Method E: Suzuki-Coupling 
The corresponding brominated aromatic compound (1.0 eq.) was dissolved in toluene (7 mL / mmol), and 
an aqueous 2.0 M Na2CO3 solution (3.2 mL / mmol), an ethanolic solution (3.2 mL / mmol) of the 
corresponding boronic acid (1.5-2.0 eq.) and tetrabutylammonium bromide (1.0 eq) were added. The mixture 
was deoxygenated under reduced pressure and flushed with nitrogen. After having repeated this cycle several 
3 Results and Discussions 
胡庆忠博士论文 
- 114 - 
times Pd(OAc)2 (5 mol%) was added and the resulting suspension was heated under reflux for 2-6 h. After 
cooling, ethyl acetate (10 mL) and water (10 mL) were added and the organic phase was separated. The 
water phase was extracted with ethyl acetate (2 x 10 mL). The combined organic phases were washed with 
brine, dried over Na2SO4, filtered over a short plug of celite® and evaporated under reduced pressure. The 
compounds were purified by flash chromatography on silica gel.  
7-Fluoro-6-pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one (1). Synthesized according to Method E using 
1a (0.35 g, 1.43 mmol) and pyridin-3-ylboronic acid (0.21 g, 1.72 mmol); yield: 0.32 g (91%); white solid: 
mp 230–231 °C;  Rf = 0.23 (DCM/MeOH, 50:1); δH (CDCl3, 500 MHz) 2.70 (t, J = 7.8 Hz, 2H, CH2), 3.02 (t, 
J = 7.8 Hz, 2H, CH2), 6.69 (d, 3JHF = 10.8 Hz, 1H), 7.23 (d, 4JHF = 7.9 Hz, 1H), 7.35 (ddd, J = 0.7, 4.9, 8.0 
Hz, 1H), 7.83 (dt, J = 2.2, 7.9 Hz, 1H), 8.60 (dd, J = 1.6, 4.8 Hz, 1H), 8.76 (d, J = 2.2 Hz, 1H), 8.92 (s, br, 
1H, NH); MS (ESI): m/z = 243 [M++H]. 
8-Fluoro-6-pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one (2). Synthesized according to Method E using 
2a (0.35 g, 1.43 mmol) and pyridin-3-ylboronic acid (0.21 g, 1.72 mmol); yield: 0.29 g (87%); white solid: 
mp 204–205 °C;  Rf = 0.21 (DCM/MeOH, 50:1); δH (CDCl3, 500 MHz) 2.72 (t, J = 7.8 Hz, 2H, CH2), 3.10 (t, 
J = 7.8 Hz, 2H, CH2), 7.20 (s, 1H), 7.21 (dd, J = 1.6 Hz, 3JHF = 11.0 Hz, 1H), 7.36 (dd, J = 4.8, 7.9 Hz, 1H), 
7.76 (s, br, 1H, NH), 7.81 (dt, J = 2.2, 7.9 Hz, 1H), 8.60 (dd, J = 1.5, 4.8 Hz, 1H), 8.80 (d, J = 2.2 Hz, 1H); 
MS (ESI): m/z = 243 [M++H]. 
7-Fluoro-6-isoquinolin-4-yl-3,4-dihydro-1H-quinolin-2-one (3). Synthesized according to Method E 
using 5a (0.35 g, 1.43 mmol) and isoquinolin-4-ylboronic acid (0.30 g, 1.72 mmol); yield: 0.39 g (93%); 
white solid: mp 283–284 °C;  Rf = 0.25 (DCM/MeOH, 50:1); δH (CDCl3, 500 MHz) 2.73 (t, J = 7.2 Hz, 2H, 
CH2), 3.03 (t, J = 7.3 Hz, 2H, CH2), 6.74 (d, 3JHF = 9.8 Hz, 1H), 7.21 (d, 4JHF = 7.4 Hz, 1H), 7.64 (ddd, J = 
0.7, 4.9, 8.0 Hz, 1H), 7.69–7.70 (m, 2H), 8.05 (d, J = 8.0 Hz, 1H), 8.48 (s, 1H), 8.62 (s, br, 1H, NH), 9.29 (s, 
1H); MS (ESI): m/z = 293 [M++H]. 
8-Fluoro-6-isoquinolin-4-yl-3,4-dihydro-1H-quinolin-2-one (4). Synthesized according to Method E 
using 5a (0.35 g, 1.43 mmol) and isoquinolin-4-ylboronic acid (0.30 g, 1.72 mmol); yield: 0.35 g (88%); 
white solid: mp 202–203 °C;  Rf = 0.26 (DCM/MeOH, 50:1); δH (CDCl3, 500 MHz) 2.75 (t, J = 7.9 Hz, 2H, 
CH2), 3.11 (t, J = 7.9 Hz, 2H, CH2), 7.13 (s, 1H), 7.17 (dd, J = 1.5 Hz, 3JHF = 10.7 Hz, 1H), 7.44–7.56 (m, 
1H), 7.54–7.73 (m, 2H), 7.75 (s, br, 1H, NH), 7.90 (d, J = 8.5 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 8.45 (s, 1H), 
9.26 (s, 1H); MS (ESI): m/z = 293 [M++H]. 
7-Methoxy-1-methyl-6-pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one (9). Synthesized according to 
Method E using 9a (0.50 g, 1.85 mmol) and pyridin-3-ylboronic acid (0.22 g, 2.22 mmol); yield: 0.46 g 
(93%); white solid: mp 207–208 °C;  Rf = 0.19 (DCM/MeOH, 50:1); δH (CDCl3, 500 MHz) 2.62 (t, J = 7.9 
Hz, 2H, CH2), 2.83 (t, J = 7.9 Hz, 2H, CH2), 3.35 (s, 3H, NCH3), 3.79 (s, 3H, OCH3), 6.56 (s, 1H), 7.01 (s, 
1H), 7.25 (ddd, J = 0.7, 5.3, 8.3 Hz, 1H), 7.76 (dt, J = 2.0, 8.0 Hz, 1H), 8.46 (dd, J = 1.6, 4.8 Hz, 1H), 8.68 
(d, J = 1.7 Hz, 1H); MS (ESI): m/z = 269 [M++H]. 
7-Ethoxy-1-methyl-6-pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one (11). Synthesized according to 
Method E using 11a (0.50 g, 1.76 mmol) and pyridin-3-ylboronic acid (0.26 g, 2.11mmol); yield: 0.43 g 
(86%); white solid: mp 217–218 °C;  Rf = 0.20 (DCM/MeOH, 50:1); δH (CDCl3, 500 MHz) 1.35 (t, J = 6.9 
Hz, 3H, CH3), 2.66 (t, J = 7.9 Hz, 2H, CH2), 2.88 (t, J = 7.9 Hz, 2H, CH2), 3.38 (s, 3H, NCH3), 4.04 (q, J = 
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6.9 Hz, 2H, OCH2), 6.61 (s, 1H), 7.11 (s, 1H), 7.30 (ddd, J = 0.7, 4.9, 7.9 Hz, 1H), 7.84 (dt, J = 2.0, 7.9 Hz, 
1H), 8.50 (dd, J = 1.6, 4.8 Hz, 1H), 8.76 (d, J = 1.7 Hz, 1H); MS (ESI): m/z = 283 [M++H]. 
7-Cyclopentyloxy-1-methyl-6-pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one (13). Synthesized according 
to Method E using 13a (0.50 g, 1.54 mmol) and pyridin-3-ylboronic acid (0.23 g, 1.85 mmol); yield: 0.42 g 
(85%); colorless oil;  Rf = 0.23 (DCM/MeOH, 50:1); δH (CDCl3, 500 MHz) 1.52–1.89 (m, 8H, c-Pent), 2.67 
(t, J = 7.9 Hz, 2H, CH2), 2.88 (t, J = 7.9 Hz, 2H, CH2), 3.38 (s, 3H, NCH3), 4.75 (sept, J = 2.8 Hz, 1H, OCH), 
6.62 (s, 1H), 7.11 (s, 1H), 7.29 (ddd, J = 0.7, 5.3, 7.9 Hz, 1H), 7.81 (dt, J = 1.9, 7.9 Hz, 1H), 8.50 (dd, J = 1.5, 
4.8 Hz, 1H), 8.72 (d, J = 1.8 Hz, 1H); MS (ESI): m/z = 322 [M++H]. 
7-Benzyloxy-1-methyl-6-pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one (15). Synthesized according to 
Method E using 15a (0.50 g, 1.44 mmol) and pyridin-3-ylboronic acid (0.21 g, 1.73 mmol); yield: 0.45 g 
(90%); white solid: mp 209–210 °C;  Rf = 0.23 (DCM/MeOH, 50:1); δH (CDCl3, 500 MHz) 2.67 (t, J = 7.9 
Hz, 2H, CH2), 2.89 (t, J = 7.9 Hz, 2H, CH2), 3.33 (s, 3H, NCH3), 5.09 (s, 2H, bz CH2), 6.67 (s, 1H), 7.14 (s, 
1H), 7.29–7.38 (m, 6H, bz), 7.87 (dt, J = 1.9, 8.0 Hz, 1H), 8.53 (dd, J = 1.6, 4.9 Hz, 1H), 8.78 (d, J = 1.8 Hz, 
1H); MS (ESI): m/z = 345 [M++H]. 
6-Pyridin-3-yl-8-thiophen-3-yl-3,4-dihydro-1H-quinolin-2-one (19). Synthesized according to Method 
E using 16 (0.47 g, 1.55 mmol) and thiophen-3-ylboronic acid (0.24 g, 1.86 mmol); yield: 0.39 g (83%); 
white solid: mp 235–236 °C;  Rf = 0.35 (DCM/MeOH, 50:1); δH (CDCl3, 500 MHz) 2.71 (t, J = 7.9 Hz, 2H, 
CH2), 3.11 (t, J = 7.9 Hz, 2H, CH2), 7.18 (dd, J = 1.2, 4.9 Hz, 1H), 7.34–7.38 (m, 2H), 7.40 (s, 2H), 7.52 (dd, 
J = 4.8, 4.9 Hz, 1H), 7.66 (s, br, 1H, NH), 7.85 (dt, J = 1.8, 8.0 Hz, 1H), 8.58 (dd, J = 1.5, 4.9 Hz, 1H), 8.83 
(d, J = 2.1 Hz, 1H); MS (ESI): m/z = 307 [M++H]. 
Method F: Sulphuration with Lawesson’s reagent 
To the suspension of the corresponding dihydroquinolinone (1.0 eq.) in toluene (5 mL / mmol) was added 
Lawesson’s reagent (1.5 eq.). After reflux for 2 hours, toluene was distilled off to give the crude product, 
which was then purified by flash chromatography on silica gel. 
7-Fluoro-6-pyridin-3-yl-3,4-dihydro-1H-quinoline-2-thione (5). Synthesized according to Method F 
using 1 (0.35 g, 1.44 mmol); yield: 0.28 g (76%); light yellow solid: mp 245–246 °C;  Rf = 0.22 
(DCM/MeOH, 50:1); δH (DMSO, 500 MHz) 2.85 (t, J = 7.8 Hz, 2H, CH2), 2.99 (t, J = 7.8 Hz, 2H, CH2), 
7.02 (d, 3JHF = 11.5 Hz, 1H), 7.49 (ddd, J = 0.7, 4.9, 8.0 Hz, 1H), 7.50 (d, 4JHF = 8.2 Hz, 1H), 7.95 (dt, J = 
2.0, 7.9 Hz, 1H), 8.58 (dd, J = 1.6, 4.8 Hz, 1H), 8.74 (s, 1H), 12.33 (s, br, 1H, NH); MS (ESI): m/z = 258 
[M++H]. 
8-Fluoro-6-pyridin-3-yl-3,4-dihydro-1H-quinoline-2-thione (6). Synthesized according to Method F 
using 2 (0.35 g, 1.44 mmol); yield: 0.30 g (81%); light yellow solid: mp 229–230 °C;  Rf = 0.22 
(DCM/MeOH, 50:1); δH (DMSO, 500 MHz) 2.91 (t, J = 7.8 Hz, 2H, CH2), 3.00 (t, J = 7.8 Hz, 2H, CH2), 
7.47 (ddd, J = 0.7, 4.9, 8.0 Hz, 1H), 7.52 (s, 1H), 7.59 (dd, J = 1.9 Hz, 3JHF = 11.7 Hz, 1H), 8.10 (dt, J = 1.7, 
8.0 Hz, 1H), 8.56 (dd, J = 1.5, 4.7 Hz, 1H), 8.92 (d, J = 1.7 Hz, 1H), 12.16 (s, br, 1H, NH); MS (ESI): m/z = 
258 [M++H]. 
Method G: Alkylation of phenol 
The suspension of K2CO3 (2.0 eq.) and 6-bromo-7-hydroxy-3,4-dihydroquinolin-2(1H)-one (1.0 eq.) in dry 
ethanol (5 mL / mmol) was refluxed for 2 hours before KI (0.05 eq.) and the corresponding halide (2.0 eq.) 
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were added. Then the white suspension was boiling overnight. After cooling down to ambient temperature, 
ethanol was removed with reduced pressure and the residue was taken up with ethyl acetate (20 mL) and 
water (20 mL). After extraction of the water phase for 3 times with ethyl acetate (10 mL), the organic phases 
were combined, washed with brine, dried over Na2SO4, and evaporated under reduced pressure to give the 
crude product. The compounds were then purified by flash chromatography on silica gel. 
Method H: Alkylation of amide 
The suspension of potassium t-butanolate (2.0 eq.) and corresponding dihydroquinolinone (1.0 eq.) in dry 
DMF (5 mL / mmol) was heated to 50 °C for 2 hours before KI (0.05 eq.) and the iodomethane (2.0 eq.) 
were added. Then the white suspension was boiling overnight. After cooling down to ambient temperature, 
the reaction mixture was diluted with ethyl acetate (20 mL) and water (20 mL). After extraction of the water 
phase for 3 times with ethyl acetate (10 mL), the organic phases were combined, washed with brine, dried 
over Na2SO4, and evaporated under reduced pressure to give the crude product. The compounds were then 
purified by flash chromatography on silica gel. 
Method I: Selective bromination at 8-position 
To the solution of corresponding dihydroquinolinone (1.0 eq.) in DMF (5 mL / mmol) was dropped in 
NBS (1.1 eq.) solution in DMF (2 mL / mmol) at 65 °C. The addition lasted for 3 hours, and then the 
reaction mixture was hold at 65 °C for another 3 hours before extraction with ethyl acetate (20 mL) and 
water (20 mL). After extraction of the water phase for 3 times with ethyl acetate (10 mL), the organic phases 
were combined, washed with brine, dried over Na2SO4, and evaporated under reduced pressure to give the 
crude product. The compounds were then purified by flash chromatography on silica gel. 
8-Bromo-6-pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one (16). Synthesized according to Method I using 
6-(pyridin-3-yl)-3,4-dihydroquinolin-2(1H)-one (0.50 g, 2.23 mmol) and NBS (0.40 g, 2.23 mmol); yield: 
0.61 g (90%); white solid: mp 175–176 °C;  Rf = 0.25 (DCM/MeOH, 50:1); δH (CDCl3, 500 MHz) 2.70 (t, J 
= 7.9 Hz, 2H, CH2), 3.09(t, J = 7.9 Hz, 2H, CH2), 7.35–7.37 (m, 2H), 7.64 (d, J = 1.8 Hz, 1H), 7.81 (dt, J = 
1.8, 7.9 Hz, 1H), 7.84 (s, br, 1H, NH), 8.61 (dd, J = 1.5, 5.4 Hz, 1H), 8.79 (d, J = 1.8 Hz, 1H); MS (ESI): m/z 
= 303 [M++H]. 
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Abstract: Excessive aldosterone exhibits various deleterious effects on vessels, heart, kidney and central 
nervous system. It is closely related to cardiac fibrosis, congestive heart failure, chronic hypertension, 
myocardial infarction and stroke, which often lead to disability and sudden death. The inhibition of 
CYP11B2, the crucial enzyme in aldosterone biosynthesis, is a promising and superior therapy for these 
diseases related compared to the ACE inhibitors and MR antagonists. Based on our previously identified 
CYP11B2 inhibitors, a series of novel heterocycle substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines 
were designed, synthesized and bio-evaluated. The study leads to many potent and highly selective 
CYP11B2 inhibitors, especially compound 24 (IC50 = 4.2 nM, selectivity factor (IC50 CYP11B1 / IC50 CYP11B2) = 
422). This compound is considered as a promising drug candidate after further evaluation in vivo. 
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Introduction 
Aldosterone has been considered only as the mineralcorticoid in circulation to regulate electrolyte and 
fluid homeostasis for a long time since its discovery in 1953.1 It is widely accepted that after the binding of 
aldosterone to mineralocorticoid receptor (MR)a in epithelial cells of renal collecting duct, the conformation 
of MR is changed. This renders MR to migrate into the cell nucleus and finally to activate gene transcription 
modulating the activity of amiloride-sensitive epithelial sodium channel (ENaC). As results, sodium and 
water are retained leading to the increase of blood volume and consequently elevated blood pressure. 
Nevertheless, recent studies revealed that aldosterone elicits some additional, non-classic effects on vessels, 
heart, kidney and central nervous system. There are reports that the biosyntheses of aldosterone also takes 
place in other target organs like heart and vessels.2,3 Normally, the secretion of aldosterone is strictly 
regulated by the negative feedback loop of renin-angiotesin-aldosterone system (RAAS), as well as the 
concentration of potassium and adrenocorticotropic hormone (ACTH). Any disturbances of the balance will 
result in the abnormality of aldosterone level. High aldosterone concentration exhibits various deleterious 
effects on its target organs, the severest on heart.4 Aldosterone is a potent pro-inflammation factor5 and is 
capable of inducing reactive oxygen species (ROS).6 These effects result in vascular fibrosis and vascular 
endothelium stiffening7 and are thought to be closely related to atherosclerosis,8 which is a high risk factor 
for stroke and ischemia related myocardial infarction (MI) that lead to disability and death. Aldosterone also 
promotes calcium influx into smooth muscle cells,9 up-regulates the expression of adrenomedullin and 
regulator of G protein signaling-2 (RGS2)10 and engenders excitatory sympathetic tone11 after acting on CNS. 
These effects lead to vasoconstriction and, together the blood volume increase mentioned above, finally 
result into chronic hypertension. Furthermore, excessive aldosterone causes cardiac myocyte necrosis, 
collagen synthesis and fibroblast proliferation resulting in cardiac fibrosis and increase of myocardial 
stiffness.12 These damages are mediated in part via the expression of  some genes closely related to cardiac 
fibrosis, for example: tenascin-X (TNX), urokinase plasminogen activator receptor (UPAR) and a disintegrin 
and metalloprotease with thrombospondin motifs (ADAMTS1).10 Consequently, cardiac hypertrophy and 
ventricular remodelling result as the outcome of severe cardiac fibrosis. Inflammation, chronic hypertension, 
reperfusion injury, myocardial infarction and some other events stimulated by excessive aldosterone all 
contribute to this pathological process.13 The ventricular remodeling causes diastolic dysfunction, diminishes 
contractile capability, reduces stroke volume and ultimately results in congestive heart failure (CHF), which 
often leads to sudden death. Besides heart, high aldosterone level causes renal vascular fibrosis, glomerular 
injury, tubular damage and interstitial fibrosis as well.14   
Hence, the control of the high aldosterone level is necessary and urgent for the patients with related 
diseases. Since ACTH involves in the production and release of other adrenal steroids, it is not suitable for 
this purpose. On the contrary, two different approaches to suppress the RAAS components are employed in 
clinic: angiotensin converting enzyme (ACE) inhibitors and MR antagonists. ACE inhibitors, such as 
enalapril (Chart 1), block the biosyntheses of angiotensin II (Ang II) and the subsequent aldosterone. Since 
ACE inhibitors relieve the vasoconstriction irrigated by Ang II and aldosterone, they are exploited in the 
treatment of hypertension and CHF. However, the long-term plasma aldosterone level is only slightly 
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influenced by the application of ACE inhibitors, which is known as “aldosterone escape”,15 probably due to 
the complicated regulation mechanism of aldosterone biosyntheses. As for MR antagonists, such as 
spironolactone and eplerenone (Chart 1), although several clinical trails have demonstrated their 
improvement on morbidity and mortality of heart failure, adverse effects like gynaecomastia and 
hyperkalemia are common.16 Moreover, MR antagonists leave high level of aldosterone unaffected, which 
can leads to further exacerbation of heart dysfunction in a MR independent non-genomic manner.17 Given 
these facts, the inhibition of aldosterone synthase (CYP11B2) is expected as a superior therapy for these 
diseases.  
CYP11B2 is a mitochondrial cytochrome P450 enzyme, which is crucial in aldosterone production due to 
the consecutive three steps from 11-deoxycorticosterone (DOC) to aldosterone depends on its catalysis. 
Recent in vivo studies in rats proved that CYP11B2 inhibitors, for example FAD286 (R-enantiomer of the 
aromatase inhibitor Fadrozole, Chart 1), can significantly reduce the plasma aldosterone levels,18 and hence 
improve cardiac haemodynamics as well as cardiac function in rats with heart failure.19 
Chart 1. Structures of ACE inhibitor Enalapril, MR antagonists Spiromolactone and Eplerenone and 
CYP11B2 inhibitor Fadrozole. 
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Our groups has designed and synthesized several series of CYP11B2 inhibitors.20 Compared to FAD286, 
these compounds are not only potent, but also, importantly, much more selective over 11β-hydroxylase 
(CYP11B1), which is responsible for the production of glucocorticoids. This selectivity is a challenging task 
to achieve because of more than 93% homology between these two enzymes. In aim to further optimize these 
inhibitors, a series of heterocycle substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines (1–27) were 
designed. In this study, the syntheses and biological evaluation of these compounds are described. The 
inhibition of CYP11B1 and CYP11B2 are presented with Fadrozole (Chart 1) as a reference, which is a 
potent CYP19 inhibitor showing unselective inhibition toward CYP11B1 and CYP11B2. Moreover, the 
selectivity of these compounds against aromatase (CYP19) and 17α-hydroxylase-17,20-lyase (CYP17), 
which are the crucial enzymes in the biosynthesis of estrogens and androgens respectively, are also 
determined as a safety criteria. 
Inhibitors design conception 
All the reported CYP11B2 inhibitors competitively bind to the enzyme via the coordination of their sp2 
hybrid nitrogen to the heme iron, which is the common catalytic centre of all CYP enzymes. This reversible 
inhibition mechanism was first identified for CYP19 inhibitors,21a and later on was also applied to other 
CYP19,21b–g CYP17 and CYP11B1 inhibitors.22 Due to the similar structure and conformation among 
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steroidogenic enzymes and the same mode of action shown by their inhibitors, selectivity is always a tough 
aim to pursue. Fortunately, after careful design of the hydrophobic core and subsequent optimization, high 
selectivity is achieved for these steroidogenic enzymes, especially CYP11B220 and CYP17.22e It is realized 
that sometimes the key to high selectivity lays in one or two small substituents,20h,22e which also provided 
clues to design dual inhibitors.20h,22d We have identified fluorinated pyridyl 3,4-dihydroquinolin-2(1H)-one 
analogue Ref. 120h (Chart 2) as a potent and selective CYP11B2 inhibitor (IC50 = 11 nM, selectivity factor = 
122). For this series of CYP11B2 inhibitors, the O from amide is believed to form H-bond with some amino 
acids nearby, which is important for the inhibitory potency.20a,b Moreover, methylation of amide to remove 
the proton also contributes to the CYP11B2 inhibition.20a,h Assisted by these SARs, we continue with the 
structural optimization to probe the surrounding of the amide moiety, to further improve activity and 
selectivity and to conceal the amide moiety, which is possibly vulnerable in vivo. The O was firstly replaced 
by its bio-isostere N. Next, an additional ring was fused onto the 3,4-dihydroquinolin-2(1H)-one core 
embodying the N and the methyl group. Considering the possibility of extra H-bond forming, another N was 
inserted into the ring additionally. Thereby, 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline core was designed 
(Chart 2). Since fluorine substitution significantly increased the CYP11B2 inhibitory potency,20h it was 
sustained as well; and the scrutiny on influence of F in different position was performed. Introduction of 
alkyl or aryl substituents in various bulk and electrostatic potential into the triazolo moiety lead to compound 
1–16. After ascertaining the most suitable substituents and F position, the optimization on heterocycle was 
carried out. Inserting of various substituents on pyridyl or displacing pyridyl by other N containing 
heterocycles yielded compounds 17–27.  
Chart 1. Inhibitor design conception. 
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Results and Discussion 
Chemistry. The synthesis of compounds 1–27 is shown in Schemes 1–2. All the compounds can be 
disassembled into three moieties: the 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines core, substituents at the 1-
position of the core and N-containing heterocycles. According to the moieties to be optimized, different 
strategies were employed to facilitate the syntheses. For compounds with various substituents at the 1-
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position of the dihydrotriazoloquinolines core (1–16), it started with the corresponding fluorinated 6-
(pyridin-3-yl)-3,4-dihydroquinolin-2(1H)-ones.20h The starting materials were firstly sulphurated with 
Lawesson’s reagent to give the dihydroquinolinethiones intermediates 1a and 2a, which were subsequently 
annulated with acylhydrazine in cyclohexanol to afford the corresponding products. However, as for the 
compounds with different heterocycles (17–27), 9-fluoro-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-
a]quinolin-7-yl boronic acid (17a) was exploited as a common building block, which was obtained from 6-
bromo-8-fluoro-3,4-dihydroquinolin-2(1H)-one via sulphuration, cyclization and then borylation with 
triisopropyl borate and n-BuLi. This building block was subsequently coupled with corresponding 
heterocyclic bromines to yield the desired final compounds. 
Scheme 1.a  
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a Reagents and conditions: (i) Method A: Lawesson’s reagent, toluene, reflux, 2h; (ii) Method B: corresponding acylhydrazine, 
cyclohexanol, reflux, 6h. 
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a Reagents and conditions: (i) Method A: Lawesson’s reagent, toluene, reflux, 2h; (ii) Method B: corresponding acylhydrazine, 
cyclohexanol, reflux, 6h; (iii) n-BuLi, triisopropyl borate, toluene, THF, HCl, –40 °C, 3h; (iv) Method C: Pd(OAc)2, corresponding 
boronic acid, Na2CO3, TBAB, toluene, H2O, ethanol, reflux, 6h. 
CYP11B2 and CYP11B1 inhibition. The inhibitory activities of the compounds were determined in V79 
MZh cells expressing human CYP11B2 or CYP11B123a–b with [14C]-deoxycorticosterone as substrate. The 
products were measured using HPTLC with a phosphoimager. Inhibition percentage or IC50 values are 
presented in comparison to Fadrozole in Tables 1–2, which is a CYP19 inhibitor capable of reducing 
corticoid formation. 
It is apparent that the substituents on the dihydrotriazoloquinolines core showed significant influence on 
the inhibitory potency toward CYP11B2 (Table 1). The bulk of the substituent was found to be a crucial 
determinant. It can be observed that the analogues without substitution (1 and 2) exhibited potent inhibition 
around 200 nM; nevertheless, the introduction of methyl group (3 and 4) promoted the potency by 2 to 3 fold  
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Table 1. Inhibition of CYP11B1and CYP11B2 by compounds 1 – 16. 
NN
N
R
N
1
2
3
4
5 6
7
8
9 F
1 - 16  
Structure CYP11B2 CYP11B1 
Compd. 
F R Inhibit.%a,c IC50 (nM)b,c Inhibit.%a,c IC50 (nM)b,c 
SFd 
1 8 H 69.5% 244.0 3.4% 7900 32 
2 9 H 73.0% 172.2 4.8% 16100 94 
3 8 Me 66.9% 131.4 0.8% 12620 96 
4 9 Me 86.6% 62.5 1.3% 16990 272 
5 8 Et 33.8%  0.0%   
6 9 Et 48.0%  1.8%   
7 8 i-Pr 9.8%  2.3%   
8 9 i-Pr 2.4%  2.2%   
9 8 Ph 2.5%  3.5%   
10 9 Ph 0.5%  1.0%   
11 8 Bz 10.3%  0.0%   
12 9 Bz 41.4%  1.4%   
13 9 3-Thio 51.0%  8.4%   
14 9 2-Thio 52.8%  7.3%   
15 8 4-Py 1.0%  0.8%   
16 9 4-Py 0.0%  2.8%   
FDZd    0.8  6.3 8.3 
a Inhibition percentage with compound concentration of 500 nM. Standard deviations were within < ±5 %; All the data are the mean 
values of at least 3 tests.  
b Concentration of inhibitors required to give 50 % inhibition. Standard deviations were within < ±5 %; All the data are the mean 
values of at least 3 tests. 
c Hamster fibroblasts expressing human CYP11B1 or CYP11B2 are used with deoxycorticosterone as the substrate at a concentration 
of 100 nM. 
d FDZ: Fadrozole; SF: selective factor = IC50 CYP11B1 / IC50 CYP11B2; n.d. not determined. 
to 63 and 131 nM, respectively. However, ethyl analogues 5 and 6 showed largely reduced inhibition around 
40% at 500 nM; and further augment of bulk to i-propyl resulting in compounds 7 and 8 dramatically 
decreased the inhibition to less than 10%. The demolishment of inhibition was also observed for aryl 
substitution such as phenyl (9 and 10), benzyl (11 and 12) and 4-pyridyl (15 and 16). Interestingly, 
thiophenyl as a bio-isostere of phenyl rendered the compounds 13 and 14 to be modest inhibitors with about 
50% inhibition at 500 nM. This is probably due to its smaller bulk compared to phenyl made it tolerable to 
the hydrophobic pocket of the enzyme. Furthermore, the position that fluorine furnished also profoundly 
influence the inhibition. 9-F analogue 4 (IC50 = 63 nM) is two fold more potent than the corresponding 8-F 
analogue 3 (IC50 = 131 nM). Same phenomenon can be observed for compounds pairs of 1 and 2 (244 nM vs 
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172 nM), 5 and 6 (34% vs 48%) and so on. As for the CYP11B1 inhibition, no response to the substituents 
alternation was found. Almost all compounds exhibited less than 5% inhibition at 500 nM, which rendered 
the potent CYP11B2 inhibitors also very selective, especially compound 4 with 9-F, 1-Me substitution 
exhibiting IC50 value of 63 nM and selectivity of 272. This substitution pattern was therefore sustained when 
investigation of heterocycles was further performed. 
Because the inhibitors coordinate to the heme iron of the enzyme with the sp2 hybrid N, the heterocycle 
presenting N is considered to be an important influence factor for the inhibitory potency. Hence, various 
substituents in different bulk and electro features are introduced to the meta- or para- position of pyridyl ring 
leading to compounds 17–24 (Table 2) and different N containing heterocycles were employed to replace 
pyridyl resulting in compounds 25–27 (Table 2). It can be seen that when electron donating groups like 
methoxyl (17) and 1-OH-ethyl (18) furnished at the meta-position of pyridyl, the analogues showed 3 fold 
more potent inhibition than their precursor compound 4 with IC50 values around 25 nM. These 
twocompounds also exhibited good selectivity over CYP11B1 with selective factors (IC50 CYP11B1 / IC50 CYP11B2) 
of 89 and 138, respectively. However, introduction of electron withdrawing groups such as acetyl (19), 
trifluoromethyl (20) and fluoro (22) conferred these analogues similar to or slightly less potent than parent 
compound 4 with IC50 values ranged 57 to 90 nM. Interestingly, compound 21 with cyano substituted lost 
inhibitory ability showing only 30% inhibition at 500 nM. After the substitution of electron withdrawing 
groups, these compounds still exhibited good selectivity around 70, excepting fluoro analogue 22, for which 
excellent selectivity of 329 was achieved. Moreover, after the bulky electron donating group phenyl was 
introduced to the meta-position of pyridyl leading to compound 23, significant elevation of inhibitory 
potency toward both CYP11B2 and CYP11B1 was observed. Since similar phenomenon was also noticed for 
pyridyl substituted 3,4-dihydroquinolin-2(1H)-ones,20a the class Ref. 1 belongs to; this may indicates the 
same binding mode is adopted by these two series of CYP11B2 inhibitors. Despite compound 23 showed 
increased inhibition toward CYP11B1 (IC50 = 428 nM), good selectivity of 60 was achieved due to really 
strong inhibition exhibited toward CYP11B2 with an IC50 value of 7 nM. Subsequently, fusing the phenyl 
group to pyridyl to form 4-isoquinolinyl, which is a kind of bio-isostere transformation of pyridyl substituted 
by phenyl, was further performed leading to compound 26. This bio-isostere transformation led to significant 
increase of inhibition toward both enzymes rendering 26 as the most potent inhibitor for both enzymes in this 
study with IC50 values of 2.2 nM for CYP11B2 and 110 nM for CYP11B1. Three possible reasons were 
considered for the improvement of CYP11B2 inhibition. Firstly, electron donating feature of the fused 
phenyl group increased the electron density on the N atom, which facilitated the coordination of the inhibitor 
to the heme iron. Secondly, the fused phenyl as a hydrophobic moiety occupied the spar pocket nearby and 
formed extra interactions. Finally, the fused phenyl reduced the rotation freedom of the 4,5-dihydro-
[1,2,4]triazolo[4,3-a]quinolines core resulting in a more favourable conformation. Meanwhile, the increased 
bulk by the fused phenyl occupying the spar pocket was thought also to be responsible for the elevation of 
CYP11B1 inhibition. Therefore, to improve selectivity the fused phenyl was removed; whereas a methyl 
group was sustained at the para-position as a residue to donate electron and to limit rotation. The yielded 
compound 24 showed potent inhibition toward CYP11B2 with an IC50 of 4.2 nM, while its inhibition of 
CYP11B1 was largely decreased (IC50 = 1772 nM). Since excellent selectivity of 422 was also achieved, this  
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Table 2. Inhibition of CYP11B1and CYP11B2 by compounds 17 – 24. 
NN
N F
NN
N
N
F
R
o
m
p
17 - 24
N
N
NN
N F
N
NN
N F
N
25 26 27  
CYP11B2 CYP11B1 
Compd. R 
Inhibit.%a,c IC50 (nM)b,c Inhibit.%a,c IC50 (nM)b,c 
SFd 
17 m-OMe 95.8% 20.3 12.4% 1810 89 
18 m-(1-OH)-Et 90.6% 28.3 3.1% 3910 138 
19 m-Ac 86.1% 87.6 7.4% 6970 78 
20 m-CF3 87.7% 57.2 16.1% 3570 63 
21 m-CN 29.8% n.d.d 0.0% n.d.d n.d.d 
22 m-F 81.8% 89.7 6.5% 29540 329 
23 m-Ph 100.0% 7.1 44.1% 428 60 
24 p-Me 100.0% 4.2 19.8% 1770 422 
25  18.5% n.d.d 0.0% n.d.d n.d.d 
26  100.0% 2.2 76.1% 110 49 
27  5.3% n.d.d 1.9% n.d.d n.d.d 
FDZd   0.8  6.3 8.3 
a Inhibition percentage with compound concentration of 500 nM. Standard deviations were within < ±5 %; All the data are the mean 
values of at least 3 tests.  
b Concentration of inhibitors required to give 50 % inhibition. Standard deviations were within < ±5 %; All the data are the mean 
values of at least 3 tests. 
c Hamster fibroblasts expressing human CYP11B1 or CYP11B2 are used with deoxycorticosterone as the substrate at a concentration 
of 100 nM. 
d FDZ: Fadrozole; SF: selective factor = IC50 CYP11B1 / IC50 CYP11B2; n.d. not determined. 
compound was considered as the most promising inhibitor throughout this study. Furthermore, the 
replacement of pyridyl by other heterocycles such as pyrimidinyl or 5-isoquinolinyl ended up loss of 
inhibitory potency probably due to low electron density of N and unsuitable distance between hydrophobic 
core and N, respectively. 
Selectivity. The inhibition of other steroidogenic enzymes like CYP17 and CYP19 by synthesized 
compounds was also determined as criterions to evaluate safety. CYP17 and CYP19 are crucial enzymes in 
the biosynthesis of androgen and estrogen, respectively. Their inhibition would result in severe disorder of 
the sexual hormone dependent organs. Moreover, estrogen has been shown some protection effects on heart; 
the estrogen deficiency caused by CYP19 inhibition would increase the risk of cardiovascular diseases. It 
turned out all compounds exhibited IC50 values more than 10000 nM for each enzyme (data not shown) 
indicating no interference with CYP17 and CYP19. 
Conclusion 
The benefits of CYP11B2 inhibition as a promising treatment for diseases related to high aldosterone level 
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has been demonstrated in rats with heart failure19 with FAD286. However, although this compound is very 
potent, it exhibits poor selectivity over CYP11B1, which indicates potential side effects associated with 
glucocorticoids dysfunction. Therefore, potent and selective CYP11B2 inhibitors are still in urgent need to 
be developed. Based on our previously identified CYP11B2 inhibitors, a series of novel heterocycle 
substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines were designed, synthesized and biologically 
evaluated.  
It has been elucidated that the substituents on the 1-position of triazolo moiety have profound influence on 
the CYP11B2 inhibitory potency, where the bulk is the crucial determinant. Methyl, as the most suitable 
group, was found significantly improve the potency; whereas larger substituents led to lost of activity. 
Moreover, analogues with fluorine furnished at 9-position are more potent than the ones with 8-F 
substitution. Furthermore, substituents on the pyridyl are important for the affinity of compounds to the 
enzyme by altering the electron density on sp2 hybrid N, where electron donating groups increase inhibition, 
whereas electron withdrawing groups slightly reduce it. Increase of inhibitory potency by occupancy of 
additional hydrophobic pocket near heme is also observed, despite of coinstantaneous selectivity impairment. 
Conformation rigidification is considered as an advantageous factor for the CYP11B2 inhibition as well, 
which is substantiated by the fusion of additional phenyl and para-methyl substituted on pyridyl. The current 
study results in many potent and highly selective CYP11B2 inhibitors, especially compound 24 (IC50 = 4.2 
nM, selectivity factor = 422). This compound is considered as a promising drug candidate after further 
evaluation in vivo. 
Experimental Section 
Inhibition of CYP11B1 and CYP11B2 
V79 MZh cells expressing human CYP11B2 or CYP11B123a were incubated with [14C]-
deoxycorticosterone as substrate and inhibitors in various concentrations. After 6 hours, the reaction was 
stopped and the steroids were extracted with ethyl acetate, separated by HPTLC and quantified using a 
phosphoimager. Then the inhibitory potency was calculated from the reduced substrate conversion.23b  
Inhibition of CYP19 
The inhibition of CYP19 was determined in vitro using human placental microsomes with [1β-
3H]androstenedione as substrate.23c 
Inhibition of CYP17 
Human CYP17 was expressed in E. coli23d (coexpressing human CYP17 and NADPH-P450 reductase) and 
the assay was performed as previously described.23e  
Chemistry Section 
General 
Melting points were determined on a Mettler FP1 melting point apparatus and are uncorrected. IR spectra 
were recorded neat on a Bruker Vector 33FT-infrared spectrometer. 1H-NMR spectra were measured on a 
Bruker DRX-500 (500 MHz). Chemical shifts are given in parts per million (ppm), and TMS was used as an 
internal standard for spectra obtained. All coupling constants (J) are given in Hz. ESI (electrospray 
ionization) mass spectra were determined on a TSQ quantum (Thermo Electron Corporation) instrument. 
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The purities of the final compounds were controlled by Surveyor®-LC-system. Purities were greater than 
95%. Column chromatography was performed using silica-gel 60 (50-200 µm), and reaction progress was 
determined by TLC analysis on Alugram® SIL G/UV254 (Macherey-Nagel).  
Method A: Sulphuration with Lawesson’s reagent 
To the suspension of the corresponding dihydroquinolinone (1.0 eq.) in toluene (5 mL / mmol) was added 
Lawesson’s reagent (1.5 eq.). After reflux for 2 hours, toluene was distilled off to give the crude product, 
which was then purified by flash chromatography on silica gel. 
7-Fluoro-6-pyridin-3-yl-3,4-dihydro-1H-quinoline-2-thione (1a). Synthesized according to Method A 
using 7-fluoro-6-(pyridin-3-yl)-3,4-dihydroquinolin-2(1H)-one (0.35 g, 1.44 mmol); yield: 0.28 g (76%); 
light yellow solid: mp 245–246 °C;  Rf = 0.22 (DCM/MeOH, 50:1);δH (DMSO, 500 MHz) 2.85 (t, J = 7.8 Hz, 
2H, CH2), 2.99 (t, J = 7.8 Hz, 2H, CH2), 7.02 (d, 3JHF = 11.5 Hz, 1H), 7.49 (ddd, J = 0.7, 4.9, 8.0 Hz, 1H), 
7.50 (d, 4JHF = 8.2 Hz, 1H), 7.95 (dt, J = 2.0, 7.9 Hz, 1H), 8.58 (dd, J = 1.6, 4.8 Hz, 1H), 8.74 (s, 1H), 12.33 
(s, br, 1H, NH); MS (ESI): m/z = 258 [M++H]. 
8-Fluoro-6-pyridin-3-yl-3,4-dihydro-1H-quinoline-2-thione (2a). Synthesized according to Method A 
using 8-fluoro-6-(pyridin-3-yl)-3,4-dihydroquinolin-2(1H)-one (0.35 g, 1.44 mmol); yield: 0.30 g (81%); 
light yellow solid: mp 229–230 °C;  Rf = 0.22 (DCM/MeOH, 50:1); δH (DMSO, 500 MHz) 2.91 (t, J = 7.8 
Hz, 2H, CH2), 3.00 (t, J = 7.8 Hz, 2H, CH2), 7.47 (ddd, J = 0.7, 4.9, 8.0 Hz, 1H), 7.52 (s, 1H), 7.59 (dd, J = 
1.9 Hz, 3JHF = 11.7 Hz, 1H), 8.10 (dt, J = 1.7, 8.0 Hz, 1H), 8.56 (dd, J = 1.5, 4.7 Hz, 1H), 8.92 (d, J = 1.7 Hz, 
1H), 12.16 (s, br, 1H, NH); MS (ESI): m/z = 258 [M++H]. 
Method B: Cyclization with acylhydrazine 
The suspension of dihydroquinoline-2-thione (1.0 eq.) and corresponding acylhydrazine (1.2 eq.) in 
cyclohexanol (1 mL / mmol) was refluxed for 6 hours under inert atmosphere. After cooling down to 
ambient temperature, cyclohexanol was distilled off, and the residue was taken up with ethyl acetate (10 mL) 
and water (10 mL). Then the organic phase was separated, and the water phase was extracted with ethyl 
acetate (2 x 10 mL). The combined organic phases were washed with brine, dried over Na2SO4, and 
evaporated under reduced pressure to afford the crude products. The compounds were purified by flash 
chromatography on silica gel. 
8-Fluoro-7-pyridin-3-yl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline (1). Synthesized according to 
Method B using 1a (0.50 g, 1.94 mmol) and formohydrazide (0.14 g, 2.32 mmol); yield: 0.39 g (75%); white 
solid: mp 246–247 °C;  Rf = 0.21 (DCM/MeOH, 20:1); δH (CDCl3, 500 MHz) 3.11 (t, J = 7.5 Hz, 2H, CH2), 
3.27 (t, J = 7.5 Hz, 2H, CH2), 7.27 (d, 3JHF = 10.0 Hz, 1H), 7.41 (ddd, J = 0.7, 4.8, 8.0 Hz, 1H), 7.45 (d, 4JHF 
= 7.7 Hz, 1H), 7.88 (dq, J = 1.8, 7.9 Hz, 1H), 8.61 (s, 1H), 8.66 (dd, J = 1.6, 4.8 Hz, 1H), 8.79 (s, 1H); MS 
(ESI): m/z = 267 [M++H]. 
9-Fluoro-7-pyridin-3-yl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline (2). Synthesized according to 
Method B using 2a (0.50 g, 1.94 mmol) and 4-aminophenyl boronic acid (0.14 g, 2.32 mmol); yield: 0.41 g 
(79%); white solid: mp 210–211 °C;  Rf = 0.19 (DCM/MeOH, 20:1); δH (CDCl3, 500 MHz) 3.19 (t, J = 7.5 
Hz, 2H, CH2), 3.30 (t, J = 7.5 Hz, 2H, CH2), 7.39–7.43 (m, 3H), 7.87 (dt, J = 2.1, 7.9 Hz, 1H), 8.66 (dd, J = 
1.3, 4.8 Hz, 1H), 8.83 (d, JHF = 3.5 Hz, 1H), 8.84 (d, J = 2.0 Hz, 1H); MS (ESI): m/z = 267 [M++H]. 
8-Fluoro-1-methyl-7-pyridin-3-yl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline (3). Synthesized 
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according to Method B using 1a (0.50 g, 1.94 mmol) and acetohydrazide (0.17 g, 2.32 mmol); yield: 0.42 g 
(78%); white solid: mp 227–228 °C;  Rf = 0.19 (DCM/MeOH, 20:1); δH (CDCl3, 500 MHz) 2.78 (s, 3H, 
CH3), 3.04 (t, J = 7.5 Hz, 2H, CH2), 3.15 (t, J = 7.5 Hz, 2H, CH2), 7.33 (d, 3JHF = 10.9 Hz, 1H), 7.39 (ddd, J 
= 0.7, 4.8, 8.0 Hz, 1H), 7.44 (d, 4JHF = 8.0 Hz, 1H), 7.86 (dq, J = 1.8, 8.0 Hz, 1H), 8.62 (dd, J = 1.6, 4.8 Hz, 
1H), 8.77 (s, 1H); MS (ESI): m/z = 281 [M++H]. 
9-Fluoro-1-methyl-7-pyridin-3-yl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline (4). Synthesized 
according to Method B using 2a (0.50 g, 1.94 mmol) and acetohydrazide (0.17 g, 2.32 mmol); yield: 0.44 g 
(81%); white solid: mp 195–196 °C;  Rf = 0.20 (DCM/MeOH, 20:1); δH (CDCl3, 500 MHz) 2.51 (d, JHF = 8.2 
Hz, 3H, CH3), 2.89 (t, J = 7.5 Hz, 2H, CH2), 2.99 (t, J = 7.5 Hz, 2H, CH2), 7.11 (s, 1H), 7.23–7.28 (m, 2H), 
7.73 (dt, J = 2.1, 8.0 Hz, 1H), 8.51 (dd, J = 1.3, 4.8 Hz, 1H), 8.71 (d, J = 2.0 Hz, 1H); MS (ESI): m/z = 281 
[M++H]. 
Method C: Suzuki-Coupling 
The corresponding brominated aromatic compound (1.0 eq.) was dissolved in toluene (7 mL / mmol), and 
an aqueous 2.0 M Na2CO3 solution (3.2 mL / mmol), an ethanolic solution (3.2 mL / mmol) of the 
corresponding boronic acid (1.5-2.0 eq.) and tetrabutylammonium bromide (1.0 eq) were added. The mixture 
was deoxygenated under reduced pressure and flushed with nitrogen. After having repeated this cycle several 
times Pd(OAc)2 (5 mol%) was added and the resulting suspension was heated under reflux for 2-6 h. After 
cooling, ethyl acetate (10 mL) and water (10 mL) were added and the organic phase was separated. The 
water phase was extracted with ethyl acetate (2 x 10 mL). The combined organic phases were washed with 
brine, dried over Na2SO4, filtered over a short plug of celite® and evaporated under reduced pressure. The 
compounds were purified by flash chromatography on silica gel.  
9-Fluoro-7-(5-methoxy-pyridin-3-yl)-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-a] quinoline (17). 
Synthesized according to Method C using 17a (0.35 g, 1.42 mmol) and 3-bromo-5-methoxypyridine (0.32 g, 
1.70 mmol); yield: 0.39 g (89%); white solid: mp 196–197 °C;  Rf = 0.22 (DCM/MeOH, 20:1); δH (CDCl3, 
500 MHz) 2.65 (d, JHF = 8.2 Hz, 3H, CH3), 3.04 (t, J = 7.5 Hz, 2H, CH2), 3.12 (t, J = 7.5 Hz, 2H, CH2), 3.95 
(s, 3H, OCH3), 7.34 (dd, J = 1.9, 2.6 Hz, 1H), 7.38 (dd, J = 1.8 Hz, 3JHF = 11.4 Hz, 1H), 7.40 (d, J = 1.7 Hz, 
1H), 8.35 (d, J = 2.7 Hz, 1H), 8.45 (d, J = 1.8 Hz, 1H); MS (ESI): m/z = 311 [M++H]. 
1-[5-(9-Fluoro-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolin-7-yl)-pyridin-3-yl]-ethanol (18). 
Synthesized according to Method C using 17a (0.35 g, 1.42 mmol) and 1-(5-bromopyridin-3-yl)ethanol (0.34 
g, 1.70 mmol);  yield: 0.33 g (72%); white solid: mp 228–229 °C;  Rf = 0.12 (DCM/MeOH, 20:1); δH 
(CDCl3, 500 MHz) 1.59 (d, J = 6.5 Hz, 3H, CH3), 2.01 (s, br, 1H, OH), 2.65 (d, JHF = 8.2 Hz, 3H, CH3), 3.04 
(t, J = 7.5 Hz, 2H, CH2), 3.09 (t, J = 7.5 Hz, 2H, CH2), 5.08 (q, J = 6.5 Hz, 1H, CH), 7.42 (dd, J = 1.8 Hz, 
3JHF = 13.2 Hz, 1H), 7.43 (d, J = 1.7 Hz, 1H), 7.99 (dd, J = 1.9, 2.6 Hz, 1H), 8.61 (d, J = 2.7 Hz, 1H), 8.71 (d, 
J = 1.8 Hz, 1H); MS (ESI): m/z = 325 [M++H]. 
1-[5-(9-Fluoro-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolin-7-yl)-pyridin-3-yl]-ethanone (19). 
Synthesized according to Method C using 17a (0.35 g, 1.42 mmol) and 1-(5-bromopyridin-3-yl)ethanone 
(0.34 g, 1.70 mmol); yield: 0.39 g (86%); white solid: mp 216–217 °C;  Rf = 0.19 (DCM/MeOH, 20:1); δH 
(CDCl3, 500 MHz) 2.66 (d, JHF = 8.3 Hz, 3H, CH3), 2.72 (s, 3H, CH3), 3.07 (t, J = 7.5 Hz, 2H, CH2), 3.14 (t, 
J = 7.5 Hz, 2H, CH2), 7.45 (dd, J = 1.8 Hz, 3JHF = 13.3 Hz, 1H), 7.46 (d, J = 1.7 Hz, 1H), 8.43 (dd, J = 2.0, 
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2.1 Hz, 1H), 9.02 (d, J = 2.2 Hz, 1H), 9.19 (d, J = 1.9 Hz, 1H); MS (ESI): m/z = 323 [M++H]. 
9-Fluoro-1-methyl-7-(5-trifluoromethyl-pyridin-3-yl)-4,5-dihydro-[1,2,4]triazolo[4,3-a] quinoline 
(20). Synthesized according to Method C using 17a (0.35 g, 1.42 mmol) and 3-bromo-5-
(trifluoromethyl)pyridine (0.38 g, 1.70 mmol); yield: 0.43 g (88%); white solid: mp 243–244 °C;  Rf = 0.21 
(DCM/MeOH, 20:1); δH (CDCl3, 500 MHz) 2.66 (d, JHF = 8.3 Hz, 3H, CH3), 3.07 (t, J = 7.5 Hz, 2H, CH2), 
3.14 (t, J = 7.5 Hz, 2H, CH2), 7.43 (dd, J = 1.8 Hz, 3JHF = 10.2 Hz, 1H), 7.45 (d, J = 1.7 Hz, 1H), 8.10 (dd, J 
= 2.0, 2.1 Hz, 1H), 8.94 (d, J = 2.2 Hz, 1H), 9.03 (d, J = 2.0 Hz, 1H); MS (ESI): m/z = 349 [M++H]. 
5-(9-Fluoro-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolin-7-yl)-nicotinonitrile (21). Synthesized 
according to Method C using 17a (0.35 g, 1.42 mmol) and 5-bromonicotinonitrile (0.31 g, 1.70 mmol); yield: 
0.38 g (89%); white solid: mp 267–268 °C;  Rf = 0.20 (DCM/MeOH, 20:1); δH (CDCl3, 500 MHz) 2.66 (d, 
JHF = 8.3 Hz, 3H, CH3), 3.07 (t, J = 7.5 Hz, 2H, CH2), 3.14 (t, J = 7.5 Hz, 2H, CH2), 7.41 (dd, J = 1.8 Hz, 
3JHF = 11.9 Hz, 1H), 7.42 (d, J = 1.7 Hz, 1H), 8.15 (dd, J = 2.0, 2.1 Hz, 1H), 8.92 (d, J = 1.9 Hz, 1H), 9.03 (d, 
J = 2.3 Hz, 1H); MS (ESI): m/z = 306 [M++H]. 
9-Fluoro-7-(5-fluoro-pyridin-3-yl)-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline (22). 
Synthesized according to Method C using 17a (0.35 g, 1.42 mmol) and 3-bromo-5-fluoropyridine (0.30 g, 
1.70 mmol); yield: 0.39 g (92%); white solid: mp 215–216 °C;  Rf = 0.23 (DCM/MeOH, 20:1); δH (CDCl3, 
500 MHz) 2.65 (d, JHF = 8.3 Hz, 3H, CH3), 3.04 (t, J = 7.5 Hz, 2H, CH2), 3.13 (t, J = 7.5 Hz, 2H, CH2), 7.39 
(dd, J = 1.9 Hz, 3JHF = 14.6 Hz, 1H), 7.41 (d, J = 1.7 Hz, 1H), 7.59 (ddd, J = 2.0, 2.6 Hz, 3JHF = 9.2 Hz,  1H), 
8.52 (d, J = 2.7 Hz, 1H), 8.67 (t, J = 1.5 Hz, 1H); MS (ESI): m/z = 299 [M++H]. 
9-Fluoro-1-methyl-7-(5-phenyl-pyridin-3-yl)-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline (23). 
Synthesized according to Method C using 17a (0.35 g, 1.42 mmol) and 3-bromo-5-phenylpyridine (0.40 g, 
1.70 mmol);  yield: 0.43 g (85%); white solid: mp 209–210 °C;  Rf = 0.20 (DCM/MeOH, 20:1); δH (CDCl3, 
500 MHz) 2.65 (d, JHF = 8.3 Hz, 3H, CH3), 3.05 (t, J = 7.5 Hz, 2H, CH2), 3.14 (t, J = 7.5 Hz, 2H, CH2), 
7.44–7.47 (m, 3H), 7.51 (dd, J = 7.6, 7.8 Hz, 2H), 7.64 (d, J = 7.7 Hz, 1H), 8.03 (t, J = 2.1 Hz, 1H), 8.81 (d, 
J = 1.8 Hz, 1H), 8.88 (d, J = 2.3 Hz, 1H); MS (ESI): m/z = 357 [M++H]. 
9-Fluoro-1-methyl-7-(4-methyl-pyridin-3-yl)-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline (24). 
Synthesized according to Method C using 17a (0.35 g, 1.42 mmol) and 3-bromo-4-methylpyridine (0.29 g, 
1.70 mmol); yield: 0.38 g (91%); white solid: mp 157–158 °C;  Rf = 0.22 (DCM/MeOH, 20:1); δH (CDCl3, 
500 MHz) 2.62 (d, JHF = 8.2 Hz, 3H, CH3), 2.99 (t, J = 7.5 Hz, 2H, CH2), 3.09 (t, J = 7.5 Hz, 2H, CH2), 7.12 
(dd, J = 1.8 Hz, 3JHF = 11.7 Hz, 1H), 7.13 (d, J = 1.9 Hz, 1H), 7.20 (d, J = 5.0 Hz, 1H), 8.39 (s, 1H), 8.45 (d, 
J = 5.0 Hz, 1H); MS (ESI): m/z = 295 [M++H]. 
9-Fluoro-7-isoquinolin-4-yl-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline (26). Synthesized 
according to Method C using 17a (0.35 g, 1.42 mmol) and 4-bromoisoquinoline (0.35 g, 1.70 mmol);  yield: 
0.25 g (86%); white solid: mp 209–210 °C;  Rf = 0.19 (DCM/MeOH, 20:1); δH (CDCl3, 500 MHz) 2.69 (d, 
JHF = 8.3 Hz, 3H, CH3), 3.05 (t, J = 7.5 Hz, 2H, CH2), 3.17 (t, J = 7.5 Hz, 2H, CH2), 7.34–7.37 (m, 2H), 
7.67–7.70 (m, 1H), 7.74–7.77 (m, 1H), 7.89 (d, J = 8.5 Hz, 1H), 8.09 (d, J = 8.0 Hz, 1H), 8.49 (s, 2H), 9.30 
(s, 1H); MS (ESI): m/z = 331 [M++H]. 
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4 Summary and Conclusions 
4.1 CYP17 Inhibitors 
In mimicking the natural steroidal substrates, several series of biphenyl methylene heterocycles were 
designed, synthesized and tested as CYP17 inhibitors.  
The studies started with imidazoles, among which potent inhibitors were identified with IC50 values 
ranging from 100 to 350 nM (compounds I-22, I-23 and II-9, Figure 34). Several factors are found to exhibit 
a great deal of influences on the inhibitory potency. It has been revealed that alkyl groups at the methylene 
bridge, if in suitable length, can strongly improve the inhibitory potency. Screening of substituents in various 
bulk and electrostatic potential presented ethyl as the most suitable one. Moreover, analogues substituted 
with polar substituents at the A-ring, capable of H-bond formation, always led to potent inhibitors. Besides, 
the rigidification of the biphenyl core to form a carbazole or 9H-fluorene ring also significantly elevated the 
activity, probably due to planar conjugated scaffolds. However, this planar conformation impaired the 
selectivity as well. Further investigation on fluorine revealed that fluorine in the meta-position of the C-ring 
increased the activity compared with the non-substituted analogues, whereas ortho-substitution reduced the 
potency. On the contrary, multi-F substitution on the A-ring reduced the electron density of the A-ring, 
which thereby weakens the T-shaped interaction between the A-ring and Phe114, and consequently 
decreases the inhibitory potency.  
Furthermore, compounds I-23 and II-9 showed potent activity in vivo, long plasma half-lifes and high 
bioavailability. Intriguingly, only when fluorine is substituted in an appropriate position, such as in the meta-
position of the C-ring, is the plasma half life prolonged. If found in an unsuitable position, however, the t1/2 
value was decreased probably due to the electron withdrawing effects by multi F substitutions, which 
significantly weaken the adjacent aromatic C-H bonds conferring them vunerable to metabolic reactions. 
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Figure 34. Evolution of biphenyl methylene heterocycles type of CYP17 inhibitors from imidazoles to pyridines. 
Despite the fact that orally active CYP17 inhibitors were obtained in imidazoles, the inhibitory potency 
and selectivity need further improvement. The replacement of imidazolyl by 4-pyridyl significantly increase 
the inhibition toward CYP17 with the best compounds (III-8, III-9, IV-13, IV-15, IV-16, IV-21 and IV-22) 
being comparable to or even more potent than the drug candidate Abiraterone (Figure 34). This improvement 
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might be due to the prolonged distance between the sp2 hybrid N and the methylene C. The elongation of the 
molecule places the H-bond forming groups at the A-ring closer to the amino acid residues, thereby 
facilitating better H-bond formation. Similar as observated for the imidazoles, hydrogen bond forming 
groups, like OH and NH2, significantly elevated CYP17 inhibition. OH analogues were found to be more 
potent than the corresponding NH2 analogues probably because the hydrogen bonds formed by O are 
stronger than the ones formed by N. Interestingly, meta-substituted analogues are more potent than the 
corresponding para-analogues. Nevertheless, a different SAR was observed concerning the substituents on 
the methylene bridge. For imidazoles, ethyl was identified as the most suitable group. However, for pyridines, 
flexible alkyl groups reduced activity, whereas conformation rigidifying isopropylidene groups significantly 
promoted the inhibitory activity. Most of the isopropylidene compounds also exhibited better selectivity 
profiles toward CYP11B1, CYP11B2, CYP19 and hepatic CYP3A4 than the parent compounds and 
Abiraterone, which is a good example that a single substituent can be the key for selectivity among several 
CYP enzymes. 
Docking studies of the potent 
CYP17 inhibitor using our 
homology model revealed that 
both imidazoles and pyridines 
predominantely adopted a 
similar binding mode (Figure 
35). It has been observed that 
the compounds coordinated to 
the heme iron with the N-
containing heterocycle in a 
perpendicular way. The 
conjugated scaffold of biphenyl 
moiety orienting almost parallel 
to the I-helix was considered 
one of the key factors for high 
activity. This extended π-system obviously interacted not only with the π-system of the amino acid backbone 
in the I-helix (i.e. Gly301, Ala302, Gly303, Val304), but also with Phe114, which was oriented in a 
perpendicular fashion toward the A-ring (Figure 35) to form a quadrupole-quadrupole interaction. More 
importantly, H-bond forming groups, such as OH, NH2 and F, on the A-ring interacted with Arg109, Lys231 
and His235 (Figure 35). These interactions significantly increased the affinity between the inhibitors and the 
enzyme. Furthermore, the elevated activity of C-ring meta-F substituted compounds was attributed to the 
multi-polar interaction between F and the N-H group of Glu305 stabilizing the π-π interaction between the 
C-ring and the backbone π-system of Gly301-Ala302. 
Via this evolution of biphenyl methylene heterocycles from imidazoles to pyridines, CYP17 inhibitors, 
which are more potent and more selective than the drug candidate Abiraterone, were identified. These 
compounds can be considered to be promising drug candidates after further evaluation in vivo. Moreover, the 
Figure 35. Typical binding mode of biphenyl methylene heterocycles in CYP17 
(illustrated with IV-16). 
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finding of isopropylidene as a key to the excellent selectivity between CYP17 and other steroidogenic and 
hepatic CYP enzymes can be exploited in the further design of CYP17 inhibitors. It may also provide clues 
to solve the selectivity puzzles for inhibitors toward other CYP enzymes. 
4.2 Dual Inhibitors of CYP17 / CYP11B1 
The design stategy of segmentation and hybridization applied with the 
steroidal CYP17 inhibitor Abiraterone, the CYP11B1 inhibitor 
Metyrapone and our experience in non-steroidal biphenyl methylene 
based CYP17 inhibitors successfully led to dual inhibitors. Since 
maximization of CYP17 inhibition was pursued as the first priority 
during the segment selection, high inhibitory potency toward this enzyme is guaranteed; whereas the 
inhibition toward CYP11B1 will largely depend on the substituents on the core. It was found that compounds 
with one single H-bond donor showed potent to modest inhibition toward CYP11B1 (IC50 values ranged 250 
to 350 nM), whereas H-bond acceptors or two donors resulted in rather weak inhibition. Hence compound 
III-6 (Figure 36) was obtained showing a good dual inhibition of CYP17 and CYP11B1 with IC50 values 
around 200 nM for both enzymes, a three fold selectivity for CYP11B1 over CYP11B2 and nearly no 
inhibition of CYP19 and CYP3A4. As selectivity for CYP11B2 should be further enhanced, compound III-6 
could be an ideal candidate for the optimization process.  
Based on these interesting results a novel strategy for the treatment of prostate cancer was proposed: 
CYP17 inhibitors with different selectivity profiles according to the status of the patients should be applied. 
For normal patients, selective CYP17 inhibitors that do not interfere with other steroidogentic CYPs should 
be used to avoid side effects. However, for patients with mutated androgen receptors or ectopic 
adrenocorticotropic hormone syndrome, dual inhibitors of CYP17 and CYP11B1 are the best choice in the 
view of a personalized medicine. 
4.3 CYP11B2 Inhibitors 
With 6-(pyridin-3-yl)-3,4-dihydroquinolin-2(1H)-one (IC50 = 28 nM, Figure 37) as the lead compound, a 
series of optimization was performed. It has been found that introduction of F onto the core increased the 
inhibitory potency to less than 10 nM (Figure 37, V-1 and V-2). Bioisostere exchange of ketone O to S (V-5 
and V-6) or replacement of pyridyl by isoquinolinyl (V-3 and V-4) further enhanced the CYP11B2 inhibition.  
Furthermore, an additional triazolo cycle was fused to the dihydroquinolinone core to form extra H-bonds 
and to conceal amide moiety, which is possibly vulnerable in vivo. A series of novel heterocycle substituted 
4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines were thus designed, synthesized and biologically evaluated. It 
has been elucidated that the substituents on the 1-position of triazolo moiety have profound influence on the 
CYP11B2 inhibitory potency, where the bulk is the crucial determinant. Methyl, as the most suitable group, 
was found to significantly improve the potency (VI-4, Figure 37). Nevertheless, larger substituents led to the 
loss of activity. It is intriguing that analogues with fluorine furnished at 9-position are more potent than the 
NH2N
III-6  
Figure 36. The dual CYP17 / 
CYP11B1 inhibitor III-6. 
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ones with 8-F substitution. Furthermore, substituents on the pyridyl are important for the affinity of 
compounds to the enzyme by altering the electron density on sp2 hybrid N, whereby electron donating groups  
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 Figure 37. Potent CYP11B2 inhibitors designed and synthesized. 
increase inhibition (VI-17, VI-18, VI-23 and VI-24; Figure 37), whereas electron withdrawing groups 
slightly reduce it. The increase of inhibitory potency by occupancy of additional hydrophobic pocket near 
heme is also observed, despite of coinstantaneous selectivity impairment. Conformation rigidification is 
considered as an advantageous factor for the CYP11B2 inhibition as well, which is substantiated by the 
fusing of additional phenyl (VI-23) and para-methyl substituntson pyridyl (VI-24). The current study results 
in many potent (IC50 < 10 nM) and highly selective (selectivity factor > 100) CYP11B2 inhibitors, especially 
compound VI-24 (IC50 = 4.2 nM, selectivity factor = 422). These compounds are considered to be promising 
drug candidates after further evaluation in vivo. 
4.4 Dual Inhibitors of CYP19 / CYP11B2 
The approach of combining important structural features of CYP19 
and CYP11B2 inhibitors to design dual inhibitors led to the 
introduction of alkoxyl onto the dihydroquinolinone core. It has been 
found that the bulky augment of alkoxyl groups at the 7-position 
largely elevated CYP19 inhibition, yet, reduced CYP11B2 inhibition 
and selectivity over CYP11B1. On the contrary, methylation of amide 
increased inhibitory potency toward all of these three enzymes. After 
balancing the different influence on SARs, selective dual inhibitors were successfully obtained as 
compounds V-9 and V-11 (Figure 38) with IC50 values around 50 and 20 nM toward CYP19 and CYP11B2, 
respectively. These compounds also showed good selectivity against CYP11B1 with selectivity factors 
around 50 and no interference with CYP17. After further evaluation in vivo, these dual inhibitors can be 
considered to be promising drug candidates as the treatment for BC patients with risks of CVD. 
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Figure 38. The dual CYP19 / 
CYP11B2 inhibitor V-9 and V-11. 
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4 Summary and Conclusions 
4.1 CYP17 Inhibitors 
In mimicking the natural steroidal substrates, several series of biphenyl methylene heterocycles were 
designed, synthesized and tested as CYP17 inhibitors.  
The studies started with imidazoles, among which potent inhibitors were identified with IC50 values 
ranging from 100 to 350 nM (compounds I-22, I-23 and II-9, Figure 34). Several factors are found to exhibit 
a great deal of influences on the inhibitory potency. It has been revealed that alkyl groups at the methylene 
bridge, if in suitable length, can strongly improve the inhibitory potency. Screening of substituents in various 
bulk and electrostatic potential presented ethyl as the most suitable one. Moreover, analogues substituted 
with polar substituents at the A-ring, capable of H-bond formation, always led to potent inhibitors. Besides, 
the rigidification of the biphenyl core to form a carbazole or 9H-fluorene ring also significantly elevated the 
activity, probably due to planar conjugated scaffolds. However, this planar conformation impaired the 
selectivity as well. Further investigation on fluorine revealed that fluorine in the meta-position of the C-ring 
increased the activity compared with the non-substituted analogues, whereas ortho-substitution reduced the 
potency. On the contrary, multi-F substitution on the A-ring reduced the electron density of the A-ring, 
which thereby weakens the T-shaped interaction between the A-ring and Phe114, and consequently 
decreases the inhibitory potency.  
Furthermore, compounds I-23 and II-9 showed potent activity in vivo, long plasma half-lifes and high 
bioavailability. Intriguingly, only when fluorine is substituted in an appropriate position, such as in the meta-
position of the C-ring, is the plasma half life prolonged. If found in an unsuitable position, however, the t1/2 
value was decreased probably due to the electron withdrawing effects by multi F substitutions, which 
significantly weaken the adjacent aromatic C-H bonds conferring them vunerable to metabolic reactions. 
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Figure 34. Evolution of biphenyl methylene heterocycles type of CYP17 inhibitors from imidazoles to pyridines. 
Despite the fact that orally active CYP17 inhibitors were obtained in imidazoles, the inhibitory potency 
and selectivity need further improvement. The replacement of imidazolyl by 4-pyridyl significantly increase 
the inhibition toward CYP17 with the best compounds (III-8, III-9, IV-13, IV-15, IV-16, IV-21 and IV-22) 
being comparable to or even more potent than the drug candidate Abiraterone (Figure 34). This improvement 
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might be due to the prolonged distance between the sp2 hybrid N and the methylene C. The elongation of the 
molecule places the H-bond forming groups at the A-ring closer to the amino acid residues, thereby 
facilitating better H-bond formation. Similar as observated for the imidazoles, hydrogen bond forming 
groups, like OH and NH2, significantly elevated CYP17 inhibition. OH analogues were found to be more 
potent than the corresponding NH2 analogues probably because the hydrogen bonds formed by O are 
stronger than the ones formed by N. Interestingly, meta-substituted analogues are more potent than the 
corresponding para-analogues. Nevertheless, a different SAR was observed concerning the substituents on 
the methylene bridge. For imidazoles, ethyl was identified as the most suitable group. However, for pyridines, 
flexible alkyl groups reduced activity, whereas conformation rigidifying isopropylidene groups significantly 
promoted the inhibitory activity. Most of the isopropylidene compounds also exhibited better selectivity 
profiles toward CYP11B1, CYP11B2, CYP19 and hepatic CYP3A4 than the parent compounds and 
Abiraterone, which is a good example that a single substituent can be the key for selectivity among several 
CYP enzymes. 
Docking studies of the potent 
CYP17 inhibitor using our 
homology model revealed that 
both imidazoles and pyridines 
predominantely adopted a 
similar binding mode (Figure 
35). It has been observed that 
the compounds coordinated to 
the heme iron with the N-
containing heterocycle in a 
perpendicular way. The 
conjugated scaffold of biphenyl 
moiety orienting almost parallel 
to the I-helix was considered 
one of the key factors for high 
activity. This extended π-system obviously interacted not only with the π-system of the amino acid backbone 
in the I-helix (i.e. Gly301, Ala302, Gly303, Val304), but also with Phe114, which was oriented in a 
perpendicular fashion toward the A-ring (Figure 35) to form a quadrupole-quadrupole interaction. More 
importantly, H-bond forming groups, such as OH, NH2 and F, on the A-ring interacted with Arg109, Lys231 
and His235 (Figure 35). These interactions significantly increased the affinity between the inhibitors and the 
enzyme. Furthermore, the elevated activity of C-ring meta-F substituted compounds was attributed to the 
multi-polar interaction between F and the N-H group of Glu305 stabilizing the π-π interaction between the 
C-ring and the backbone π-system of Gly301-Ala302. 
Via this evolution of biphenyl methylene heterocycles from imidazoles to pyridines, CYP17 inhibitors, 
which are more potent and more selective than the drug candidate Abiraterone, were identified. These 
compounds can be considered to be promising drug candidates after further evaluation in vivo. Moreover, the 
Figure 35. Typical binding mode of biphenyl methylene heterocycles in CYP17 
(illustrated with IV-16). 
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finding of isopropylidene as a key to the excellent selectivity between CYP17 and other steroidogenic and 
hepatic CYP enzymes can be exploited in the further design of CYP17 inhibitors. It may also provide clues 
to solve the selectivity puzzles for inhibitors toward other CYP enzymes. 
4.2 Dual Inhibitors of CYP17 / CYP11B1 
The design stategy of segmentation and hybridization applied with the 
steroidal CYP17 inhibitor Abiraterone, the CYP11B1 inhibitor 
Metyrapone and our experience in non-steroidal biphenyl methylene 
based CYP17 inhibitors successfully led to dual inhibitors. Since 
maximization of CYP17 inhibition was pursued as the first priority 
during the segment selection, high inhibitory potency toward this enzyme is guaranteed; whereas the 
inhibition toward CYP11B1 will largely depend on the substituents on the core. It was found that compounds 
with one single H-bond donor showed potent to modest inhibition toward CYP11B1 (IC50 values ranged 250 
to 350 nM), whereas H-bond acceptors or two donors resulted in rather weak inhibition. Hence compound 
III-6 (Figure 36) was obtained showing a good dual inhibition of CYP17 and CYP11B1 with IC50 values 
around 200 nM for both enzymes, a three fold selectivity for CYP11B1 over CYP11B2 and nearly no 
inhibition of CYP19 and CYP3A4. As selectivity for CYP11B2 should be further enhanced, compound III-6 
could be an ideal candidate for the optimization process.  
Based on these interesting results a novel strategy for the treatment of prostate cancer was proposed: 
CYP17 inhibitors with different selectivity profiles according to the status of the patients should be applied. 
For normal patients, selective CYP17 inhibitors that do not interfere with other steroidogentic CYPs should 
be used to avoid side effects. However, for patients with mutated androgen receptors or ectopic 
adrenocorticotropic hormone syndrome, dual inhibitors of CYP17 and CYP11B1 are the best choice in the 
view of a personalized medicine. 
4.3 CYP11B2 Inhibitors 
With 6-(pyridin-3-yl)-3,4-dihydroquinolin-2(1H)-one (IC50 = 28 nM, Figure 37) as the lead compound, a 
series of optimization was performed. It has been found that introduction of F onto the core increased the 
inhibitory potency to less than 10 nM (Figure 37, V-1 and V-2). Bioisostere exchange of ketone O to S (V-5 
and V-6) or replacement of pyridyl by isoquinolinyl (V-3 and V-4) further enhanced the CYP11B2 inhibition.  
Furthermore, an additional triazolo cycle was fused to the dihydroquinolinone core to form extra H-bonds 
and to conceal amide moiety, which is possibly vulnerable in vivo. A series of novel heterocycle substituted 
4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines were thus designed, synthesized and biologically evaluated. It 
has been elucidated that the substituents on the 1-position of triazolo moiety have profound influence on the 
CYP11B2 inhibitory potency, where the bulk is the crucial determinant. Methyl, as the most suitable group, 
was found to significantly improve the potency (VI-4, Figure 37). Nevertheless, larger substituents led to the 
loss of activity. It is intriguing that analogues with fluorine furnished at 9-position are more potent than the 
NH2N
III-6  
Figure 36. The dual CYP17 / 
CYP11B1 inhibitor III-6. 
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ones with 8-F substitution. Furthermore, substituents on the pyridyl are important for the affinity of 
compounds to the enzyme by altering the electron density on sp2 hybrid N, whereby electron donating groups  
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 Figure 37. Potent CYP11B2 inhibitors designed and synthesized. 
increase inhibition (VI-17, VI-18, VI-23 and VI-24; Figure 37), whereas electron withdrawing groups 
slightly reduce it. The increase of inhibitory potency by occupancy of additional hydrophobic pocket near 
heme is also observed, despite of coinstantaneous selectivity impairment. Conformation rigidification is 
considered as an advantageous factor for the CYP11B2 inhibition as well, which is substantiated by the 
fusing of additional phenyl (VI-23) and para-methyl substituntson pyridyl (VI-24). The current study results 
in many potent (IC50 < 10 nM) and highly selective (selectivity factor > 100) CYP11B2 inhibitors, especially 
compound VI-24 (IC50 = 4.2 nM, selectivity factor = 422). These compounds are considered to be promising 
drug candidates after further evaluation in vivo. 
4.4 Dual Inhibitors of CYP19 / CYP11B2 
The approach of combining important structural features of CYP19 
and CYP11B2 inhibitors to design dual inhibitors led to the 
introduction of alkoxyl onto the dihydroquinolinone core. It has been 
found that the bulky augment of alkoxyl groups at the 7-position 
largely elevated CYP19 inhibition, yet, reduced CYP11B2 inhibition 
and selectivity over CYP11B1. On the contrary, methylation of amide 
increased inhibitory potency toward all of these three enzymes. After 
balancing the different influence on SARs, selective dual inhibitors were successfully obtained as 
compounds V-9 and V-11 (Figure 38) with IC50 values around 50 and 20 nM toward CYP19 and CYP11B2, 
respectively. These compounds also showed good selectivity against CYP11B1 with selectivity factors 
around 50 and no interference with CYP17. After further evaluation in vivo, these dual inhibitors can be 
considered to be promising drug candidates as the treatment for BC patients with risks of CVD. 
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Figure 38. The dual CYP19 / 
CYP11B2 inhibitor V-9 and V-11. 
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